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Abstract. 
 
The identification of the biomolecular interaction partners of small bioactive molecules 
is a fundamental problem in drug discovery and cell biology.  This thesis describes the 
development of fluorescent chemical probes to identify the biomolecular targets of the 
known organophosphate toxin, phenyl saligenin phosphate (PSP), and the 
cardioprotective agent diazoxide. 
PSP is an organophosphate toxin that irreversibly inhibits hydrolase enzymes such as 
trypsin and chymotrypsin along with the common organophosphate target acetylcholine 
esterase. PSP is also suspected of affecting many other cell functions and may interact 
with a large number of cellular proteins.  In this work phenyl saligenin phosphate has 
been synthesised and its inhibitory effect on the action of transglutaminase 2 (TGase2) 
demonstrated. Analogues of PSP containing an attached dansyl amide fluorescent group 
have been prepared and incubated with purified enzymes trypsin, chymotrypsin and 
TGase2. SDS-PAGE analysis demonstrates effective fluorescent labelling and a 
covalent interaction between the toxin analogue and the enzymes.  
The KATP channel opener, diazoxide displays marked cardioprotective effects and is 
reported to bind to mitochondrial KATP channels. However, the molecular structure of 
these channels is still largely unknown. This thesis describes the design and the 
synthesis of a chemical tool to covalently attach fluorescently labels to the proteins 
which will bind diazoxide.  
Chemical tools for fluorescent labelling of diazoxide targeted proteins have been 
prepared.  Each consists of a photochemically activated reactive ‘barb’ and coupled 
fluorescent component linked to modified diazoxide bait. In developing these 
molecules, a range of functionalised diazoxide bait components were prepared and 
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tested for retained biological activity compared to the parent compound.  Two active 
analogues were linked to either benzophenone or diazirine (photoreactive) and dansyl 
amide (fluorescent) components. The non-specific photochemical reactivity of these 
labelling compounds with bovine serine albumin was established. The incubation and 
photolysis with mitochondrial extracts showed selective photo labelling of only three 
biomolecular components. The identification of these biomolecules is the subject of on-
going investigation. 
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1. Chapter 1: Introduction  
 
1.1 Background 
Naturally occurring substances have been used for medicinal purposes for thousands of 
years and until relatively recent times, all drugs were obtained from Nature, often by 
serendipity, and the means by which these medicines worked was little understood. The 
advent of modern biochemistry has given rise to the concept of a drug, as a low 
molecular weight compound (< 1 kDa) which interacts selectively with specific 
biomolecules to give a potent pharmacological response.1 As the processes that regulate 
living organisms have been progressively elucidated, and biochemical science has 
developed, the process of drug discovery has also changed.  Modern drug discovery 
involves chemical synthesis of large number of both structurally diverse and 
systematically varied compounds, which are then tested for activity using sophisticated 
and rapid biological screening techniques.2  
One of the main objectives in drug discovery is identification of new chemical entities 
that are more likely to bind the target protein to have a desired biological action. High-
throughput screening of huge chemical libraries has been a main source of identification 
of new lead compounds. In conjunction with this, the study of the biochemical 
mechanism of action of natural small molecules and new drugs has become central to 
understanding the function and importance of many classes of proteins, including 
intracellular receptors membrane, signalling proteins and proteins carrying out and 
regulating the cell cycle, and to the process of drug discovery.3, 4   
In the biological system, many proteins are activated and/or deactivated by various 
ligands to transduce inputs into proper cellular responses. Understanding the types of 
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protein targets and the mechanism of molecular interactions between small bioactive 
ligands and those proteins is important for successful drug design and discovery.5 
The study of genomic information has provided an increasing number of potential drug 
targets that can be screened,6 and many high-throughput screens traditionally employed 
to identify potential drugs use biochemical essays involving purified target protein.7 
These methods directly seek to find small molecules which will affect a known target 
protein however, a high number of compounds of recent interest come from screens 
involving cell culture or complete organism.8, 9 While the chance for discovering new 
drugs or drug usages by these assays is good, these leads give no unambiguous 
indication of the probable targets. To compound matters, advances in chemical 
synthesis and high throughput biological screening have not been matched by advances 
in the identification of the biological targets of small molecules.10 
As it stands, there are currently many drugs for which the biological target are 
completely unknown and in order to further understand how these drugs work, 
identification of these protein targets is essential. It has been estimated that the 
biomolecular targets of at least half of the drugs dating from the pre-molecular period, 
when drugs action were discovered using complete tissues, and biological activity was 
just indicated by tissue-based responses are unknown. Currently, 37% of drugs come 
from phenotypic screens,11, 12 and the biomolecule targets for a number of novel drugs 
remains unknown.    
To further complicate matters, drugs selected for, or considered to specifically modify 
activity of a target protein, may also bind various other proteins. Multi-target drugs 
generally interact with a lower affinity than a drug with a single target, as high affinity 
binding to many different targets it is not expected, but this is not necessarily a 
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weakness. For instance, Memantine, currently used in the treatment of Alzheimer’s 
disease, shows no high affinity for any of particular protein but targets multiple proteins 
with relatively low affinity and exhibits lower of side effects than alternative single 
target drugs with high binding affinities.11 
Conversely, the study of the effects of small biologically active molecules and drugs 
can give an opportunity examine protein function in general. In such studies protein 
activity can be quickly switched on or off by small molecules in a controlled manner, 
which cannot be found in any other methods allowing the role of these proteins to be 
probed. The main problem of widespread use of small molecules for studying biology is 
the difficulty of identifying compounds that can specifically modify the function of a 
given protein.13 This problem can be addressed by the elucidation of the biomolecular 
targets of known biologically active molecules.13 
There are a number of methods that have been applied to the identification of protein 
targets of small molecules and drugs which are outlined below.  One instructive 
example of the drug discovery using high-throughput phenotypic screening process 
coupled with identification of the novel target is the case of Monastrol.   
Monastrol is a cell-permeable small molecule inhibitor discovered by Schreiber and 
Mayer.  This compound was identified from a phenotypic screen of 35 000 compounds 
involving cell mitosis, and was subsequently shown to inhibit kinesin Eg5, a motor 
protein important for spindle bipolarity. Monastrol has since proved to be a powerful 
tool for the investigation of cellular processes as it can quickly perturb the function of a 
protein target and unlike taxol does not target tubulin.14 The mode of action of 
Monastrol was identified from the observation that it inhibits the formation of bipolar 
spindles in a dose-dependent manner, and the morphological effect was found to be 
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similar to that seen in antibody inhibition of Eg5 in Xenopus egg extracts.15 In this case, 
systematic large scale screening allowed the identification of the small bioactive 
compound however identification of the target required a much more specific approach. 
Monastrol is an illustration example of the use of parallel synthesis to generate drug 
lead compounds. Its synthesis involves the multi component cyclocondensation of an 
aldehyde, -lacto ester and urea, which leads itself to rapid combine synthesis. Indeed, 
Monastrol can be easily synthesized using a microwave protocol, employing ethyl 
acetoacetate, 3-hydroxybenzaldehyde, and thiourea (Figure 1).16 
 
Figure 1 Monastrol preparation 
 
Identification of protein function and the mechanisms of balancing functions in life 
using small molecules as probes is an area of great interest and activity. In the 
biological system, many proteins are activated and/or deactivated by various ligands to 
transduce inputs into proper cellular responses. Understanding the types of protein 
targets and the mechanism of molecular interactions between small bioactive ligands 
and those proteins is important for successful drug design and discovery.5 
One of the main objectives in drug discovery is identification of new chemical entities 
that are more likely to bind the target protein to have a desired biological action. 
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Recently, the study of genomic information has provided an increasing number of 
potential drug targets that can be screened.6 High-throughput screening of huge 
chemical libraries has been a main source of identification of new lead compounds. In 
conjunction with this, many three-dimensional structures for several drug targets have 
been developed aiding the design of new leads. 
The high-performance computing platforms have successfully screened large chemical 
databases to identify a wide range of targets. There are two essential methods for virtual 
screening. First, a ligand-based approach aims to detect molecules which have similar 
physical and chemical properties to known drugs that are expected to interact with the 
target.17 Second, a receptor-based approach aims to utilise the molecular recognition 
between a drug and a target protein to select out chemical entities that bind strongly to 
the active sites of biologically relevant targets for which the three-dimensional 
structures are known or inferred.18 
In addition, small biologically active molecules and drugs can give an opportunity to 
examine protein function in general. Protein activity can be modified by these small 
molecules in a controlled manner, which cannot be achieved by any other methods, 
allowing the role of these proteins to be probed. However, the main problem limiting a 
widespread use of small molecules for studying biology is the difficulty of identifying 
compounds that can specifically modify the function of a given protein.13 
Ad hoc methods have been used to identify the protein targets of many small molecules 
and drugs, which have led to a deeper knowledge of the physiological functions of 
many proteins and sometimes the pathophysiology of diseases, which the drugs are used 
to treat. Modern chemical biology, high-throughput phenotypic screening, together with 
an increase in the number of drugs have resulted in the emergence of small molecules as 
tools to perturb and elucidate biological processes.13 
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Even when small molecules are known to cause phenotype responses, the identification 
of biological targets is a problem. Therefore, the targets identification has been 
addressed via many methods: including genome-wide genetic approaches, affinity 
purification, molecular profiling strategies and in silico computational modelling and 
automated prediction of drug targets. Affinity purification and genetics are the most 
popular methods used for target identification and each application has its strengths and 
weaknesses. 
1.2 Genetic methods 
In essence, the genetic method for target identification is to carry out genetic 
perturbation of an organism and select for clones that have resistance to action of a 
certain small molecule by screening.19 The identification of the gene(s) that created the 
resistance can then help to determine the target of a small molecule. It is possible for the 
bacterial and yeast cells to select resistant clones which are made by mutations. After 
these resistant clones are isolated, genomic DNA can be extracted and sequenced, and 
compared with the wild type cells. From this it is possible to identify the mutation on 
the gene that provides increase to resistance to the drug under investigation. For 
example the target of the immunosuppressive of antiproliferative Rabamycin was 
identified by means of yeast genetics.20 While effective, these genetic approaches 
require a considerable amount of work to produce clones, and such genetic modification 
is not always possible.   
This approach is further limited, as many mammalian cellular pathways do not exist in 
yeast. Hence, yeast genetics are not valid for many small molecules which affect 
specific processes in mammalian cells. Furthermore, some small molecules cannot be 
used in yeast due to a poor permeability of yeast cells. Some of these problems have 
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been addressed by a similar approach using mammalian cells which can easily be 
mutagenized, to select for clones which have resistance to a specific small molecule.21 
1.3 Affinity methods 
Chemical methods are essential in chemical biology and provide an alternative route for 
direct identification of target proteins in biomolecules mixtures as well as their ligand 
binding site structures. Affinity purification is a powerful method which can be applied 
to identify targets of small molecules and drugs, which show biological activity only in 
mammalian cells or whole organisms. These analyses are based on the affinity between 
the ligand and the target protein, affinity-based chemical modification introduces a 
useful tag for analysing the target protein.22 
For example, single-molecular imaging with a fluorophore
 
visualizes target 
biomolecules in complex systems for imaging of the localization of these biomolecules 
and processing the flow of bioactive compounds in cell units.23 Affinity labelling
 
is 
limited by the necessity to specifically attach the required tag on the target protein. 
Generally the method requires the presence of nucleophilic residues near to a ligand 
binding site in order to avoid non-specific introduction of the tag at a site different from 
the binding site or onto other parallel biomolecules.24 
1.3.1 Tagging biomolecules using reactive sites   
Tagging biomolecules using reactive sites have found much application in the field of 
enzyme identification. A principal component of this field is the proposal of specific 
protein-modifying reagents that can be applied for functional studies of enzyme families 
within a complex proteome. These chemical probes are designed to covalently bind to a 
target enzyme in such a way that it can be then identified and/or purified by tagging the 
protein of interest.25 The probes can be prepared to react with diverse families or 
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subfamilies of enzymes. With this area, much work has focused on activity based 
probes (ABPs) which modify the enzyme using covalent bond formation. Other probes 
can target non-catalytic residues on proteins and enzymes, and these affinity-based 
probes (AFBPs) should have a high selectivity and, tight binding to tag the proteins.  
In general, chemical probes are being increasingly applied in the field of proteomics and 
have good capability to help in drug target identification, validation, and drug 
discovery. In the most basic form, chemical probes consist of three functional 
elements;26 i) a reactive group for covalent reaction with the enzyme, ii) a linker, that 
can modulate reactivity and specificity of the reactive group, iii) and a tag for 
identification and purification.(Figure 2). 
 
 
 
Figure 2 Structure of a chemical probe 
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1.3.1.1 Reactive groups 
One of the major difficulties in designing a chemical probe is finding a reactive group 
that can undergo selective covalent modification of a target protein. The group must be 
reactive towards a specific residue on a protein but at the same time unreactive towards 
other species within the cell or cell extract (Figure 3). 
 
 
Figure 3 Reactive groups 
 
In general, most of the successful chemical probes are based on the chemistries of the 
enzyme active site, and are, effectively, covalent, mechanism-based inhibitors of the 
enzyme. Generally, four general classes of reactive groups are used to design chemical 
probes (Figure 4). 
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Figure 4 Mechanism of the four primary classes of chemical probe 
The first two types (I and II) require active target enzymes to react with the probe are 
based on enzyme reaction mechanism or suicide inhibitors. For the mechanism-based 
probes (type I), the reactive nucleophile is the catalytic residue of the enzyme normally 
involved in reaction with a substrate. The selectivity of this probe uses knowledge of 
catalytic mechanism and is often uses chemistry specific to the nucleophilic atom used 
by the enzyme class. The suicide inhibitor ABPs (type II) contain a `masked 
electrophile' that is uncovered after the probe functions as substrate for the target 
enzyme. Once unmasked, the electrophile reacts with adjacent nucleophilic residues in 
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the active site. Affinity alkylating probes (AFBPs, type III) have affinity-based labelling 
groups that need only a strong nucleophile or electrophile nearby  the active- site pocket 
and do not require a fully active enzyme. As such these probes rely upon guest/host 
recognition to bring the reaction partners together. The final class of reactive groups 
used (type IV) contains non-specific alkylating groups that react with targets based only 
on the reactivity of nucleophilic amino acid residues such as cysteine. This class of 
probe has recently found much application in bulk proteomic analysis by mass 
spectrometry.27 
1.3.1.2 Linkers  
The linker section of a chemical probe connects the reactive group to the tag used for 
identification and/or purification. The linker section has multiple purposes. Its primary 
function is to separate the reactive group and the tag to avoid steric hinderance that 
could either block reaction of the reactive group or access to the tag during purification 
process. Linkers often used are a long-chain alkyl or polyethylene glycol (PEG) spacer, 
the choice of linker can control hydrophobicity and alkyl linker can confer membrane 
permeability, while the PEG linker can confer water solubility to hydrophobic probes. 
Polypeptide linkers have also been used. (Figure 5).28 
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Figure 5 Linker structure 
1.3.1.3 Tags  
The function of the tag on a chemical probe is to enable identification, and often 
purification, of probe-modified proteins. The most commonly applied tags are biotin, 
fluorescent, and radioactive tags. The simplest method to separate proteins involves gel 
electrophoresis, and tags used in a probe must be suitable for use with SDS-PAGE 
methods. Fluorescent and radioactive tags have several advantages over biotin. Both 
fluorescence and radioactivity detection methods are more sensitive than streptavidin-
biotin detection methods (Figure 6).29 
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Figure 6 Tags used for labelling 
In addition, fluorescent tagging methods have an added advantage, in that tags emitting  
different wavelengths can be used. For example using different coloured fluorescent 
tags in different experiments allows all results to still be obtained on a single gel.30, 31
 
Despite the benefits of fluorescent and radioactive tags, biotin still remains the most 
commonly used tag since it allows both a gel-based detection and a method for 
purification of labelled enzymes on streptavidin – agarose beads. The use of very large 
peptides or proteins tags holds much promise by providing a high selectivity to a 
chemical probe and simplicity of isolation, but it also has disadvantages, specifically the 
peptide tags are large in size, hard to integrate into small molecule skeletons and greatly 
alter the cell permeability of probes.32 
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1.3.2 Tagging proteins with no reactive sites 
As discussed above, the content labelling of enzymes can be achieved by exploiting the 
reactive nature of enzyme active sites, however it is highly desirable to be able to tag 
proteins that are not enzymes in order to identify and elucidate their functions. Indeed, 
chemical probes can be applied to study all aspects of proteomics from protein 
expression and identification to cellular localization and regulation.26 Chemical 
proteomics has the potential to uncover these targets in a rapid, systematic and 
comprehensive manner through design, synthesis, and application of relevant probes. 
1.3.2.1 Photoaffinity labelling (PAL) 
The concept of photoaffinity labelling (PAL) was introduced by Frank Westheimer in 
the early 1960s,33 and has since become one of the most common methods used in 
biology for the specific detection of the protein targets of bioactive ligands. The 
identification of interacting partners allows immediate access to the discovery of 
medicinal leads. The method of photoaffinity labelling enables the direct identification 
of target protein through the formation of a covalent bond between a ligand and its 
specific receptor.34 This technique is based on ligand-receptor complex formation 
between a photoreactive probe and receptor protein which, when exposed to ultra violet 
light, results in carbene or nitrene reactive intermediates which facilitate covalent 
attachment of the probe to receptor binding site of the ligand (Figure 7).35, 36 
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Figure 7 Photoaffinity labelling; (i) incubation of cell lysate with tagging molecule; (ii) 
irradiation; (iii) fluorescence directed purification 
1.3.2.1.1 Photoactivating groups 
 The main role of photoreactive groups attached to a ligand is to provide covalent 
binding between the ligand and receptor. The success of a photoaffinity labelling 
experiment relies on the selection of appropriate photoactivating groups which is crucial 
in this process.37 There are several considerations in selecting reactive groups for a 
photoaffinity labelling experiment. Generally, the photophore size should not be very 
large, in order to avoid a negative effect on the binding affinity of ligand-receptor due to 
a steric interference. The photophore should be also chemically activated under ultra 
violet light irradiation, and the photo-activated lifespan under ultra violet should also be 
considered. The covalent attachment of photophore to its active binding receptor site 
must occur before dissociation of the ligand receptor complex, which can only happen 
when the duration of the activation lifespan is short.  
On the other hand, if the photophore remains very close to the binding site, more 
efficient covalent attachment will be achieved when a photophore with a long excited 
state is chosen. Furthermore, the wavelengths used for activation of photophore should 
not negatively cause damage to the target protein of interest.34 Nitrene or carbene 
reactive intermediates are strong electrophiles with the ability to selectively react with 
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nucleophilic hetero atoms (N, O or S) or even double bonds, but also inert groups such 
as C-H and N-H sigma bonds. 
 The most widely used photoreactive groups are phenylazides, phenyldiazirines and 
benzophenones due to their ease of handling, simple synthesis and commercial 
availability (Figure 8).38  
 
Figure 8 Photoreactive groups used in tagging biomolecules 
The photolysis of azides produces a nitrene intermediate while carbene intermediates 
are generated by a diazirine precursor. Carbenes are generally considered better reactive 
intermediates than nitrenes, and for instance, carbenes are more reactive in crosslinking 
reactions with nitrogen-carbon bonds than nitrenes, especially in amino acid sequence 
identification.  
These photoreactive groups require different wavelengths of light to activate the 
photolysis process. A wavelength of 300 nm is required for the azide photolysis, which 
upon prolonged irradiation, may affect bio-macromolecules. On the other hand, carbene 
precursors require a longer wavelength of ~360 nm which less damaging to proteins.39 
Benzophenone derivatives are also a powerful agent for efficient crosslinking,34 and 
benzophenones offer advantages which make them attractive for reaction with target 
proteins over the use of diazirine and azide photo probes. The photo-dissociation is a 
potential side reaction in diazirine and azide chemistry while with benzophenone this 
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phenomenon does not occur. Similar to carbenes, the carbonyl group can be excited at 
approximately 360 nm to generate a triplet excitation state
 
which shows high reactivity 
with C-H bonds even in the presence of water.39  
Comparative irradiation studies of these three photophores types in living cells suggest 
that the irradiation needed for the generation of active species from azide and 
benzophenone may cause cell death, because long irradiation times are needed to 
integrate the photophores into cell membrane surface biomolecules. On the other hand, 
the carbene precursor – 3-phenyl-3-(trifluoromethyl) diazirine (TPD) – did not promote 
cell death in the generation of active species, but the other photophores are effective in 
photoaffinity experiments in vitro.40 
1.3.2.1.2 Mechanisms of action of the photophores 
All the three photophore molecules have different reactivity profiles in reaction with the 
biomolecule targets. The mechanisms of action depend on the reactive intermediates 
generated during the course of the reaction, which can possibly lead to a variation of 
products.  
i) Phenyl azide potential mode of reaction  
The photochemistry of aryl azides is quite rich and is illustrated by reactions of phenyl 
azide. The irradiation of the aryl azide A1 with UV light with a wavelength of 280 nm, 
leads to the release of nitrogen (N2) and a singlet nitrene A2 is produced. This highly 
reactive intermediate has a short lifetime and quickly converts into other reactive 
intermediates.41
 
Intersystem crossing (ISC) can lead to a triplet nitrene A3.42 These two 
nitrenes have different modes of reaction; however the product is the same C-H 
insertion product A4. The singlet nitrene acts as an electrophile and undergoes a direct 
insertion reaction with C-H bonds, while the triplet nitrene behaves as a diradical which 
can abstract a hydrogen radical from the adjacent C-H then bind with the resultant 
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carbon radical A9. Singlet nitrenes can also rapidly rearrange into the appropriate 
benzazirine A5 and dehydroazepine A7, which can react with the adjacent nucleophile 
producing A6 and A8 correspondingly. Finally the highly reactive nitrene is also 
susceptible to aerobic oxidation from the triplet state to form the nitro compound A10 
(Figure 9).43 
 
Figure 9 Possible reaction modes of the reactive intermediates formed upon irradiation 
of aryl azides 
 
In addition, a non-specific labelling generated from rearrangements of short lived 
phenylnitrenes result in undesirable ketenimines.44  
The preparation of aryl azides is relatively simple and aryl azides can be obtained from 
the corresponding amines in one or two synthetic steps. The most common route is the 
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diazotization of the amine with subsequent addition of sodium azide.45
 
A superior 
preparatory method utilises triflyl azide (TfN3), to derivative the amine directly in one 
step reaction with high yield.46 Recently, a more stable reagent imidazole-1-sufonyl 
azide has been developed, which gave a good conversion under mild conditions (Figure 
10).47    
 
Figure 10 Some methods of azides preparation 
ii) Diazirine possible modes of reaction  
Diazirines are increasingly finding utility as carbene precursors for biological tagging.48 
When alkyl or aryl diazirines are exposed to UV light of 360 nm, molecular nitrogen is 
released with formation of a singlet carbene D2, along with about 30% rearrangement to 
form the diazo-isomer D3. This diazo compound may then be slowly converted into the 
singlet carbene at the wavelengths normally used for irradiation. The diazo compound is 
fairly long-lived and potentially has time to diffuse and undergo both labelling or 
hydrolysis reactions. The rearrangement process can be supressed by the introduction of 
CF3 group α to the diazirine and 3-aryl-3-(trifluoromethyl)-3H-diazirine D1 was 
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developed by Brunner and co-workers as a photoaffinity labelling substrates.49 Singlet 
carbene D2 is considerably short-lived (t1/2 ~1 ns) and can convert to a triplet state D10 
by intersystem crossing (ISC). Singlet and triplet carbenes show similar reactions 
compared to the analogous nitrenes. A singlet carbene can behave as an electrophile, 
nucleophile or ambiphile, depending on the nature of its substituents, while triplet 
carbenes react as diradicals. The produced singlet carbenes can quickly give insertion 
reactions; with insertion into hydroxyl groups D4 usually giving a higher yield than for 
C-H insertions D5.50 Insertion into N-H amine bond can lead to produce intermediate 
D6, which can give undesired by-products. N-H insertion products can easily lose HF, 
forming enamine D7, which can be hydrolysed in presence of water to the 
corresponding ketone D9. As a result, the covalently bonded biomolecule target may be 
lost.50 The triplet carbene behaves in a similar fashion to the triplet nitrene with the C-H 
bond, firstly abstracting the hydrogen to form the radical D11, which combines with the 
produced radical to give the same net product as in the singlet carbene insertion D5. 
Alternatively, a second H-abstraction may occur to give reduced the intermediate to 
D12. Undesired oxidation reaction may also occur from the triplet carbene intermediate 
in presence of oxygen, affording the corresponding ketone D13 (Figure 11).51  
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Figure 11   Intermediates and reactions in diazirine photolysis. 
iii) Benzophenone possible mechanism of action 
In contrast to the diazirine and nitrene, benzophenone does not react irreversibly to form 
a reactive intermediate. The benzophenone B1 upon irradiation with the UV light at 
≈350 nm forms a benzhydril diradical B2. This is a reversible excitation and the 
compound reverts to a stable ground state in the absence of a suitable reaction partner. 
In the presence of a suitable hydrogen atom source, abstraction of hydrogen occurs to 
create the active species and the rate of this step is dependent on the nature of X-H 
bond.52 Generally, C-H bond cleavage is preferred to O-H bond cleavage, especially 
when hydrogen abstraction creates a stable carbon radical, for example, at the-
positions in -amino acids, at benzylic or tertiary carbon centres and adjacent to 
heteroatoms. As a result of reaction of the benzhydril diradical B2 with an amino acid 
-centre B3, a ketyl formula B4 and alkyl radical B5 are produced, which after a fast 
recombination create a benzhydril B6.  The major benefits of using the benzophenone 
22 
 
group are: it is more reactive toward C-H bonds than nitrenes and less prone to 
intermolecular rearrangements than the carbene. Moreover, when the diradical interacts 
with water it forms a hydrate B7, which can then dehydrate to reform the ketone. One 
unproductive side reaction is the homodimerization of ketyl B4 to give benzopinacol B8 
however, because of the difference in reaction rates of hydrogen abstraction and 
recombination, only a small amount of this by-product is generally formed (Figure 12).  
 
Figure 12  Benzophenone irradiation mechanisms 
1.3.2.2 The use of tags in photoaffinity labelling experiments 
To be effective, photochemical labelling requires the attachment of some other function 
to allow tracking or identification of the targeted proteins. Tags historically used are 
radioactive isotopes, or biotin. Recently, many biochemical studies have used 
fluorescent tags to detect ligand-receptor complexes and facilitate isolation. Whatever 
method is used, tagging strategy is fundamentally important for the observation of the 
new protein targets.53 The interaction of receptors and ligands can be also identified 
when the photoaffinity labelling is combined with mass spectrometry (MS). In such an 
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experiment the tagged protein is identified by a characteristic change in mass of the 
protein, and detection by mass spectrometry.34 
i) Biotin Tags 
Purification and identification of probe-bound proteins is the key step for the use of 
chemical probes to proteomics. The most popular widely utilized affinity tag in ABPS is 
biotin which has a particular strong non-covalent affinity for avidin and streptavidin 
proteins.40 By using this intervention, proteins can be purified and/or immobilized by 
efficiently using affinity tags of streptavidin/avidin interaction and can be used in a 
wide variety of biotechnological and biochemical applications (Figure 13). 
   
 
Figure 13 Streptavidin protein and biotin tag complex molecule 
Biotin is a vitamin exists mostly in all cells, whereas avidin is a protein extracted from 
chicken egg white. Streptavidin is a bacterial protein similar to avidin, isolated from 
Streptomyces avidinii, and is more commonly used than avidin. Biotin is an effective 
handle which can be bound to immobiliable streptavidin or avidin allowing purification 
of the probe labelled enzyme and isolation of the targeted protein. Biotin- streptavidin 
binding is very fast and stable under various conditions of pH and temperature.54, 55 The 
biotin-streptavidin interaction bond is one of the strongest known non-covalent 
interactions (Kd = 10
-15
M)56 allowing for quantitative binding of low abundance 
biotinylated enzymes.57 The mechanics of such an assay is that streptavidin is fitted to a 
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solid surface, like a magnetic bead, or biosensor chip, and biotin is linked to molecules 
of interest, for example a protein, nucleic acid or antibody (Figure 14). 
Although derived tags are useful in protein isolations, its use is hampered in vivo 
applications since incorporation of this moiety confers poor cell permeability on the 
biomolecule probes. This disadvantage limits its uses as an affinity tag in ABP 
applications and therefore biotin was mainly utilised in vitro applications for target 
isolation.40 
 
Figure 14 Biotin-avidin interactions for protein target identification 
The strong binding interaction of biotin with streptavidin has further disadvantages as it 
cannot be easily removed from streptavidin resins without using harsh conditions, for 
example by treatment with formamide and using high temperatures, which may lead to 
denaturing target proteins and streptavidin molecules.55 For this reason, probe design has 
recently focussed on the inclusion of cleavable linkers between the reactive group and 
the biotin tag that allow mild and selective elution of the probe-bound proteins from the 
solid support. A photocleavable linker has been reported for use with isotope-coded 
affinity tagging (ICAT) probes
 
(Figure 15) and other types of cleavable linkers are 
under development.58 
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Figure 15  Photocleavable linker for (ICAT) probes 
ii) Fluorescent Tags. 
Fluorescence is a phenomenon where a fluorophore or fluorescent dye (generally 
polyaromatic hydrocarbons or heterocycles) absorbs a light at a specific wavelength 
which then leads to emission of visible light at a lower wavelength. The absorbance of 
the light by such molecule or atom leads to promotion of electrons in the valance 
orbitals, generally at a specific wavelength of UV light. The fluorescence then occurs 
via a three-stage route within such fluorescent molecules, outlined in the Jablonski 
electronic-state diagram shown in (Figure 16). 
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Figure 16 Jablonski electronic-state diagram for simple fluorescence 
Excitation state   
A photon of energy hνEX is supplied by a UV light source absorbed by the fluorescence 
dye, generating an excited singlet state (S1'). This process differentiates fluorescence 
from chemiluminescence, wherein the excited state is occurred by a chemical reaction.  
Excited-State Lifetime  
The excited state continues for a limited time (normally 1–10 nanoseconds). In this 
time, conformational changes of fluorophore may occur and fluorophores are also 
subject to many interactions with the molecular environment. Once excitation occurs, 
the energy of S1' is degraded via intersystem crossing, leading to a relaxed singlet 
excited state (S1), which initiates fluorescence emission.  
Fluorescence Emission  
The emission occurs when the photon energy hνEM is emitted and the fluorescent 
molecule returns to the ground state S0. The emission is lower than the excitation 
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energy, because part of the energy is lost during the excited state lifetime; the emission 
wavelength is longer than in the excitation wavelength hνEX. This difference in the 
energy is called the Stokes shift. The Stokes shift is essential to the fluorescence 
performance, since it allows emission photons to be sensed with a low background 
isolated from excitation photons.  
In the fluorescence process, not all molecules excited by the absorption return back to 
the ground state (S0) by fluorescence emission. The quantum yield of the fluorescence is 
the ratio of the number of photons emitted compared to the number of photons 
absorbed, and is measure of the efficiency of the fluorescence process.59 Both the Stokes 
shift and quantum yield are important factors in choosing effective fluorescent tags.  
In the life sciences, fluorescence is generally used as a safe way of tracking and 
analysing biological molecules via fluorescent emission at a specific wavelength.60 The 
fluorescence can be affected by the background emission from the excitation light, as 
relatively few cellular components are naturally fluorescent. The fluorescence has 
become one of the most useful methods in the field of the biological molecule 
purification and detection processes, this is because of many reasons. First is the 
variation of the wavelength can be used in the fluorescence detection of the 
biomolecules, allowing the application of such fluorophores in different environments, 
since some biomolecules fluoresce under a certain wavelengths of light. Second because 
of the efficient quantum yield, fluorescence can be applied with the very low 
abundances of biomolecules. Finally the availability and the ease of laboratory 
preparation give more advantages of using the fluorescent labelling than the other dyes. 
Fluorophores need not only be small molecules and the development of fluorescent 
proteins (FPs) has revolutionised biomolecular tagging. Initial efforts in protein 
fluorescent labelling in vivo was performed after the genetic sequences of green 
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fluorescent proteins (GFPs) from the jellyfish Aequorea victoria. GFP was firstly used 
for labelling proteins of interest in 1994.61 Later after Osamu Shimomnura, Martin 
Chalfie and Roger Y. Tsien won The Noble Prize in chemistry in 2008 for discovering 
and developing GFP. This protein has become well recognized as an indicator of gene 
expression and to target protein in cells and organisms. However, the size and the 
narrow range of the fluorescent spectra of GFPs may limit their application. As a result 
there are necessities to find alternative smaller fluorophores with wide range of different 
properties and emitted wavelength spectra.  
Synthetic chemistry has introduced fluorescent probes of small molecular size with 
improved photochemical properties, which can offer variety of colours. The small 
fluorescent molecules are widely used in many biological applications and each of these 
molecules has advantages and disadvantages (Table 1).   
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The fluorophore    Advantages  Disadvantages  
Fluorescein 
 
Relative high absorptivity; 
excellent quantum yield; 
 high water solubility; 
inexpensive; stable to 
solid-phase peptide 
synthesis method 
 
Fast photobleaching;  
pH sensitive below 7; 
Relative broad 
emission; self-
quenching; lack of cell 
permeability. 
Rhodamine 
 
Readily excited, more 
photostable than 
ﬂuorescein. 
 
Low quantum yield 
(1/4 of ﬂuorescein); 
complex absorption 
complex; lack of cell 
permeability. 
 
Dansyl sulphonamide 
 
Fluorescent as dansyl 
amide and not chloride; 
large stokes shifts; 
inexpensive  
Environmental-
dependent quantum 
yields and emission 
maxima. 
BODIPY 
 
High extinction 
coefﬁcients; excellent 
photostability; high 
ﬂuorescence quantum 
yields; narrow emission 
bandwidth; good 
photostability; pH 
insensitive; no ionic 
charge; non-polar; 
minimal effect on 
electrophoresis mobility; 
cell permeable. 
More expensive than 
rhodamine and 
fluorescein, shows 
unstablility under the 
majority of solid phase 
synthesis, lack of rapid 
photobleaching 
Cyanine 
 
pH insensitive (3–10); 
DMSO tolerance; good 
aqueous solubility; 
superior photostability; 
stable to standard peptide 
synthesis 
Expensive  
 
 
Table 1 The advantages and disadvantages of the most common fluorophores 
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In many biological and biochemical investigations, tagging proteins with an effective 
small molecule fluorophores can lead to in vivo and in vitro investigations of their 
functions and structures.62 
There are several problems that could negatively affect the generation of a good 
fluorescence. For instance, fluorophores can absorb photons, but sometimes does not 
result in high rate of excitement, this can lead to high brightness level within the 
fluorescence. This very bright light affects the visibility of fluorescence and cannot be 
clearly detected and the good fluorescence observation can be detected in the dark.63 
Generally, establishing a powerful fluorescent label requires maximising the number of 
emitted photons. This can be performed via a high absorption/quantum yield. On the 
other hand, the efficiency of photo-induced-chemical alteration must be also considered, 
because this can negatively cause production of non-fluorescent molecules.64 
The fluorophore performance and photostability can be affected by undesirable 
phenomenon that decreases both the quantum yield and the number of emitted photons. 
These affecting factors are underlined as photoblinking and photobleaching. 
Photoblinking is a phenomenon described as reversible reduction or fading of the 
emitted light proceeding in an average time of microseconds to seconds, which is 
significantly longer than the emission from the singlet state (normally 1-10 ns).  
Photoblinking is also can be as result of the triplet state excitation,65 and it can also cause 
a bad measurement of single molecule by affecting the process timescale. It may be 
difficult to discriminate the case of prolonged time photoblinking from permanent 
photobleaching. 
 Photobleaching occurs when a fluorophore molecule becomes unable to fluoresce, 
because of photon-induced chemical damage and covalent binding modification.  
During the transition from the excited singlet state to the excited triplet state, 
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irreversible covalent interaction may occur between the fluorescent molecule and 
another molecule in the environment. This interaction occurs because the triplet state is 
relatively longer than the singlet state, which allows the excited molecule to have 
sufficient time to undergo chemical modification. The main factors affecting the 
photobleaching of a fluorophore are the molecular structure and the nature of 
environment. Limiting these variable changes is crucial to improve the photostability. 
Photobleaching can be minimised by decreasing the lifetime of the fluorophore triplet 
state by limiting the exposure time or by lowering the excitation energy. Lowering the 
oxygen levels may also reduce photobleaching, if oxygen reacts with the excited 
fluorophore.63 
Overall, photoaffinity labelling (PAL) is a technique which employs a suitable linker of 
a fluorophore, photoreactive group and small bioactive molecule. This method has been 
used for identification of small molecule protein targets, using a variety of different 
photoactive and fluorescent groups, in order to achieve the optimum analysis 
environment.   
An instructive example of the PAL method was described by Bringmann et.al (2007) 
who investigated the mode of action of antiplasmodial naphthylisoquinoline (NIQ) 
alkaloids. In this study an NIQ derivative was functionalized with benzophenone and 
dansyl amide moieties in order to identify the protein target for this antimalarial drug.66 
It was found that, the modified NIQ was slightly weaker than the original compound 
itself, however the functionalized alkaloid derivatives retained antiplasmodial activity 
and also microscopic studies evidenced that these molecules entered inside the cells, 
which is a promising model compound for applying PAL assays. 
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The benzophenone and dansylamide were introduced in this investigation as a 
photoaffinity and fluorescent moieties, respectively. In preliminary study, the dansyl 
functionalized derivatives with no photoaffinity functionality were also investigated 
showing that these molecules are good candidates for in vitro visualization of the 
alkaloids. Microscopic investigation showed that the fluorescent derivatives centred 
exclusively inside the infected cells (Figure 17). 
 
Figure 17 Dansylated and fully functionalized dioncophylline alkaloid  
The general approach is illustrated by the following example. Partha et.al (2013) 
described a method of employing the tri-substituted benzenes as a tripodal template 
fluorescent photoaffinity probe for capturing human carbonic anhydrase.67 In this 
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investigation, sulphonamide derivatives which are inhibitors for human carbonic 
anhydrase II (HCA II) were chosen to be a selectively function. An aryl azide was 
utilized as a photoaffinity molecule and a propargylated pyrene was employed as a 
fluorescent tag. These three molecules were joined together to build up two capture 
compounds. An investigation was carried out by incubation of these two molecules with 
a mixture of three deferent proteins, HCA II, bovine serum albumin (BSA) and 
lysozyme. The under UV- transillumination results showed that the only visible band 
corresponded to HCA II protein. A confirmation of this selectivity capture was also 
obtained from the MALDI mass spectrometric analysis, which provided evidence of the 
reliability of this method (Figure 18).     
 
 
 
Figure 18 Photoaffinity capture compound for human carbonic anhydrase II inhibiters 
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1.3 The project plan 
The project focused on the development of functional probes to identify protein targets 
of two classes of biologically active small molecules: (i) organophosphate neurotoxins 
and (ii) the putative targets of the cardioprotective drug diazoxide 
The strategy is to design and prepare probes for the identification of biological 
molecules based on the non-covalent, specific binding, of the bait to a target protein. 
Upon exposure to light, the probes will activate and form covalent bonds and tag the 
target or proximal proteins. The isolation and identification of tagged proteins will be 
investigated by fluorescence monitoring, chromatography and mass spectrometry. 
However in the case of the organophosphate, the small molecule will be attached to a 
fluorescent tag via linker without using any photoaffinity molecules. This is because 
these molecules tend to bind covalently with the biomolecule targets and one of the 
aims is to prove the nature of binding (Figure 19).  
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Figure 19 General strategy of the project 
(A) Labelling with Photoreactive molecules; incubation followed by irradiation, 
washing then purification. (B) Labelling using covalent biological interactions; 
incubation is followed by washing then purification.   
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2. Chapter 2: Organophosphates 
 
2.1 Introduction 
 
 Organophosphates are organic chemical substances that are generally produced by 
reacting alcohols with phosphoric acid. In the early 19
th 
century, organophosphates were 
widely used as pesticides and insecticides in agriculture and as well as in wide range of 
chemical and industrial processes. The dangers to health posed by these species were 
also well known and these compounds were used as chemical weapons in World War II. 
The acute toxicity of these compounds is associated with the ability to inhibit the 
enzyme acetylcholinesterase, thereby affecting neuromuscular transmission. More 
recently public concern has increased regarding the frequent use of organophosphates as 
chemical agents, their acute toxicity and their damaging effects to the environment and 
human health in general.68  
Many anticholinesterase organophosphate products have been tried for therapeutic 
purposes. Physostigmine anticholinesterase was used to treat glaucoma in the 1870s and 
later after in the 1930s, synthetic cholinesterase inhibitors were being used for skeletal 
muscle and autonomic disorders. Some organophosphates were tried in the treatment of 
Parkinsonism, and they might also be useful for treating dementia 
In 1986, testing began for tacrine, the first cholinesterase inhibitor to be tried for 
Alzheimer’ disease; it was released for clinical use in 1993 and it is no longer in use. 
The blood-brain barrier has been the limiting factor in developing a cholinesterase 
inhibitor for use in dementia. Metrifonate has been used for schistosomiasis treatment 
and it was used for the treatment of primary degenerative dementia (Figure 20). Sung 
and others have reported on the ability of these substances to induce nicotinic receptor 
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modulation.69 This explains the action of these drugs and may result in development of 
more effective agents.  
 
Figure 20 Metrifonate, used for schistosomiasis treatment 
2.1.1 Acute toxicity mechanism of organophosphorus compounds 
Following exposure, organophosphates are distributed widely around the body and 
eventually reach the nervous system.  Organophosphates can be found in all parts of the 
nervous system, but the most serious symptoms appear due to the effect on the 
automatic involuntary nervous system in the parasympathetic part. The acute toxicity 
target of organophosphate compounds is known to be acetylcholinesterase (AChE) 
which normally provides the relaxation of the neurotransmitter acetylcholine (ACh).70 
Acetylcholine is one of several physiologically important neurotransmitter agents and is 
involved in the transmission of nerve signals. The rapid hydrolytic degradation of 
acetylcholine into the inactive products choline and acetic acid is performed by AChE.71   
Organophosphates are non-competitive inhibitors of AChE and completely block the 
active site of the enzyme.72 These compounds are initially non-covalently and reversibly 
bound to the acetylcholinesterase enzyme followed by an irreversible phosphorylation 
of the serine oxygen atom in the active site, which causes deactivation of 
acetylcholinesterase enzyme in the synaptic cleft (Figure 21).73 Ultimately, the increase 
of acetylcholine at the synapses of neuromuscular junctions can result in 
overstimulation of acetylcholine receptors. This causes a great influx of Na
+
 into the 
neurons, inducing electrical signals that lead to extreme muscle contraction to the point 
of paralysis, secretions, and convulsions.74 
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Figure 21 Inhibition of acetylcholinesterase by organophosphate;A. ACh hydrolysis 
AChE, B. De-activation of AChE 
 
2.1.2 Other organophosphate targets  
Many studies have demonstrated that, in vitro, organophosphates can interfere with 
many proteins, and bind to the tyrosine residues in for example transferrin, serum 
albumin and tubulin. Toxins which have been shown to bind to targets other than AChE 
are; FP-biotin, chlorpyrifos-oxon, diisopropylfluorophosphate, dichlorvos, soman, and 
sarin (Figure 22).75, 76 In addition, there is a possibility that other more reactive and low 
abundance proteins could react with organophosphates causing toxicity at low doses  
and toxic effects may also arise by mechanisms different to the inhibition of AChE.  
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Figure 22 Toxins bind to targets other than acetylcholinesterase 
Although exposure to low levels of organophosphates does not cause noticeable 
inhibition of AChE, however other neurological deficits may be caused. For example, 
Parkinson’s disease, neurologic dysfunction and Gulf War Illness have been linked to 
prolonged low levels of organophosphate exposure.77, 78  
Bronchoconstriction is a condition involving a narrowing of the airways in the lungs, 
which may result from low levels of exposure to organophosphorus pesticides. It is 
thought that some organophosphates can inhibit the function of muscarinic ACh 
receptors, which would facilitate transmission of an extracellular signal induced by free 
acetylcholine to neuronal or effector cells as opposed to inhibiting acetylcholinesterase 
activity.79 These receptor proteins recognise ACh but do not belong to the serine 
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hydrolase family. However, the binding of a low concentration of organophosphate 
affects function.  
More generally, signalling mechanisms in cells depend on the phosphorylation reaction 
of the intracellular macromolecules,80 and it has been suggested that irreversible binding 
of organophosphate to a site which is normally reversibly phosphorylated can cause 
cellular dysfunction. The development of an understanding of the relationship between 
disease and low dose OP exposure will be greatly enhanced by the identification protein 
targets susceptible to organophosphate interference.  
2.1.3 Organophosphate-induced delayed neuropathy (OPIDN) 
In addition to the chronic toxic effects, acute poisoning by organophosphate compounds 
generally cause significant injuries to both the central and peripheral nervous systems, 
as well as leading to a significant effect on the spinal cord in particular. After exposure 
to a variety of organophosphates, an inhibition of the enzyme neuropathy target esterase 
(NTE) has been clearly detected in several animals. This enzyme is a phospholipase 
which deacylates intracellular phosphatidylcholine and hydrolyses fatty acids to 
generate water-soluble glycerophosphocholine.81 When this enzyme is inhibited, 
abnormally elevated levels of phosphatidylcholine can occur in the brain, leading to 
deficiency of the constitutive secretory pathway in neurons.82 Many studies have 
established that inhibition of the NTE target causes a condition called (OPIDN).83 In 
addition, irreversible inhibition of NTE can cause a chronic cholinergic crisis associated 
with significant development of OPIDN after massive exposure to organophosphates.84 
 While rare, OPIDN is a condition which can occur in some other mammalian species 
subsequent to extensive exposure to organophosphate neurotoxins. It has been stated 
that a number of avian and mammalian species exhibit elevated sensitivity to 
organophosphates.85 Moreover, neurodegenerative forms of OPIDN has been also 
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observed in animals and humans, and the precise damaging impact of OPIDN in 
neuropathological alteration of those systems remains to be clearly diagnosed.86, 87 
Several organophosphates are known to cause OPIDN in sensitive mammals. These 
include phenyl saligenin phosphate PSP, tri-ortho-cresyl phosphate TOCP,88 and 
saligenin cyclic ortho-tolylphosphate  SCOTP (Figure 23). 
All these compounds are pentavalent, tetra-coordinate molecules containing an oxygen 
atom and three substituent groups or atoms via single bonds. Each had a phenol group 
bonded to phosphorus by a relatively weak single P-O, which can be displaced during 
reaction with nucleophilic residues and allow the organophosphate to covalently attach 
to protein target. In the course of the phosphorylation reaction, the organophosphate 
compound is destroyed in a stoichiometric reaction with the enzyme. The caused 
inhibition is persistent, but is potentially chemically reversible. The treatment for acute 
organophosphate poisoning focused on the use of non-enzymatic reagents for de-
phosphorylation and the consequent restoration of activity.89  
 
Figure 23 Organophosphates known to induce OPIDN 
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Phenyl saligenin phosphate PSP is an organophosphate neurotoxin and 
acetylcholinesterase was identified as a primary toxicity target. In addition, SCOTP was 
discovered to be a highly active metabolite of the neurotoxins, TOCP, and neurotoxin 
TOCP can be actively converted to SCOTP in vivo. Several studies have also explored 
the possibility that this analogue of PSP is a more potent cause of OPIDN than the 
parent compound itself.90                                                                                                                                                                 
2.1.4 The effect of phenyl saligenin phosphate (PSP) on the phosphorylation 
of neurofilament heavy chain (NFH) and MAP kinase activation (ERK1/2) 
A number of studies have suggested that PSP is a phosphorylation promoter for many 
protein networks.91 For instance, a significant rise of the phosphorylation state was 
demonstrated for microtubule associated protein-2 (MAP-2) following exposure of the 
cultured neurons to PSP, whereas transient changes have been observed in the 
neurofilament heavy chain NFH phosphorylation after exposure of cultured neurons to 
this neurotoxin.87, 92 The NF protein subunits can be found in neurons and are considered 
to be essential protein classes for the regulation of axonal diameter,93 while MAPs 
function as stabilising agents of microtubules and the interaction with different classes 
of protein subunits can be regulated by MAPs. The hyperphosphorylation of these 
proteins can eventually affect their function and lead to failure in axonal transport, 
which can be also clearly observed in OPIDN after extensive exposure to PSP. The 
obvious changes of phosphorylation in these proteins have not been well identified. 
However, some recent investigations have proposed that PSP might induce influx of 
calcium outside cells and consequent activation of the dependent enzymes which 
mediate the mechanism of OPIDN,94 and phosphorylation of several proteins such as 
protein kinase.68 For example, calcium calmodulin-dependent protein kinases have been 
implicated in (MAP-2) and NF protein phosphorylation.95 Additionally, it was 
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demonstrated that calcium plays an essential role in the degeneration of axons in 
OPIDN after exposure to those neurotoxins.68, 91 
 Due to its ability to phosphorylate the cytoskeletal protein networks, PSP is also an 
efficient neurotoxin capable of generating pharmacological and histopathological 
effects which are common in OPIDN.68 
2.1.5 The effect of phenyl saligenin phosphate PSP on serine/threonine 
phosphorylation   
PSP was also demonstrated to have an effect on serine/threonine phosphorylation in 
experimental work using several mammalian species with high sensitivity to OPIDN 
such as pigs. Flaskos et al., 2006 showed that PSP can induce a rise in serine 
phosphorylation in the presence of calcium; thus, in addition to affecting the calcium 
balance it may also modulate calcium dependent enzymes.68 Most of this increased 
phosphorylation of serine residues occurred in tubulin with little effect on threonine 
phosphorylation. The increase of protein phosphorylation by PSP can be also compared 
with TOCP which also induced an increase in phosphorylation of - and -tubulin, 
microtubule associated protein-2 (MAP-2) and neuroﬁlament (NF) in hen brain 
cytosol.86  
2.1.6 The effect of phenyl saligenin phosphate PSP on the neurite outgrowth 
and the activity of NTE  
Hargreaves and co-workers investigated the effect of PSP on neurite outgrowth, finding 
it to be a selective inhibitor of the production of axon-like processes by differentiating 
N2a cells with no effect on outgrowth of smaller processes or cell body shape.87 PSP is 
similar to the neuropathic metabolites of TOCP,96 this was confirmed by another study 
that the in vitro inhibition of TOCP was improved by metabolic processing with 
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NADPH in rat liver.97 Furthermore, it was found that the neurite outgrowth was also 
affected by the neuropathic influence of PSP neurotoxin and in vitro cellular models 
caused complete inhibition of neurite outgrowth.98   
NTE was the first identified target of OPIDN, and was also found to be a target of PSP, 
causing an inhibition upon the exposure of mouse N2a neuronal cell line.99 It has been 
proposed that NTE may be able to hydrolyse lipids or perform as an ion channel,100, 101 
and the disruption of these functions is involved in the response to organophosphates 
exposure. 
2.1.7 The effect of phenyl saligenin phosphate on transglutaminase activity 
As was previously mentioned, PSP is able to disrupt neurite outgrowth, and the 
inhibition of neurite outgrowth level could be the result of transglutaminase enzyme 
(TGase) inhibition, which is known to be important for the proper function of 
cytoskeletal proteins.102 These studies indicated that calcium-activated TGase enzyme is 
also inhibited by the effect of PSP neurotoxin. The disruption of calcium homeostasis, 
which was proposed to be one of the early events of OPIDN, is possibly responsible for 
the calcium-dependent activation of enzymes and its disruption might cause an unusual 
level of TGase activity.103 TGase up-regulation could be further involved in a variety of 
neurodegenerative disorders including Huntington’s and also Alzheimer’s diseases.104  
TGase is implicated in the regulation of various physiological activities, which involves 
the cross linking of different protein subunits.105 According to Harris et al. (2009), the 
protein level of TGase was reduced by sub-lethal and high doses of PSP neurotoxin as 
investigated in vitro using cell lines such as mouse N2a and human hepG2 hepatoma 
(HepG2) treated with different concentrations of PSP. This can be compared with low 
concentration of PSP that showed only little or no effect on TGase inhibition. Thus, it is 
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a great of interest to determine whether the disruption of neurite outgrowth by PSP is 
generally due to the fact that PSP has the ability to modulate TGase activity.  
Taken together with the ability of organophosphates to cause transient changes in the 
phosphorylation of NFH in correlation with reduction of neurite outgrowth, it is likely 
that these agents affect not only their acute toxicity target AChE, but also other different 
and multiple protein targets.106 
2.1.8 Aim of investigation  
The mode of action of organophosphate neurotoxins is more complex than originally 
thought, with increasing evidence for the existence of novel protein targets in addition 
to the acute toxicity target AChE, and the identification of proteins targeted by these 
toxins is central to understanding the processes involved.107, 108 Based on the proposed 
mode of toxicity, many organophosphates can react covalently with proteins and other 
biomolecules.109 This is the reason why not to employ any affinity molecules with these 
molecules to build up the tool and also to investigate and prove the nature of binding, 
which is one of the priority goals of this study.  
This work seeks to construct a probe for the fluorescent tagging of biomolecules which 
bind and react with the organophosphate neurotoxin PSP, by mode of covalent 
interaction. The design is that the organophosphate neurotoxins incorporating a linker 
and fluorescent tag will be prepared, and then biological activity assays of these 
modified toxins will be verified in in order to assess the toxicity.  The active analogue 
will then be used for the identification of the parent toxin targets. It is envisaged that 
incubation of the functional probes with neuronal cell extracts followed by fluorescence 
directed chromatography will allow the isolation of the targeted proteins (Figure 24).  
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Figure 24 Strategy of organophosphate protein targeting  
 
2.2 Results and Discussion 
The aim of this work was to link the PSP to a fluorescent tag to explore which protein 
this toxin binds to. Phenyl saligenin phosphate is of interest because many studies have 
suggested that toxicity is caused by interaction with multiple biomolecules, as discussed 
above. The chemical hydrolysis of saligenin organophosphate has been studied, and the 
results were dependent on the nature of the attached R groups in the O=P-(OR)3 
molecule.110, 111 When R is a phenyl group as in the case of PSP, there are three possible 
hydrolysis products, as shown in Figure 25 A. Because the phenoxy is a good leaving 
group, a fluorescent tag linked to the aromatic phenyl ring may be subjected to cleavage 
from the PSP upon the phosphorylation of the biomolecules. However, using an alkoxy 
linker for fluorescent tag attachment gives more stability, and the fluorescent 
component should not be cleaved, as described in Figure 25 B, since the alkoxy group is 
a much poorer leaving group than the phenoxy. 
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Figure 25 Possible mechanisms of the inhibition and binding of saligenin phosphate 
with biomolecules 
Furthermore, there is evidence to suggest that the toxicity of these compounds is 
affected by the variation of the group attached to the phosphorus atom through the 
oxygen ,112 the toxicity of the PSP has been found to behave in a similar manner to the 
alkyl saligenin phosphate, which means using an alkyl linker may not affect the 
molecules activity significantly. For example, an investigation about the inhibition of 
NTE with alkyl-, alkoxy- and phenoxy- saligenin phosphate was performed by Casida, 
at.el. This study showed that the inhibition of NTE by the alkoxy-saligenin phosphate 
and phenoxy substituted material were relatively similar, giving IC50 values of 6.0 and 
4.5 nM respectively (Figure 26). 
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Figure 26 Saligenin-phosphonate and phosphate analogues 
The goal of this work was to prepare organophosphate neurotoxins incorporating linkers 
for attachment of fluorescent tag to identify novel protein targets. The biological 
activity of these modified toxins was verified by esterase assays, after which they were 
elaborated into functional probes to identify the targets of the parent toxins (Figure 27).  
 
 
Figure 27 Organophosphate neurotoxin linked with fluorescent tag 
 
2.2.1 Synthesis of phenyl saligenin phosphate 
 Synthesis work commenced with preparation of the parent PSP as a model reaction and 
for the purposes of toxicity tests. In a modification of a published procedure, 
commercially available 4-hydroxybenzyl alcohol (saligenin) was treated with phenyl 
phosphorodichloridate with triethylamine. This reaction successfully gave (PSP) phenyl 
saligenin phosphate 1 in a good yield (70%) after recrystallization (Scheme 2.1). 
Confirmation that this product was obtained was by 
1
H NMR spectra, which showed 
that there were no peaks arising from starting materials, and a complex splitting pattern 
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was seen and multiplet observed at 5.25-5.36 ppm for CH2-O-P protons; in addition to a 
multiplet at 7.12-7.26 ppm for protons in the aromatic rings. Also, the 
13
C NMR spectra 
showed a noticable shift in the region of CH2 carbon, from 64.6 ppm of the starting 
material to 69.3 ppm of the PSP product. Further the 
31
P NMR spectra showed only one 
signal peak at -15.31 ppm, corresponding to an oxygenated tetrahedral phosphorus 
atom. 
                
2.2.2 Preparation of 2-chloro-4H-benzo[d] [1, 3, 2]dioxaphosphinine 2-oxide 
To finish binding the organophosphate with a linker for a further step of attachment to a 
fluorescent tag, compound 2 was successfully prepared by a treatment of a mixture of 4-
hydroxybenzyl alcohol and triethylamine with phosphorus oxychloride (POCl3) to yield 
the desired compound in a good yield of 91%.113 Pure product 2 was isolated after 
filtering the precipitate of triethylammonium chloride from dry toluene and the product 
used directly in the next step (Scheme 2.2). Because of the instability of this product 
even after being stored in the freezer, it was always necessary to use freshly prepared 
material.     
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Product 2 was confirmed from the 
1
H NMR spectra, which showed a complex splitting 
pattern and multiplet at 5.4-5.5 ppm belonging to CH2-O-P, also the 
13
C spectra showed 
a peak at 70.1 ppm for the CH2-O-P. Further the 
31
P NMR spectra showed one single 
diagnostic peak at -5.5 ppm belonging to the phosphorus atom.    
2.2.3 Reaction of saligenin phosphate with 1, 6 hexane diol 
The first objective after preparation of saligenin phosphate chloride 2 was to attach it to 
a fluorescent tag via linker. The six carbon alkyl chain was the linker of choice. Thus, 
1,6 hexane diol was reacted with freshly prepared compound 2 (Scheme 2.3), but, the 
product was a complex mixture and the NMR spectra for the crude material did not give 
clear evidence for production of the desired compound. In addition, purification using a 
silica flash chromatography was not a suitable method for the separation, even by using 
very polar solvents.    
 
 
2.2.4 Preparation of saligenin phosphate with a linker for attachment to a 
fluorescent tag 
For simplicity a six carbon chain alkyl linker was chosen for the attachment with the 
fluorescent tag. 1, 6-Aminohexanol contains two reactive functions, a hydroxyl group 
that will react with the chloride attached to the phosphorus atom to create the phosphate, 
and the other side provides amine group to facilitate the attachment with the fluorescent 
51 
 
component (dansyl chloride). In order to prevent preferential amidate   formation, 
protection of the amine group was carried out. Treatment of 1, 6-aminohexanol with 
commercially available di-tert-butyl dicarbonate gave the desired compound 3 in yield 
of 99% (Scheme 2.4). The product was confirmed from the 
1
H NMR spectra where a 
peak at 1.38 ppm belonging to the BOC group and a peak at 4.61 ppm for HN-CO. The 
13
C NMR spectrum showed a diagnostic peak for the carbonyl group at 156 ppm and 
peak at 79 ppm belonging to the central carbon of the t-butyl group.  
 
 
 
The second step of the preparation, treated the freshly prepared saligenin phosphate 2 
with product 3 under variety of different conditions. A number of bases (NaH, Et3N, 
pyridine) were used however, no evidence of product formation was observed in 
31
P and 
1
H NMR spectra and mixtures were obtained that were highly polar and not suitable for 
chromatography with silica gel (Scheme 2.5).   
 
 
 
Examination of the 
31
P NMR spectra indicated that a tetrahedral phosphate compound 
was formed, along with other phosphorus containing compounds, while the 
1
H NMR 
spectra showed a number of compounds. Silica chromatography of the mixtures was 
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hampered by the high polarity of the materials and poor yields of a mixture of 
unidentified compounds were obtained. Investigation then turned to alternative 
strategies for linking the PSP moiety to the fluorescent component.  
2.2.5 Preparation of BODIPY- FL fluorescent component with linker  
There are many advantages of using BODIPY fluorescent derivatives, such as the high 
extinction coefﬁcients, excellent photostability and high ﬂuorescence quantum yields. A 
number of studies on fluorescence have suggested that BODIPY derivatives are highly 
recommended fluorophore for many macromolecule visualization applications including 
proteins.114 Thus, a first attempt was made to bind saligenin phosphate with BODIPY-
FL via alkyl linker, starting from compound 2 to gain the desired molecule ready for 
biological application (Figure 28). 
  
 
Figure 28  Saligenin phosphate with BODIPY via alkyl linker 
BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) has been prepared starting from  
commercially available 1H-pyrrole-2-carbaldehyde which was treated with ethyl 2-
(diethoxymethyl)hydrophosphoryl)acetate to give the product 4. This product was then 
reduced by catalytic hydrogenation,115 producing 5 in yield of 98% (Scheme 2.6).    
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 Further, the starting material 2-formyl-3,5-dimethylpyrrole 6 was prepared by reacting 
2,4-dimethylpyrrole with phosphorus oxychloride and N,N-dimethylformamide 
followed by a treatment with sodium acetate, producing compound 6 in 74% yield. With 
compound 5 in hand, condensation reaction with 2-formyl-3,5-dimethylpyrrole 6 in 
presence of POCl3 was carried out. The intermediate obtained was then reacted with 
BF3.OEt2 and DIPEA, giving the desired BODIPY- ester 7 with a yield of 63% after 
flash chromatography purification. The ester product 7 was then hydrolysed with 4 M 
HCl in dioxane yielding BODIPY acid 8 in yield of 89% after chromatography 
purification (Scheme 2.7). The identity of the final product was confirmed from the 
NMR data which were consistent with the literature.116      
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The coupling of the BODIPY 8 to alkyl linker was then briefly explored. A reaction of 
BODIPY 8 with commercially available 1-amino-6-hexanol was applied with 
employment of N-methylmorpholine and isobutylchroroformate. However, the NMR 
data for the crude product showed no evidence for the desired product formation 
(Scheme 2.8). Further work in preparing this fluorescent tag with linker was not 
pursued. 
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2.2.6 Dansylamide with PEG linker 
In order to investigate the impact of using a PEG spacer linker, preparation of 
dansylamide 10 was explored. Commercially available dansyl chloride was treated with 
liquid ammonia giving dansylamide 9 in yield of 87%. This product was confirmed 
from the NMR data which was consistent with the literature.117 The product 9 was then 
refluxed with commercially available 2-[2-(2-chloroethoxy)ethoxy]ethanol and 
potassium carbonate to give a 1:1 mixture of mono and di-PEG dansylamide 10 and 10a 
in yield of 32% and 33%, respectively, despite the fact that the reactant materials had 
been used in ratio of 1:1 equivalent (Scheme 2.9). This suggests that mono substituted 
sulfonamide 10 might be more reactive than the sulfonamide 9. Further evidence to 
support this was confirmed when the reaction was performed at room temperature and 
the product was more than 90% di-substituted 10a. Therefore perhaps it might be a 
good suggestion if product 9 could be firstly protected via acylation reaction followed 
by addition of 2-[2-(2-chloroethoxy)ethoxy]ethanol, to direct the reaction undergoing a 
mono-substitution product. The identity of compound 10 was evidenced from the 
1
H 
NMR spectra, showing a triplet peak at 6.08 ppm for one proton of SO2-NH and HR-
MS gave a mass consistent with the structure.  
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2.2.7 Dansylamide with six carbon alkyl linker 
Following the successful preparation of the PEG linker, the coupling the dansylamide to 
the saligenin phosphorochloridate 2 via an alkyl linker was next considered, in order to 
compare the effects of different linker properties on the biological activity.      
In order to prepare a six carbon atom linker, a reaction starting from 1, 6-aminohexanol 
with dansyl chloride in the presence of triethylamine and DMAP produced sulfonamide 
12 in yield of 81% after chromatography. This compound was evidenced from 
1
H NMR 
spectra which showed multiplet peaks at 1.08, 1.29 and 1.80 ppm belonging to the 
aliphatic chain, also a triplet peak at 5.15 ppm for NH, and the mass spectrometry data 
confirmed the chemical structure (Scheme 2.10). 
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2.2.8 Coupling the organophosphate compound with the florescent tag 
In order to couple compound 10 with saligenin phosphochloride 2, various reaction 
conditions were applied, for example triethylamine at -78 
o
C in DCM, sodium hydride 
at -20 
o
C in THF, and pyridine in DCM at -78 
o
C. However by looking to the NMR 
spectra for the crude product, there was no clear evidence that the desired compound 
was produced (Scheme 2.11).    
 
 
 
The reaction of the dansylamide 10 with saligenin phosphochloridate 2 was not 
successful, so an alternative plan was established to try attaching the phosphochloridate 
group to the linker first, followed by reaction with 2-hydroxybenzyl alcohol. 
Phosphorus oxychloride was reacted with 2-[2-(2-chloroethoxy)ethoxy]ethanol in ratio 
58 
 
of 3: 1 equivalents, respectively, in the presence of triethylamine. The product obtained 
was not the desired product but unexpectedly gave 1,2-bis(2-chloroethoxy)ethane, 
exhibiting three peaks in the 
13
C NMR spectrum for the symmetrical compound product 
(Scheme 2.12). The identity was confirmed by a comparison of spectroscopic data with 
the literature.118 
 
 
 
2.2.9 Coupling the organophosphate compound 2 with dansyl amide 12 
Finally, after the unsuccessful coupling with dansylamide 10, linking of the 
dansylamide 12 to the saligenin phosphochloridate 2 was achieved by means of a six 
carbon atom alkyl linker. The reaction of dansyl amide 12 with saligenin 
phosphochloridate 8 successfully gave dansylated saligenin phosphate 13 in yield of 
22% after flash chromatography purification (Scheme 2.13). Despite the poor yield, the 
product was easily purified over silica gel. The 
1
H NMR spectrum exhibited a difficult 
to recognise ABX pattern with coupling to phosphorus of three bands 14.8, 19.2 and 7.6 
Hz of the CH2 protons coupled to P=O at 5.30 ppm (Figure 29). The 
31
P NMR spectra, 
which showed a single peak at - 8.87 ppm for the phosphorus atom and HR-MS analysis 
data, are also consistent with the structure.  
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Figure 29 NMR spectra for compound 13 
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2.2.10 Biological testing  
In collaboration with Dr Alan Hargreaves, studies have been undertaken into the 
inhibition of several enzymes by phenyl saligenin phosphate. Prior to studying the 
biological effects of the prepared dansylated saligenin phosphate, the biochemical 
effects of non-dansylated PSP on serine hydrolase enzymes were studied using the 
known targets, trypsin and chymotrypsin, in an activity assay. 
Furthermore, transglutaminase 2 is a suspected target of the PSP and the inhibition of 
this enzyme has also now been studied. In support of these studies, the fluorescent 
tagging was expected to confirm the covalent inhibition of this enzyme with PSP.  
2.2.10.1 Effect of PSP on the inhibition of trypsin 
Saligenin phosphate is known to inhibit the serine protease trypsin, and a colorimetric 
assay was used to confirm inhibition of the enzyme by PSP. Trypsin (0.025 mg/ml) was 
pre-incubated with PSP of various concentrations, and then the indicator substrate 
benzyl-L- arginine 4-nitroaniline hydrochloride, was introduced. Active trypsin cleaves 
the substrate producing p-nitroaniline which can be observed at 415 nm (Figure 30), and 
the concentration of the released p-nitroaniline indicates the enzyme activity, and the 
effect of the PSP on the trypsin activity. 
  
 
 
Figure 30 Cleavage site and reaction product released by trypsin  
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From the assay results obtained, it can be seen that the activity of trypsin was 
significantly inhibited by the increasing of the PSP concentration. The initial effect 
could be seen with PSP concentration of 10 M while nearly complete inhibition was 
observed at 50 M (Figure 31). 
 
 
Figure 31 Effect of PSP on trypsin activity 
 
2.2.10.2 Effect of PSP on the inhibition of Chymotrypsin 
A similar assay to that used for trypsin was applied to chymotrypsin, in order to assess 
the PSP inhibition of the enzyme. Using the indicator substrate the N-Succinyl- Gly- 
Gly- Phe-p- nitroanilide, selective cleavage occurs on the carboxy terminal side of the 
phenylalanine residues releasing p-nitroaniline, as in the trypsin assay (Figure 32). 
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Figure 32 Cleavage site and substrate released by chymotrypsin 
 
Similar incubation experiments confirmed that PSP was a potent inhibitor of 
chymotrypsin with significant inhibition at a PSP concentration of only 0.5 M and the 
complete inhibition at 6.2 M (Figure 33). 
 
Figure 33 Effect of PSP on chymotrypsin activity 
2.2.10.3 Effect of PSP on the inhibition of Transglutaminase 2 activity 
TGase 2 catalyses the amination of protein-bound glutamine residues, an assay for 
TGase activity developed by Slaughter,119 was employed to assess inhibition of this 
enzyme by PSP. Purified samples of TGase 2 were pre-incubated at room temperature 
for 15 min with different PSP concentrations, before performing the biotin cadaverine 
assay to elucidate the effect of TGase 2 activity. The principle of this assay is to use N-
N’-dimethyl casein as the amine acceptor substrate and biotin-cadaverine as an amine 
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donor. In the 1st step, TGase is primed to catalyse the covalent addition of biotinylated 
cadaverine to N-N’-dimethyl casein that has already been coupled to the microtite plate. 
In the second step, streptavidin-coupled peroxidase is added to the wells and 
immobilised through the interaction with biotin. The amount of biotinylated casein is 
then measured by means of a coupled peroxidation reaction. The peroxidase is activated 
using H2O2 in presence of tetramethyl benzidine as electron acceptor (chromogen), and 
once the reaction has been stopped by the addition of sulphuric acid, the initial TGase 
activity is measured by the absorbance at 450 nm (Figure 34). 
 
 
 
 
Figure 34 Biotin cadaverine assay for TGase 2 activity 
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In these experiments it was found that the PSP could inhibit TGase activity, and the 
results showed a discernible effect on the activity compared to the control at 0.09 M to 
about 50% inhibition at 6.25 M of PSP. The TGase inhibition by PSP was 
concentration dependent (Figure 35).    
 
 
Figure 35 In vitro effects of different concentrations of PSP on TGase 2 activity 
 
2.2.10.4 Gel electrophoresis and UV transillumination for dansylated PSP 13 
Given the observed effect of the PSP on the activity of the three enzymes, as previously 
described, it was envisaged that these purified enzymes would provide an effective test 
for the tagging ability of the labelled saligenin phosphate. The strategy in choosing 
these enzymes is that the first two enzymes are established targets of PSP, while TGase 
2 is thought to be a target of the same molecule.120 Dansylated saligenin phosphate 13 
was incubated with both trypsin and chymotrypsin then subjected to one dimensional 
gel electrophoresis. Any dansylated organophosphate 13 covalently bound to these 
target enzymes was then visualized using UV light. Due to the denaturing gel 
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electrophoresis conditions, only covalently labelled proteins should appear a fluorescent 
bands and unreacted neutral labelling compound will not move on the gel. 
i) Trypsin and chymotrypsin gel electrophoresis   
In the event, trypsin and chymotrypsin enzymes of 1mg/ml concentration were 
incubated with 50 µM dansylated saligenin phosphate for 15 minutes, and then the 
samples were electrophoretically separated on the gel. The visualization step was 
carried out using a UV transilluminator, showing clear fluorescent bands for the 
organophosphate labelled enzyme. In quantitative terms, the labelled saligenin 
phosphate was covalently bonded to both enzymes; however, binding with the 
chymotrypsin gave much brighter bands than with trypsin. This finding is in agreement 
with the previous work where saligenin phosphate was a more potent inhibitor of 
chymotrypsin than trypsin (Figure 36).    
 
Figure 36 Incubation of dansylated saligenin phosphate with trypsin and chymotrypsin 
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ii) Transglutaminase 2  Gel electrophoresis 
A similar experiment was then carried out using purified transglutaminase 2. The 
enzyme, 1mg/ml concentration, was incubated with dansylated saligenin phosphate 13, 
then the samples loaded on a gel and separated by electrophoresis, and the gel was then 
visualized using a UV transilluminator. Examination of the gel showed a fluorescent 
band at a position consistent with the molecular weight of the enzyme target and 
confirmed that this enzyme was covalently bound to saligenin phosphate, in agreement 
with the inhibition studies (Figure 37).     
 
Figure 37 a) fluorescent band of dansylated saligenin phosphate with TGase2,  
b) TGase band with coomassie blue stain 
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2.3 Conclusion  
The enzyme targets of the organophosphate toxin “saligenin phosphate” have been 
investigated. Saligenin phosphate was coupled to a fluorescent tag via an alkyl chain 
linker.  
In collaboration work, biological investigation on the inhibition of PSP molecule has 
been performed by means of established assays of saligenin phosphate 13 enzyme 
interactions. The inhibition of known PSP targets trypsin and chymotrypsin enzymes 
was established along with evidence for the inhibition of a new target, transglutaminase 
2 enzyme. 
Subsequent inhibition experiments using the fluorescent probe showed labelling of all 
three enzymes with fluorescent bands observed in all cases. This labelling was also 
confirmed the covalent binding of the PSP with the enzymes investigated. The 
experiments demonstrate the utility of using this tagging method for determination of 
the enzyme targets of PSP, and as a result method will find use in discovering novel 
targets of PSP, similar approaches may also be useful with organophosphates in general.  
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3. Chapter 3: The mKATP activator “diazoxide”  
 
1.  Introduction 
 
Heart disease is one of the major causes of mortality and disability in the western 
world.121 The most common type of heart disease affects the arteries feeding the heart, 
and is termed coronary artery disease (CAD). This disease is caused by a blockage or 
narrowing the arteries by accumulation of lipid-containing plaques on the innermost 
layer of the walls of the coronary arteries. The heart muscle fed by these blocked 
arteries is damaged because of a lack of oxygen and blood supply.122 This condition 
affecting these arteries causes heart muscle injury called ischaemia heart syndrome, 
which may cause early death through heart attacks. In this event, much damage is 
caused not by initial loss of oxygen supply but during oxygen resupply to the heart 
tissue, and this is named myocardial reperfusion injury. Ischaemia injury happens when 
the blood supply to an area of tissue is discontinued. The time a tissue can survive a 
lack of oxygen differs, but eventually all ischaemic tissue becomes necrotic. Restoration 
of the blood supply should decrease the damage,123 but studies of reperfused tissues after 
blockage led to the discovery that the level of injury often increased when the blood 
supply was restored. It has been proposed that this additional damage, reperfusion 
injury (IR), is due to the activity of oxygen free radicals.124 Generally, the anti-oxidant 
protection systems in the aerobic myocardium can dispose of the oxygen free radicals. 
However, ischaemia decreases this ability, particularly in the mitochondrial 
compartment, causing the tissue to be highly subjected to damage.125 
The mechanism of causing such damage may be that lack of oxygen can lead to an 
accumulation of metabolic intermediates,126 during the reperfusion these intermediates 
react causing a rapid increase in oxygen radicals (H2O2, O2
-
 and 
.
OH). This increase can 
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result in overcome cellular defences causing uncontrolled oxidation of cell components, 
leading to cell death.127 Investigating novel ways of protecting the heart from this 
damage is a major research objective.  
3.1.2 Introduction to cardioprotection 
Cardioprotection works to find mechanisms and to preserve the heart through 
decreasing or even avoiding myocardial injury. The event of this protection can occur 
by two types of interventions. First is the endogenous activation which includes many 
phenomena such as classical ischaemic preconditioning, second-window or delayed 
ischaemic preconditioning and ischaemic postconditioning and their pharmacological 
recruitment. The latter involves the use of pharmacological agents to directly activate 
the signalling pathways involved in cardioprotection. Second is the surgical intervention. 
3.1.2.1 Ischaemia preconditioning 
Ischaemic preconditioning (classical preconditioning) is a powerful method of 
endogenous protection, and was first described by Murry and co-workers as a short-
term period of intermittent ischemia and reperfusion before a prolonged ischaemic event 
which can give protection from cellular damage.128 The first ischaemia event activates 
several signal transduction pathways, which help to keep myocytes contractility and 
function.129 Current preconditioning has been achieved by applying stimuli directly to 
the heart muscle. It has also been discovered that ischaemia at a site distant to the heart 
may give the similar protection through circulating or neural mediators produced from 
distant tissues exposed to ischaemia.130 It has been suggested that ischaemia 
preconditioning (PC) leads to cardioprotection.131 
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3.1.2.2 Second window of ischaemic preconditioning (SWOP) 
There is another phase of preconditioning which occurs after a longer time than the first 
phase, which is between 24 to 72 hours after the reperfusion, and this later phase of 
preconditioning is called the second window of ischaemic preconditioning (SWOP). 
This phenomenon has been observed in many species such as dogs, rabbits and rat 
hearts,132, 133 however, it has not been found to occur in pig hearts.134 Protection triggered 
by delayed preconditioning is thought to involve the prevention of the mitochondrial 
permeability transition pore opening by up-regulation of Bcl-2 expression.135 Bcl-2 is 
member of the regulatory proteins that control apoptotic cell death,136  
3.1.2.3 Ischaemic post-conditioning  
In addition to the phenomena of classical and delayed ischaemic preconditioning, a third 
phenomenon of ischaemic postconditioning has also been observed. Ischaemic 
postconditioning involves the gradual restoration of reperfusion (short periods of 
reperfusion) following an ischaemic insult and was first reported by Zhao et al. 
(2003).137 It is apparent that the signalling mechanisms associated with ischaemic 
preconditioning and ischaemic postconditioning are very similar.138 For example, 
reactive oxygen species may play a role in the protection as activators in the initial 
phase of postconditioning.139 Also, postconditioning was found to be effective in 
reducing the generation of superoxide anion (
-
O2) in vivo in post-ischaemic 
myocardium.137 Reduction of reactive oxygen species can be effected by increasing the 
endogenous anti-oxidant mechanisms of the myocardium.140 In addition KATP channels 
and protein kinase C pathways are also thought to act as mediators.141 
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3.1.2.4 Role of the mitochondria in cardioprotection  
Cardiac muscle cells have high numbers of mitochondria due to the dependence of heart 
tissue on oxidative phosphorylation.142 It is now clear that mitochondria are also central 
to the process causing cell death after ischaemia/reperfusion (I/R) injury.143 Therefore, 
mitochondria have been identified as a key player in building a strategy of protection 
against I/R injury. 
Activation of the mitochondrial ATP-sensitive potassium channel (mKATP) has a 
protective effect against many types of ischaemia.144 The opening and closure of KATP 
channels is regulated by the ATP and ADP levels in cells, and therefore, the membrane 
potential is coupled to the metabolic process of the cell.145 Functions of KATP channels 
include regulation of numerous physiological functions such as secretion, 
neurotransmission, contraction, and control of cell volume. In the mitochondria, mKATP 
is implicated in improvement of resistance for many injuries, for instance induction of 
apoptosis caused by a variety of stimuli.146 Much interest has recently concentrated on a 
supposed mitochondrial KATP channel assumed to have an action in cytoprotection and 
myocardial preconditioning in variety of tissues; however the identity of the channel 
subunits remains unclear.147, 148 
3.1.2.5 Pharmacological preconditioning by diazoxide (PPC) 
There are many studies suggesting that protection of the myocardium against ischaemia-
reperfusion damage follows from activation of ATP sensitive potassium (KATP) 
channels.149Opening of the mKATP channels with the small molecule channel activator 
diazoxide can help in the early and delayed phases of preconditioning after ischaemia–
reperfusion in rabbits.150 This effect was also confirmed by applying the selective 
mKATP channel blocker sodium 5-hydroxydecanoate (5-HD), which prevented the 
protective effect of diazoxide. As a result, drugs with potassium channel opening 
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properties appear to have a broad clinical potential in pharmacological preconditioning 
during the ischemia/reperfusion injury. In addition, the treatment with diazoxide can 
also improve production of reactive oxygen species (ROS) which are thought to play an 
important role in cardioprotection. This effect suggests that the cardioprotective 
properties of diazoxide are mediated by the generation of pro-oxidants. However, the 
mechanism(s) of this cardioprotection are not fully understood and discovering the 
mechanism will enhance the potential treatment applications of this drug. 
3.1.3 Potassium channel activation and diazoxide 
The mKATP channel was first discovered in rat liver by Inoue et al.
151 and Keith Garlid’s 
group first isolated and characterized the mKATP channel found in the internal 
membrane of cow heart.152 Grover and Garlid have since demonstrated that this channel 
was responsible for the cardioprotection action of KATP channel openers.
153 
Previous studies showed a poor correlation between sarcolemmal K
+
 currents and 
cardioprotection for ATP-sensitive K
+
 channel (KATP) openers. It has also been found 
that all the KATP openers can cause mitochondrial oxidation. Nevertheless, the KATP 
opener pinacidil for example stimulates these channels in the surface membrane, while 
diazoxide can particularly open the channels in mitochondria but not activate the 
sarcolemmal KATP. This discovery is compatible with the recognized pharmacology of 
several KATP channel drugs, which shows that diazoxide is the only selective drug for 
the mitoKATP channel.
154 This selectivity of diazoxide can make it a powerful tool for 
investigating the actual mechanism of the cardioprotection and the molecular 
composition of these channels.153 Moreover, it has been shown that the mKATP of cow 
heart varied in the sensitivity towards diazoxide, indicating heterogeneity amongst 
mKATP channels.
155 Although diazoxide is of distinctly lower potency than newer 
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hypotensive vasodilators like Cromakalim or Pinacidil in opening smooth muscle K
+
-
channels, it is still a drug of great interest (Figure 38).156 
 
Figure 38 Hypotensive vasodilators; Diazoxide, Cromakalim and Pinacidil 
The KATP channel opener diazoxide can provide the cardioprotection effect by opening 
mitochondrial KATP channels, which leads to relaxation in smooth muscles by increasing 
membrane permeability to potassium ions. This switches off voltage-gated calcium ion 
channels which inhibits the generation of an action potential. KATP channels are thought 
to play a key role in the cardioprotection with both KATP channel openers and ischaemic 
preconditioning, since in both cases, protection can be blocked by KATP channel 
blockers such as glibenclamide or sodium 5-hydroxydecanoate (5-HD) (Figure 39).157 
 
Figure 39 KATP  blockers; Glibenclamide and Sodium 5-hydroxydecanoate 
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Diazoxide is also used as a vasodilator in the treatment of acute hypertension or 
malignant hypertension.158 Diazoxide is often used in concentrations of up to several 
hundred µM to achieve a maximal opening of KATP channels and possible other effects 
are hardly ever taken into account.159 
3.1.4 Structure of the mK
ATP 
channel  
Although the mKATP channel was first discovered in 1991, its structure and 
cardioprotection mechanism(s) of action are still poorly understood. Pharmacologically, 
mKATP can be activated and targeted by diazoxide, which can also activate the 
sarcolemmal KATP in the presence of ADP.
160 Diazoxide can also modulate the rat heart 
sarcolemmal KATP channel.
161 The similar pharmacological action between these two 
KATP channels might suggest that the mKATP channel consists of the sulfonylurea 
receptors (SUR1, SUR2A, SUR2B) and the pore forming  subunits (Kir6.1 and Kir6.2) 
as is the case with sarcolemmal KATP channels.
162 However, experiments using 
mitochondrial-targeted SUR1 knock-out mice have revealed that diazoxide still induces 
protection against ischaemia-induced brain injury. These effects are also blocked by 5-
HD showing that the SUR1 is not an effective component in the mKATP channel.
163 
Moreover, another study using isolated rabbit myocytes has shown that transfection of a 
dominant negative construct of Kir6.1 did not modify the mKATP channel function, 
which is clear evidence that Kir6.1 is not one of the channel components.164 It was also 
proposed that the mKATP channel contains ATP synthetase, adenine nucleotide 
translocator, mitochondrial ATP-binding cassette protein 1, phosphate carrier and 
succinate dehydrogenase (Figure 40),165 if this is the case the mitoKATP has completely 
different structure to the sarcolemmal KATP. The identification of the exact molecular 
structure of this channel will help in understanding the role of mKATP channels in 
cardioprotection and aid of development of selective drugs targeting this channel. 
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SDH: Succinate dehydrogenase 
mABC1: Mitochondrial ATP-binding cassette protein-1 
ANT: Adenine nucleotide translocator 
PIC: Mitochondrial phosphate carrier 
IMS: Intermembrane space 
Mito IM: Inner mitochondrial membrane 
Matrix: Viscous space contains ptoteins, DNA and ribosomes  
 
 
Figure 40 Proposal Structure of the mitoKATP channel 
3.1.5 Aim of investigation  
The aim of this work is to fluorescently label proteins which bind the “selective” mKATP 
channel opener diazoxide and potentially identify the associated proteins. This will be 
achieved by preparing a photochemical harpoon linked to fluorescent components and 
diazoxide bait, which will covalently label the targeted proteins (Figure 41). 
 
Figure 41 Identification strategy for the protein target of drug molecule 
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In pursuit of a chemical approach to identify the nature of the mKATP channel of the 
targeted by diazoxide, it was proposed to construct a chemical molecule which  consists 
of four components: (a) a small biologically active ‘bait’ molecule which selectively 
binds to a specific protein target; (b) a photochemically activated reactive ‘barb’ 
component, which upon irradiation will covalently bond to an adjacent protein 
backbone (via a carbene or nitrene reactive intermediate); (c) a fluorescent tag attached 
to the photoreactive ‘barb’ component; and (d) a flexible linker between the bait and 
reactive barb/tag components.  
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3.2 Results and discussion 
Diazoxide activates a wide number of K channels in a variety of tissue types, and 
structure activity relationships with different receptors and tissues have been studied. In 
1994 Patrick Jimonet et al. synthesised and tested the activity of 2H-1,2,4-
Benzothiadiazine-1,l-dioxide-3-carboxylic acid derivatives as an antagonists of the 
NMDA (N-methyl-D-aspartate) receptor-channel.166 Comparing to the analogue with 
(R1, R2, R3= H) the affinity is greatly enhanced by appropriate introduction of chlorine 
atom(s) to the phenyl ring in position(s) 5 and 7 as in the followed structure.167 
 
In 2003 Smail Khelili et al. synthesised and evaluated diazoxide derivatives bearing NH 
group or sulfonylurea on positions 5 and 7.168 The compounds efficiency was compared 
with the KATP channel openers diazoxide and Cromakalim in an assay examining the 
vasodilatory effects. Substitutions on these positions by means of NH group produced 
molecules of low efficiency, however, when sulfonylurea moiety was attached through 
a SO2 group on position 7, potent vasodilators were obtained. 
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In other study, Pascal de Tullio et al.169 have synthesized pyridothiadiazines and 
benzothiadiazines bearing a variety of 3- or 4-alkyl and 3-aminoalkyl side chains. These 
benzothiadiazines as well as the pyridothiadiazines were tested vs diazoxide as 
inhibitors of insulin release on pancreatic B-cells and as vasorelaxants on isolated rat 
aorta. The pyridothiadiazines compounds were found to be powerful inhibitors of 
insulin release and are clearly more selective than their benzothiadiazines 
chlorobenzenic homolog compounds or than diazoxide. 
 
In 2010, Bernard Pirotte et al. demonstrated that the position of the chlorine atom on the 
benzene ring strongly affected the potency and selectivity toward pancreatic type KATP 
channels.170 The best position for a chlorine atom on the aromatic ring of 3-
alkylamino/cycloalkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides is the 6- rather 
than the 7-position. 6-Chloro-3-alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide 
emerged as potent and highly selective pancreatic β-cell KATP channel openers, while 
the compounds bearing chlorine atom at the 5-position of the aromatic ring, were found 
to be almost inactive, at all the nature of the alkylamino side chain at the 3-positionn.  
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The linking of the essential components of the chemical tool of investigation was the 
first priority. Thus, it was envisaged that the use of nitrogen atom junction would 
engender synthetic versatility and exceptional atom economy in connecting the three 
components. Because dansylamide was initially chosen as the fluorescent component, 
the linking of components was preformed via di alkylation of the sulfonamide group.  
Overall, there is broad scope in the choice photoreactive ‘barb’ and fluorescent tag 
components for incorporation into a harpoon via a linker. In this work it was proposed 
to prepare simple fluorophore (dansyl) linked to -trifluorodiazirene or benzophenone 
photoreactive component to create hybrid fluorescent tagging molecules with suitable 
functionality for rapid coupling and linking to the bioactive ‘bait’ diazoxide (Figure 42).   
 
Figure 42 Modular linked photoreactive barb and fluorescent tag with a small binding 
bait molecule 
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3.2.1 Preparing the Photoaffinity compound (-trifluoro diazirine) 
Based on the precedent work, -trifluoro diazirine has been chosen as a photoreactive 
molecule (Figure 43), because of the small molecule size and short irradiation time, 
which give use of this molecule more advantage. 
 
 
Figure 43 Retrosynthesis of diazirine 
Following literature precedent, the preparation of diazirine started from commercially 
available 4-bromobenzyl alcohol. The synthesis commenced with protection of the 
hydroxyl group of the starting material by treatment with tert-butyldimethylsilyl 
chloride and imidazole to give silylether 14 in a good yield of 78%, after purification by 
flash chromatography.  
Trifluoroacetylation was then investigated. The reported conditions171 of reaction with 
1.1 eq n-BuLi with aryl bromide 14 for one hour and half and quenching with 
trifluoromethyl acetate gave only a low yield of ketone 15 with < 10% conversion of the 
starting material. Substitution of 1-trifluoroacetyl piperidine for trifluoromethyl acetate 
had no effect and the yield remained poor with low conversion. In order to improve the 
transmetalation step, the reaction time and molar equivalence of n-BuLi were increased 
to 5 eq and the reaction time increased to 4 hours. Subsequent treatment with excess of 
trifluoro acetate led to high conversion and good yield (87%) of ketone 15 after 
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chromatography. The addition of 2 and 3 equivalents of n-BuLi did not enhance the 
yield. The structure of product 15 was confirmed from 
1
H NMR data and showed that 
the aromatic protons chemical shift changed from 7.16 and 7.41 ppm for 14 to 7.53 and 
8.07 ppm for 15. The presence of the CF3 group was apparent in the 
13
C NMR spectrum 
and a quartet was observed at chemical shift with 
1
J = 180 Hz belonging to CF3. The 
reaction was most easily monitored by 
19F NMR data which showed a single peak at δF: 
-71.2 ppm (Scheme 3.1). 
 
 
With ketone 15 in hand, elaboration to diazirine was carried out by condensation of the 
ketone 15 with hydroxylamine in pyridine, to give hydroxyl oxime 16 as a single 
diastereoisomer in a yield of 86% after chromatography. The product structure was 
confirmed from 
1
H NMR data where it is clear that there the OH functionality gives a 
relatively broad peak at 8.85 to 8.96 ppm. 
13
C NMR data showed a quartet at 119.6 ppm 
belonging to CF3, and a quartet at 146.8 ppm for the (CCF3). The 
19
F NMR showed a 
significantly shifted signal at -66.4 ppm compared with the starting material. 
Based on precedent,172 the product 16 can be exist as either the E/Z diastereoisomer. 
Comparing to the 
13
C chemical shift of CF3 group of oxime analogues E and Z, δC 
=119.6 and 124 ppm respectively,173 suggested that the compound 16 has the E 
configuration (Figure 44). 
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Figure 44 
13
C NMR for E and Z diastereoisomer 
Tosylation of 16 with p-toluenesulfonyl chloride gave 17 in yield of 95% after 
purification by column chromatography, which was confirmed from 
1
H NMR data that 
showed a single peak belonging to the tosyl methyl group at 2.35 ppm (Scheme 3.2). 
 
 Product 17 was then treated with liquid ammonia to yield diaziridine 18 in yield of 
63% after chromatographic purification. The identity was confirmed from the 
1
H NMR 
data using d-chloroform where two doublet peaks at 2.20 and 2.76 ppm belonging to 
HN-NH functionality can be seen. Because of these separate doublet peaks, those 
protons are in opposite sides on the diaziridine ring as in S3 and S4 and the compound 
exists as a pair of C2-symmetric conformer, shown in Figure 45, also, the 
13
C NMR 
spectrum showed quartet peak at 58 ppm belonging to CF3 and the 
19
F NMR showed 
single peak at δF -75.5 ppm. 
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Figure 45: Symmetric possible isomers of compound 19 
A successful cleavage of the tert-butyldimethylsilyl protection group was obtained by 
treatment of diaziridine 18 with TBAF, in the presence of water to give 60% of the 
hydroxyl diaziridine 19 (Scheme 3.3). Structure of product 19 was evidenced from the 
absence of the signals in the 
1
H NMR data related to the tert-butyldimethylsilyl 
protection group, while a peak at 1.82 ppm was observed belonging to the OH group 
using d-chloroform and a similar confirmation of HN-NH protons was obtained.  
 
 
Finally the diazirine was prepared via a successful oxidation of diaziridine 18 with 
molecular iodine, and diazirine 20 was obtained in good 61% yield. Deprotection of 
diazirine 20 by treatment with TBAF, in the presence of water led to less than 50% 
conversion. A successful cleavage reaction was achieved by a treatment of 4M HCl in 
dioxane and yielded compound 21 as pale yellow oil in a good 81% yield (Scheme 3.4). 
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Compound 21 was confirmed from the 
1
H NMR data where diagnostic doublets peaks 
of the NH-NH group were now absent, and also 
13
C  NMR spectrum showed a 
significant shifting of the quartet peak of the CF3 from 58 to 28 ppm due to significant 
anisotropic shielding of the carbon by the N=N, while the 
19
F NMR spectrum gave a 
singlet at -65 ppm. 
Bromo diazirine 22 was prepared by reacting hydroxyl diazirine 21 with carbon 
tetrabromide in presence of triphenylphosphine and gave the desired product in an 
excellent yield of 96% after the purification (Scheme 3.5). The 
13
C NMR spectrum 
showed a diagnostic peak at 31.9 ppm for the Br-CH2 in place of 64.4 ppm for HO-CH2.  
 
3.2.2 Preparation of fluorescent tag (dansylamide) with linker   
 
3.2.2.1 Dansylamide with vinyl linker 
In order to introduce the required sulfonamide linking group and for reasons of 
synthetic expediency, a dansyl fluorescent component was selected. This group 
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represents a compromise in fluorescent performance but provide access to the required 
sulfonamide functionality.    
 To test the feasibility of the linking strategy, allyl dansyl sulfonamide 23 was initially 
prepared as model compound. Commercially available dansyl chloride was reacted with 
allyl amine, in presence of triethylamine and DMAP, to give sulfonamide 23 in a yield 
of 80%. The product was easily confirmed from the 
1
H NMR spectrum due to the peaks 
belonging to the vinyl functionality at δH: 4.86, 5.06 ppm and 5.53 ppm. The 
introduction of this functionality gives the opportunity to potentially apply coupling 
reactions on the terminal vinyl group, for example by Grubbs metathesis reactions, and 
provides a good handle for spectroscopic identification in the subsequent reactions 
(Scheme 3.6).  
 
3.2.3 Coupling barb with molecule of fluorescent tag and linker 
 
3.2.3.1 Reaction with diazirine  
 Due to the concerns about the general stability of the photoreactive diazirine (-N=N-) 
moiety, initial coupling of the dansyl sulfonamide 23 to this component focused on 
coupling with the precursor diaziridine (HN-NH) 19. It was envisaged that the hydroxyl 
group of the diaziridine 19 could be activated to couple with the sulfonamide nitrogen 
in the presence of the two nucleophiles HN-NH of diaziridine 19, under 
Fukuyama/Mitsunobu conditions.174 Furthermore, this coupling reaction had the 
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advantage of using the unoxidised diaziridine (HN-NH) compound with the benzylic 
OH group directly prior to conversion to the potentially unstable final diazirine product. 
A model Fukuyama/Mitsunobu reaction
 
using benzyl alcohol in place of diaziridine 19 
was applied to verify the reaction reliability before using the valuable prepared 
diaziridine 21. Sulfonamide 23 was reacted with benzyl alcohol in the presence of 
DEAD and triphenylphosphine at room temperature. This protocol afforded 
sulfonamide 24, in a yield of 43% after chromatographic purification. The product was 
confirmed from the 
1
H NMR data which showed a diagnostic peak belonging to CH2 of 
the benzyl group at 4.3 ppm (Scheme 3.7). 
 
 
Based on these results, successful coupling of the diaziridine 19 was then achieved by 
treatment sulfonamide 23 with diaziridine 19 under the established conditions to give 
product 25 in yield of 45% after chromatography. The product 25 was confirmed from 
the 
1
H NMR spectrum which shows a peak at 4.4 ppm belonging to CH2 of the 
diaziridine, and the 
19
F NMR spectrum which showed a single peak at -75.4 ppm 
(Scheme 3.8). 
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While successful the Fukuyama/Mitsunobu conditions did not give very good 
conversion and yield using a reaction of diazirine 21, alternative method was 
investigated by converting the hydroxyl group of diazirine 21 to a bromide, by 
treatment with carbon tetrabromide and triphenylphosphine, to produce 3-(α-bromo-4-
tolyl)-3-(trifluormethyl)-3H-diazirine 22 in yield of 96 % (Scheme 5). The 
13
C NMR 
spectrum was diagnostic and a significant shift for the CH-OH 67.8 to 32.0 ppm for 
CH-Br indicated a successful conversion. The 
19
F signal remained the same at -65 ppm 
indicates the presence of the diazirine group. Bromide 22 was then applied in a further 
coupling step with the sulphonamide 12 under mild conditions and gave product 26 in a 
good yield of 88%. The product structure was confirmed from the 
1
H NMR spectrum 
with the disappearance of the signals belonging to SO2N-H proton at 5.09 ppm and the 
spectra were consistent with the structure of compound 26. The 
13
C NMR spectrum 
showed the CH2-N chemical shift at 51 ppm, significantly different to 36.6 ppm for the 
CH2-Br of the starting material. The 
19
F NMR spectrum showed same single peak at -
65.0 ppm for the diazirine 22, confirming that the diazirine function remained intact. 
High resolution mass spectrum analysis has also confirmed the compound structure 
(Scheme 3.9). 
 
88 
 
 
 
3.2.3.2 Reaction with benzophenone  
After the successful coupling of the diazirine photophore 22 with the fluorescent tag 12, 
the coupling of a benzophenone photophore was investigated in order to assess the 
influence of the variation of the photophore nature on binding to the biomolecule 
targets. Moreover, two kinds of linkers (alkyl, PEG), which are already attached with 
the fluorescent tag, were investigated as well.      
i) Initially simple alkyl chain substituted dansyl amide 12 was reacted with 
commercially available 4-(bromomethyl)benzophenone 11 in presence of potassium 
carbonate in DMF, to give molecule 27 in yield of 82 % (Scheme 3.10). Spectroscopic 
data was consistent with the structure shown.  
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ii) Dansyl amide-PEG linker 10 was reacted with a commercially available 4-
(bromomethyl)benzophenone 11 and potassium carbonate in DMF, gave molecule 28 in 
yield of 34 % (Scheme 3.11). The product was evidenced from the 
1
H NMR spectrum 
which showed a significant shifting of a singlet peak from 4.51 ppm for the 
benzophenone CH2-Br to 4.66 ppm for Ar-CH2-N confirmed the alkylation reaction. 
Also the 
13
C NMR spectrum showed a peak for the Ar-CH2-N at 51.7 ppm instead of 36 
ppm for CH2-Br group of the starting material and a peak for the carbonyl group at 
196.2 ppm. Another confirmation was obtained from the HR-MS analysis which was 
consistent with the proposed structure.  
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3.2.4 Preparation of substituted diazoxides as “baits” 
Having prepared a number of photoreactive fluorescent components, synthetic work 
then turned to the synthesis of active diazoxide analogues suitable for linking with these 
components. 
Preliminary studies focussed on the synthesis of a range of diazoxide analogues, to 
identify a suitable site for attachment of the fluorescent probe. A general synthesis for 
the preparation of diazoxide from substituted aniline was pursued. 4-Bromoaniline was 
chosen as a starting material and it was envisaged that a sulfonation reaction would 
install the sulfonyl group ortho to the amino group, giving the amino sulfonic acid 
needed to make the required diazoxide. The bromo-substituted material was also chosen 
because a variety of functionality can be obtained; for instance, the bromide group can 
be converted to a vinyl group, which after a hydroboration reaction would give the 
corresponding alcohol.  
Commercially available 4-bromoaniline was converted to acetanilide 29 to moderate the 
reactivity since the protonated form 30 was more likely to be obtained from the starting 
material after treatment with an acid. Under a wide range of conditions the sulfonation 
175of the acetanilide 29 was unsuccessful and only returned starting material (Scheme 
3.12).  
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Sulfonation reaction on the bromoaniline was not a successful route. Therefore, a 
synthetic route starting from commercially available aniline-2-sulfonic acid was also 
investigated. The amine group of aniline-2-sulfonic acid was first converted to the 
acetamide 31 by a treatment with acetic anhydride. However, attempts to prepare the 
corresponding sulfonyl chloride were unsuccessful, with a variety of reagents (PCl5, 
SOCl2, ClSO3H)
176 and wide range of temperatures and reaction times and the reactions 
generally returning starting materials (Scheme 3.13). 
 
 
A successful preparation of the parent diazoxide structure was achieved starting from 
the more expensive but also commercially available 2-amino-benzenesulfonamide. This 
aniline was reacted with acetic anhydride in acetic acid at 100 
o
C to give the amide 32, 
which was treated with sodium hydroxide and then acidified with 2M hydrochloric acid 
to obtain the unsubstituted diazoxide 33 in 74% yield over two steps. The 
1
H NMR data 
was consistent with the structure and a diagnostic resonance was observed for the NH at 
12.0 ppm, while the 
13
C NMR spectrum showed the C=N resonance at 157.2 ppm 
(Scheme 3.14). 
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3.2.5 Substitutions on diazoxide 
3.2.5.1- Halo alkylation reactions 
With unsubstituted diazoxide 33 in hand, elaboration to substituted diazoxides was 
investigated, initially via an alkylation reaction of the aromatic ring, with the 
substitution expected to occur to position 5 or 7 due to the amine functionality on the 
aromatic ring. However, all attempts at chloro-alkylation using para-formaldehyde and 
variety of reagents, such as zinc chloride with hydrochloric acid, zinc chloride with 
acetic acid and dichloromethyl methyl ether at variety different temperatures, were 
unsuccessful and the diazoxide 33 only returned starting material (Scheme 3.15). The 
low reactivity of this compound may be due to the dominant electron withdrawing 
effect of the SO2 functionality; however the poor solubility of the compound may also 
be a contributing factor. 
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3.2.5.2 Nitration reaction  
In order to assess the reactivity of the diazoxide 33, a nitration reaction was investigated 
by reacting 33 with concentrated nitric and sulfuric acid. This was successful, producing 
7-nitro-diazoxide 34, in a yield of 44%. This compound was readily identified from the 
1
H NMR spectrum where three aromatic peaks can be seen with two doublets at 7.47 
and 8.42 ppm and one singlet at 8.45 ppm, indicating substitution at the position 7. No 
product at position 5 was obtained. This nitration is useful in further elaboration but is 
not as good as bromination (Scheme 3.16). 
                                      
3.2.5.3 Bromination reaction  
While nitro-diazoxide 34 would allow access to substituted diazoxides, a more direct 
route is available from bromo-substituted material, which gives more opportunities for 
conversion to variety of different functional group. Studies focussed on finding a 
reliable bromination method.  
Treatment of the diazoxide 33 with aqueous hydrobromic acid with H2O2 was not 
successful and the reaction returned starting materials. However, sodium bromate177 
proved a successful bromination reagent. Diazoxide 33 reacted with sodium bromate in 
sulfuric acid and sodium sulfate to give the monobromo 35 and dibromo 36, along with 
unreacted starting material in ratio of 3:2:2, respectively. This result suggests that 
compound 35 is more reactive than 33 toward this reagent. After chromatography 
purification, dibrominated compound 36 was obtained in yield of 11%, characterised by 
1
H NMR spectroscopy and the structure confirmed by X-ray crystallography (X-ray 
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data collected and solved by Prof J. D. Wallis) (Figure 46). However, diazoxide 35 
could not be separated from residual starting material and this did not provide an 
effective route to 7-substituted diazoxides (Scheme 3.17). 
 
 
 
 
Figure 46 X-ray crystal structure of 36              
 
3.2.5.4 Preparation of 5'- and 7'-substituted diazoxides  
Functionalization of the unsubstituted diazoxide 33 was found to be problematic due to 
a lack of reactivity and severely hampered by poor solubility of the diazoxides in most 
solvents. Therefore, it was decided to establish a general synthesis of halo-substituted 
diazoxide precursors for elaboration into the final product. To this end we sought to 
prepare chloro or bromo amino-benzenesulfonamide precursors at the 3 and 5 positions, 
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corresponding to the 5 and 7 positions for the final diazoxide molecule, expecting the 
reactivity would be directed to those positions by the effect of the amino and 
sulfonamide groups in the parent compound.   
 
Building on this plan, 2-aminobenzenesulfonamide was used as diazoxide precursor and 
substitution reactions were successfully achieved. Treatment of 2-amino-
benezenesulfonamide with hydrobromic acid (1eq),178 in presence of hydrogen peroxide 
and water gave 2-amino-5-bromo-benzenesulfonamide 37 in a yield of 65% after 
chromatography. Furthermore, when the equivalents of hydrobromic acid were doubled, 
di-brominated 38 was formed exclusively in 82% isolated yield. When excess of the 
hydrobromic acid, with elevated temperatures, was applied the product was only tri-
bromoaniline 39 in yield of 89%. Subsequently, compounds 37 and 38 were reacted 
with acetic anhydride, then with NaOH followed by HCl, to produce 40 and 41, in yield 
of 82% and 61% respectively, the structure of which were confirmed from the 
1
H NMR 
spectroscopy and HR-MS data (Scheme 3.18). 
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3.2.5.5 7-Vinyl-diazoxide 43 
In order to prepare a variety of  functionalised diazoxide analogues suitable for linking, 
the introduction of an appropriate group was again pursued. 2-Amino-5-bromo 
benzenesulfonamide 37 was reacted with 2,4,6 trivinylcyclotriboroxane-pyridine 
complex in presence of tetrakis(triphenylphosphine)palladium(0) and potassium 
carbonate,179 to give the vinyl compound 40, in a yield of 77% after purification. The 
product was confirmed from the 
1
H NMR spectrum where the two doublets at 5.02, 5.54 
ppm and one doublet-doublet (dd) at 6.57 ppm belonging to the vinyl group were 
apparent. The conversion of the bromide to a vinyl group offers a variety of 
opportunities for further functionalization. Compound 40 was then reacted with acetic 
anhydride and then treated with NaOH followed by HCl to give pure diazoxide 41 in 
yield of 57%, which was confirmed from the 
1
H NMR data and HR-MS. The similar 
vinylation reaction of diazoxide 35 produced vinyl-diazoxide 41 in a poorer 40 % of 
yield (Scheme 3.19). 
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3.2.5.6 Conversion of vinyl group to the corresponding alcohol-diazoxide 45 
With the vinyl-products 40 and 41 in hand the hydroboration/oxidation180 of these 
materials was explored using 9-BBN followed by oxidation with peroxide. In the event 
hydroboration/oxidation of diazoxide 41 returned starting material, however, treatment 
of the vinyl compound 40 under the same conditions gave the alcohol 42 in yield of 
72%. This compound 42 was reacted with acetic anhydride and then treated with 
sodium hydroxide followed by hydrochloric acid and produced diazoxide 43 in an 
overall yield of 40% (Scheme 3.20). 
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3.2.5.7 6-Bromo-diazoxide 45 
Preparation of diazoxide functionalised at the 6 position was then performed. The 4-
bromo derivative of 2-aminobenzenesulfonamide 44, was prepared in a three step 
reaction,181 starting from commercially available 4-bromo-1-fluoro-2-nitrobenzene by 
reaction with aqueous sodium sulfite, followed by treatment with concentrated 
hydrochloric acid, to give 4-bromo-2-nitrobenzenesulfonic acid 44a. Compound 44a 
was reacted with thionyl chloride and DMF to afford intermediate, 4-bromo-2-
nitrobenzenesulfonyl chloride, which was then treated with ammonia to yield 4-bromo-
2-nitrobenzenesulfonamide 44b, which was then reduced to yield the title compound 44 
in 59% yield after chromatography. The obtained product was then elaborated in the 
usual way to produce pure diazoxide 45, in yield of 64% (Scheme 3.21).  
 
3.2.5.8 8-Chloro-diazoxide 47 
For the preparation of 8-chlorodiazoxide 47, commercially available 1,2-chloro-3-
nitrobenzene was reacted with benzyl mercaptan (freshly prepared) to produce 2-
(benzylsulfanyl)-1-chloro-3-nitrobenzene.170 Oxidation of this material with chlorine gas 
presumably afforded an intermediate sulfonyl chloride, which was treated directly with 
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aqueous ammonia to give 6-chloro-2-nitrobenzenesulfonamide. This compound was 
then reduced with iron powder and ammonium chloride to yield the title compound 46, 
in 44% yield, which was reacted with acetic anhydride, then NaOH followed by HCl, to 
produce 47, in yield of 54% (Scheme 3.22). 
 
           
3.2.5.9 Preparation of C-3 side chain diazoxides 
As well as preparing analogues substituted on the aromatic ring, hetero ring side chain 
analogues were also prepared. In order to prepare these, the unsubstituted and bromo-
substituted 2-amino-benzenesulfonamides, 37 and 38 were reacted with glutaric acid 
monomethylester chloride.182
 
The amide products obtained were then treated with 
sodium hydroxide, followed by acidification with hydrochloric acid to give the 
corresponding diazoxides 48, 49 and 50 in yield of 53%, 51% and 51% respectively. In 
all cases the cyclization was accompanied by ester hydrolysis, which resulted in 
production of the corresponding carboxylic acids (Scheme 3.23).  
Pure products were obtained after washing the crude materials with ether. The structure 
of all three products were evident from the 
1
H NMR spectra, where in the case of 48, 
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resonances  at 1.89, 2.32 and 2.59 ppm indicated an aliphatic chain, while those at 11.96 
and 12.14 ppm  indicated NH and OH groups, respectively. In addition, 49, 50 showed 
signals at 1.75, 2.19 and 2.47 ppm for the aliphatic chain and 2H signal at 12.03 ppm 
for NH and OH functionalities. In contrast to the literature precedent, dioxane was used 
as a reaction solvent instead of DMF, which is hard to evaporate and remove from the 
final product. 
 
 
 
3.2.6 Biologically active testing for the modified diazoxide results 
Having prepared a variety of diazoxide analogues which display additional functionality 
in varying positions around the parent diazoxide skeleton, an assay of the biological 
activity of these analogues was carried out. The cardioprotection activity of the 
analogues were assessed by incubation with myocardial slices from the human right 
atrial appendage, in ischaemia/reperfusion experiments and the viability of the treated 
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tissue was determined as described in literatures.183, 184 Two biological assays were used 
to determine cell viability, lactic acid dehydrogenase activity (LDH) assay,185 and MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay for cell viability. 
These assays were performed in collaboration with Dr Manuel Galiñanes, Department 
of  Cardiac Surgery, Area University Hospital Vall d'Hebron Pg, Spain.  
3.2.6.1 LDH assay  
Lactate dehydrogenase (LDH) is a cellular enzyme which is released into the culture 
medium as a result of cell death caused by apoptosis or necrosis. LDH activity, 
therefore, can be used as an indicator of cell death and is used as a general means to 
evaluate cytotoxicity resulting from different cell treatment factors. Cayman’s LDH 
cytotoxicity assay measures LDH activity present in the culture medium using a 
coupled two-step reaction. In the first step, LDH activates the reduction of NAD
+
 to 
NADH and H
+
 by oxidation of lactate to pyruvate. In the second step, a diaphorase 
enzyme, using NADH and H
+
, reduces the tetrazolium salt to intensively coloured 
formazan, then the coloured product can be measured colorimetrically with the intensity 
of the colour indicating how much damaged tissue or cell death is present (Figure 47). 
This assay is a general indicator of the presence of dangerous, acute, or chronic, tissue 
damage and sometimes also used to help diagnose and monitor a heart attack. 
 
102 
 
 
Figure 47 Mechanism of LDH assay 
3.2.6.2 MTT assay 
The MTT-[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide] colorimetric 
assay has been described by Mosmann et al. (1983).186 This assay can be used for 
determining the number of living cells by following the reduction the yellow 
tetrazolium salt to insoluble purple formazan salt by mitochondrial succinate 
dehydrogenase, and is a measure of residual mitochondria activity. The enzyme is 
produced by viable cells and the quantity of formazan produced is relative to the 
number of living cells present (Figure 48). Results are obtained via a simple 
colorimetric assay.  
 
Figure 48 Reduction of MTT to Formazan 
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Ischaemic reperfusion experiments were performed in the presence of all the diazoxide 
analogues (Figure 49) six times (n=6), except for analogue 50 which was tested twice 
(n=2). As controls, unmodified ischaemia reperfusion (I/R) experimental were 
performed along with an ischaemic preconditioning experiment. The results of the LDH 
assays confirm that IP (preconditioning) reduces cell death and the mean values in this 
assay were approximately one of third of that observed in ischaemia reperfusion control 
(I/R). In general terms for the analogues tested, the mean LDH values vary greatly from 
a reduction comparable to that seen in the IP group for compounds 43 and 47, to a 
negligible effect for compounds 33 and 36 (Figure 50). 
The MTT assay control experiments also confirmed the protective effect of the IP 
protected. However, this assay suggests high levels of cell death in the ischaemia 
reperfusion control experiments than indicated by the LDH assay. The MTT assay 
results for the diazoxide analogues indicate significantly more modest protection for 
near all compounds when compared to I/R group. The results do not directly follow 
those obtained by the LDH assay. In this assay compound 35 was the only analogue 
showing cell viability comparable to the protective control. This compound has a very 
similar structure to the parent cardioprotection diazoxide, but with a direct replacement 
of chloride for bromide in position 7 (Figure 49). 
 
Taking both sets of assay results into account a number of conclusions can be drawn: 
i) All the analogues provide a varying positive protective effect except for 
analogue 36, which did not show a clear response assumed by both assays and 
has two bromo substitutions in positions 5 and 7. This negative result suggests 
that the protection activity may be lost when both positions 5, 7 are substituted. 
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ii) The analogues 43 and 47 showed a significant reduction in the death measured 
by the LDH assay in contrast to a moderate cell protection as determined from 
the MTT assay. 
iii) A comparison between the activity of the analogues with alkyl carboxylic 
groups at position 3 (analogues 48 and 50) with those with a methyl group in 
the same position indicate that the extended side chain is not detrimental to 
activity as assessed by the LDH assay. The MTT assay results are less 
conclusive (Figure 50).    
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Figure 49 Diazoxide analogues tested in cell viability assays 
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Figure 50 LDH and MTT Assays Results; Ischaemic reperfusion experiments were 
performed in the presence of all the diazoxide analogues six times (n=6), except for 
analogue 50 which was tested twice (n=2). 
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3.2.7 Fully functionalised diazoxide tagging molecules 
Based on the above biological testing results, the most active analogues 43 and 47 were 
identified as the most promising analogues for further elaboration to the 
fluorescent/photoaffinity hybrid molecule. Analogue 43 has a hydroxyethyl group in 
position 7 which was initially installed as a handle for linking to the other components. 
Given that retention of activity might be expected as this group is increased in size, one 
proposal is to link the other components via this hydroxyl group.  
For the analogue 47, the presence of a chloro group at position 8 led to an increase in 
activity and elaboration of this molecule may be beneficial. However no suitable 
functionality for linking is present in this molecule, and given the activity of analogues 
48 and 50, it was decided to elaborate via installation of alkyl carboxylate in position 3 
(Figure 51). 
 
Figure 51 Elaboration plan for the analogues 43 and 47 
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3.2.7.1 8-Chloro diazoxide-alkyl linker-benzophenone-dansylamide molecule  
The preparation of the side chain carboxylic acid analogue of active compound 47 was 
then pursued. First step was to prepare the diazoxide with a side carboxylic chain by the 
same method as previously employed for diazoxide 48. Thus, compound 46 was reacted 
with glutaric acid monomethylester chloride,182
 
and the intermediate amide was treated 
with sodium hydroxide, followed by acidification with hydrochloric acid, to give the 
diazoxide 53 in 86% yield (Scheme 3.24).  
The identity of product 53 was easily confirmed from the 
1
H NMR spectrum by the NH 
proton at 12.31 ppm, with no presence of the peaks belong to the NH2 protons of the 
amine and sulphonamide. In addition, the 
13
C NMR spectrum showed diagnostic signals 
for the C=N at 117 ppm and C=O of the carboxylic acid at 173.9 ppm. 
 
 
 
3.2.7.2 Coupling of the 8-chloro-diazoxide 48 with the hybrid molecule 27 
Having prepared compound 53, coupling to the other components was explored. Given 
the long synthetic route to 43, coupling of 47 was first explored. In a preliminary study, 
the more readily available diazoxide analogue 48 was used as a model compound for 
establishing an esterification method. A variety of different esterification conditions 
were tried, initially using a Brønsted acid. Treatment of diazoxide carboxylic acid 48 
and hybrid molecule 27 with a catalytic amount of concentrated sulphuric acid in THF 
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and heating at reflux for 4 hours, gave no evidence of the desired ester and returned 
starting materials. 
Activation of the carboxylic acid was the explored using the Yamaguchi esterification 
method. Following the method of Dhimitruka,187 diazoxide 48 was treated with 2,4,6-
trichlorobenzoyl chloride, triethylamine and 4-dimethylaminopyridine for four hours, 
followed by alcohol 27. However this procedure afforded only ester 51, with no 
evidence of the desired coupling product. Presumably the initial formation of the 
intermediate anhydride was not rapid and the acid chloride preferentially reacted with 
alcohol 27 (Scheme 3.25).  
   
  
 
Pleasingly coupling was achieved by activation of the carboxylic acid using p-
toluenesulfonyl chloride, triethylamine and 4-dimethylaminopyridine.188 The reaction of 
p-toluenesulfonyl chloride with diazoxide 48 in presence of triethylamine and 4-
dimethylaminopyridine for 45 minutes followed by addition of hybrid molecule 27 
produced the desired ester 52 in yield of 57%. The identity of coupled product was 
confirmed from the 
1
H NMR spectrum which showed a triplet peak at 3.81 ppm arising 
from the CH2 group adjacent to the ester oxygen. The 
13
C NMR spectrum gave 
diagnostic peaks at 64.5 and 173.1 ppm (Scheme 3.26).  
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In the event, compound 53 was reacted with p-toluenesulfonyl chloride in presence of 
triethylamine and 4-dimethylaminopyridine,188 then the hybrid molecule 27 was added, 
to afford  54 in a purified yield of 44% (Scheme 3.27). 
 
 
 
The 
1
H NMR spectrum was consistent with the structure with a signal at 10.26 ppm 
belonging to N-H and a triplet at 3.96 ppm for the two CH2-O-C=O protons signalling 
the formation of ester. Moreover the 
13
C NMR spectrum showed a peak for the ester 
carbonyl at 173.1 ppm (Figure 52), and HR-MS analysis data also confirmed the 
structure of the molecule 
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Figure 52 NMR spectra for compound 54  
3.2.7.3 8-Chloro diazoxide-alkyl linker-diazirine-dansylamide molecule  
Following the successful synthesis of benzophenone photoreactive probes, diazirine 
photoreactive probes were then prepared. The compound 53 was reacted with p-
toluenesulfonyl chloride in presence of triethylamine and 4-dimethylaminopyridine,188 
then diazirine hybrid molecule 26 was introduced to give compound 55 in a yield of 
33%, after column chromatography. The 
1
H NMR spectrum confirmed a successful 
coupling with the diagnostic triplet peak at 3.92 ppm, and a singlet at 10.24 ppm 
belonging to the N-H of the diazoxide moiety (Figure 53). The 
19
F NMR spectrum once 
again showed a singlet peak at –65 ppm belonging to the intact diazirine functionality 
and HR-MS data was consistent the expected structure (Scheme 3.28). 
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Figure 53 NMR spectra for compound 55 
 
3. 2.7.4 8-Chloro diazoxide-PEG linker-benzophenone-dansylamide molecule  
Several further functional probes were also prepared. As stated earlier, the introduction 
of a polyethylene glycol (PEG) linker might confer different solubility properties on the 
probe and affect the binding ability of the small molecule to the biomolecule targets. 
Preparation of this probe was achieved by coupling of compound 53 to the hybrid 
molecule with PEG linker 10 using the established method, to give compound 56 in 
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49% yield after chromatography (Scheme 3.29). All spectroscopic data was consistent 
with the expected structure (Figure 54).  
 
 
  
Figure 54 NMR spectra for compound 56 
  
3.2.7.5 Coupling of the 7-(2-hydroxyethyl)-diazoxide with the hybrid molecule 
Gives the success of the carboxy side chain installation and ester coupling protocol the 
preparation of compound 59 was then pursued. For this reason an alternative method 
was tried by preparing the fully functionalised vinyl molecule 57 then attempting 
conversion to the desired product 58 as follows:    
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Due to the concerns about interference for the unprotected hydroxyl group, the strategy 
chosen was to elaborate vinyl sulfonamide 40, then couple to the linker, followed by 
late stage oxidation to give compound 59. Hence, 2-amino-5-vinyl-benzenesufonamide 
40 was treated with glutaric acid monomethylester chloride,182 and the amide product 
was then treated with sodium hydroxide, followed by acidification by hydrochloric acid 
to give the corresponding diazoxide 57 in purified yield of 53% (Scheme 3.30). 
 
 
 
 
 
 
114 
 
7-Vinyl-diazoxide-butric acid 57 was then coupled with photoreactive benzophenone 
molecule 27, to produce the desired ester 58 in a yield of 35 % after chromatography 
(Scheme 3.31).  
 
Hydroboration-oxidation of compound 58 by reaction with 9-BBN and hydrogen 
peroxide was unsuccessful and the reaction returned components of starting materials 
the result of hydrolysis of the ester 58 (Scheme 3.32).     
 
At this late stage of the project elaboration of active analogue 43, via the hydroxyl 
group was abandoned and studies turned to investigation of the protein tagging probes.  
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3.2.8 Photolysis investigation of the fully functional molecules 54, 55 and 56 
In order to identify the proper UV wavelength of light for the irradiation process, an 
investigation utilising the fully functional diazoxide 54 was established. Initially, an 
ethanol solution of the fully functional compound 54, at a concentration of 10 mM was 
prepared. The second step was to measure the sample under a wavelength range from 
250- 900 nm. UV/Vis measurements were then performed in order to assess the 
optimum excitation and emission wavelengths. An absorption maxima was observed at 
395 nm with an emission maxima at 520 nm, both due to the dansyl amide group. The 
excitation maxima at 340 nm of the benzophenone moiety is presumably swamped by 
the strong dansyl absorption, but these promising results permitted the irradiation step to 
be safe for the biomolecule targets (Figure 55).     
 
  
Figure 55 Excitation and emission for 54 
  
520 
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In order to investigate the photo reactivity of the compounds 54, 55 and 56 with protein 
molecules in general, a preliminary study was then conducted using the three analogues 
of the fully functional diazoxides (benzophenone probes 54 and 56, diazirine probe 
molecule 55) to assess the reactivity toward bovine serum albumin (BSA) as a 
representative protein target. While this protein is not expected to be a diazoxide target 
it is readily available and allows the photoaffinity labeling capacity and fluorescent 
properties of the probes to be examined. It was anticipated that the photolysis the 
photophore moiety would generate an active species which then covalently binds with 
any adjacent protein. In these preliminary experiments, 2 mM of each of the fully 
functional molecules 54, 55 and 56 was incubated with the same concentration of BSA 
protein in ratio of 1:1. UV irradiation was then carried out under at wavelength of 360 
nm, for various time periods (10, 30, 60 min). The irradiated BSA was then subjected to 
polyacrylamide gel electrophoresis (PAGE), with gel loading of 10 and 20 µg.  
Visualization of the separated protein by UV-transillumination showed visible bands for 
the BSA protein bound by diazirine molecule 55 for all the applied irradiation times. 
However, benzophenone molecules 54 and 56, showed no clear bands for the exposure 
time of 10 minutes (Figure 56), and clear bands were seen for the experiments involving 
at 30 and 60 minutes exposure (Figure 57). No qualitative difference in reactivity was 
observed between alkyl linked 54 and poly ethylene glycol (PEG) 56 in this experiment, 
perhaps due to the simple nature of the experiment and the high concentrations 
involved.  
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Figure 56 Exposure of BSA protein mixed with the three compounds in 10 minutes 
  
 
Figure 57 Exposure of BSA protein mixed with the two compounds for 30 minutes 54a, 
56a and for 60 minutes 54b, 56b  
 
Overall, the experiments for testing the validity of these molecules to bind to the 
adjacent proteins, and the diazirine moiety molecule has been found more efficient in 
short irradiation experiments, which is consistent with literature precedent.189 The 
efficacy of the fluorescent moiety has also been established and showed discernable 
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bands on the gel under the UV transilluminator. Given these promising results the 
selective binding and tagging of mitochondrial proteins was explored.   
3.2.9 Investigation of mitochondrial component targets of diazoxide 
analogues. 
After the preliminary investigation into the binding efficiency of the functional 
molecules to proteins in general, the interaction with mitochondrial targets was 
examined. In these experiments mitochondria extracts were used instead of whole 
tissues or cells, in order to avoid permeability issues.  
In these experiments mitochondrial extract provided by Dr Alan Hargreaves, was 
extracted from pig brain. Protein concentration was determined using Bio-Rad DC 
Protein assay (Bio-Rad laboratories, Hertfordshire, UK) with bovine serum albumin as 
the standard. Mitochondrial extract (100 µg/ml) were incubated with a 100 µM solution 
of the diazoxide functional molecules 54, 55 and 56 at room temperature for 30 minutes. 
The samples were then divided to two parts, and one of each sample was irradiated 
directly under 360 nm UV light, and the other half of the samples were suspended in 
buffer solution and centrifuged to remove any non-binding functional molecules, then 
irradiated under the same UV wavelength. The irradiation period was optimised using 
the preliminary study results, and the diazirine analogue molecule 55 was irradiated for 
10 minutes and the benzophenone 54 and 56 molecules were irradiated for 30 minutes.  
Following irradiation, SDS-PAGE gel was applied to separate the biomolecule targets, 
and several fluorescent bands were observed on the gel under UV transillumination. 
Similar results were observed for all three compounds, with three major bands labelled 
in each experiment two at ~ 25 KDa and one at ~150 KDa. This finding indicates that 
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the three diazoxide molecules incubated with the mitochondria extracts specifically 
target only a few biomolecules found in mitochondria. 
These data also showed no significant differences between the non-centrifuged and 
centrifuged samples, which might be related to the high specificity of these molecules. 
Close examination of the gels revealed that the diazirine probe gave brighter bands 
compared to the two benzophenone based probes. The clearer bands may be due to the 
greater efficiency of the diazirine functionality in photoreactive binding to the 
biomolecules (Figure 58). 
 
Figure 58 a) Fluorescent bands  from the incubation of molecules 54, 55 and 56 with 
mitochondrial extract b) coomassie blue pigments showing all the protein bands. 
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3.2.10 Incubation of diazirine compound 55 with the mitochondrial extract 
Diazirine molecule 55 demonstrated promising binding results with the mitochondrial 
extract in the above experiment (Figure 58). In order to further establish whether this 
molecule is targeting the same biomolecules as the parent diazoxide, two competition 
experiments were performed. In the first competition experiment molecule 55 was 
administered with unlabelled diazoxide, which is more likely to bind to the protein 
targets with high efficiency than the labelled diazoxide, displace the probe can lead to 
less labelling. The second strategy was to introduce a known blocker of the mKATP 
channel (5-HD) along with the molecule 55. The presence of the blocker should also 
inhibit the binding of diazoxide probe.  
In the event, mitochondrial extract was treated with the three different combinations of 
molecule 55 and additives. As a control mitochondrial extract with protein 
concentration of 100 M was incubated with molecule 55, a second sample was 
incubated with a 1:1 mixture of molecule 55 and unlabelled diazoxide, and a third 
sample was incubated with a 1:1 mixture of molecule 55 and the mKATP blocker 5-HD. 
These samples were then irradiated by UV for 10 minutes, and an electrophoresis SDS-
PAGE gel was used for separation (Figure 59). 
 
Figure 59 Specificity targeting test; mitochondrial extract incubated with 55+5-HD: 
probe with channel blocker 5-HD,55+ D: the probe with unlabelled diazoxide, 55: just 
probe 
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In these experiments, both control and competition samples exhibited similar bands to 
these seen in the previous results. However, slightly less bright bands were observed in 
the case of the mKATP blocker 5-HD competition experiment, suggesting that the probe 
may be labelling the mKATP channel. However, at this point in time, these experiments 
are inconclusive and further incubation experiments employing excess of channel 
blocker are required. Further work will also encompass the characterisation of the 
targeted biomolecules potentially using mass spectrometry of gel purified sample.   
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3.3 Conclusion  
A number of diazoxide analogues, functionalised at different positions around the 
molecule, have been prepared, and biologically tested. Two analogues 43 and 47 were 
found to be the most active. These active analogues were then incorporated to 
photoreactive-fluorescent probe molecules 54, 55 and 56, which contain a photoaffinity 
component (diazirine or benzophenone), and fluorescent tag, dansylamide, attached to 
the diazoxide by a linker (alkyl or PEG). The probe photo reactivity was assessed by 
incubating these fully functional molecules with pure BSA protein, under UV light 
irradiation followed by gel electrophoresis. Fluorescent bands were observed consistent 
with the protein molecular weight, indicating covalent reaction of the probe with the 
BSA. Incubation and irradiation of these probes with a mitochondria extract gave three 
distinct fluorescent bands on the gel after electrophoresis, confirming selective binding 
to mitochondrial biomolecules. Finally a competitive assay was applied using diazirine 
molecule 55 with diazoxide and mKATP channel blocker, with the same extract to 
determine if the probe is labelling the targets of these small molecule. Results are 
inconclusive and further work is ongoing. 
Future work in this project will require the application of the probes in identifying 
targets of diazoxide. First is to isolate and identify the biomolecules in the 
mitochondrial extract targeted by the diazoxide using HPLC and MS techniques. The 
development of second generation probes will involve the incorporation of brighter 
fluorescent molecules, like BODIPY, to enhance the sensitivity and allow identification 
of less abundant biomolecules of interest. Finally the incorporation of different length, 
and different polarity linkers will allow us to assess the effect of spacer variation on the 
affinity of the bait molecule and photoreactive binding.          
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4. Chapter 4:  Experimental   
                                                               
4.1 General  
For the reactions performed under anhydrous conditions, the glassware for the 
experiment was dried in an oven (100 
o
C or higher) overnight when needed and allowed 
to cool completely to room temperature under a flow of nitrogen before any reagents 
were introduced. All metal needles used were acetone washed and oven dried for at 
least 3 hours. Air- and moisture-sensitive liquids and solutions were transferred via 
syringe. Organic solutions were concentrated under reduced pressure by rotary 
evaporation and a vacuum pump.  
4.2 Reagents and Solvents 
 All the reagents were analytical grade and used without further purification. The 
chemicals were purchased from Sigma Aldrich and Alfa Aesar and were used without 
further purification, unless otherwise stated. The solvents used in reactions were dried, 
distilled and stored under nitrogen prior to use. Ethanol was dried over Na2SO4. 
Dichloromethane was dried by distillation from CaH2. THF was dried by distillation 
from sodium with benzophenone as indicator. The solvents dichloromethane, ethyl 
acetate, hexane, methanol and cyclohexane (Reagent grade) which were used for 
chromatography and some others were purchased from Fisher Scientific Ltd. 
4.3 Purification Processes  
 Thin-layer chromatography (TLC) was carried out using silica plates, UV-active, and 
substances were detected in UV light with wavelength λ = 254 nm, or by dipping into 
iodine vapours or potassium permanganate solution. Flash column chromatography was 
performed using silica gel (Fluorochem, 60A, 40 ± 63 micron). The samples were either 
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applied in solution directly to the top of the silica/solvent column or applied absorbed 
onto dry silica gel. Pressure was applied at the column head via hand bellows or an 
electric pressure pump.  
4.4 Instrumentation  
Proton (
1
H NMR), carbon (
13
C NMR), fluorine (
19
F NMR) and phosphorus (
31
P NMR) 
nuclear magnetic resonance spectra were measured on a Jeol ECX 400 spectrometer at 
400 MHz, 100 MHz, 376 MHz and 162 MHz respectively. The chemical shifts are 
reported in parts per million (ppm) on the delta (δ) scale and coupling constants (J) are 
given in Hertz (Hz).  The solvent peaks were used as reference values. For CDCl3 
1
H 
NMR = 7.27 ppm, for 
13
C NMR: CDCl3 = 77.00 ppm; for CD3OD, the internal 
reference was designated at 3.31 ppm (
1
H) and 49.0 ppm (
13
C), for (CD3)2SO the 
internal reference was designated at 2.50 ppm (
1
H) and 39.5 ppm (
13
C). The 
abbreviations for the multiplicity for proton data were as follows: s = singlet, d = 
doublet, dd = doublet of doublets, dt = doublet of triplets, ddt = doublet of doublet of 
triplets, t = triplet, tt = triplet of triplets, q = quintet, m = multiplet, p = pentet, br = 
broad. Assignments were based on DEPT 135 and DEPT 90 pulse experiments and 
HMQC and HMBC experiments. Mass spectra were recorded under high and low 
resolution by the EPSRC National Mass Spectrometry Service Centre, School of 
Medicine, Swansea University.  Melting points were determined on a Stuart melting 
point apparatus SMP30. The UV absorptions and emissions were measured by using a 
Cary Eclipse UV instrument, at a range of wavelength from 200-900 nm. Infrared (IR) 
absorption spectra were recorded on a Perkin Elmer Spectrum 100 FT-IR Spectrometer 
using an ATR attachment, and are reported in cm
1
. 
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4.5 Experimental of Chapter 2 
4.5.1 Synthesis of phenyl saligenin phosphate-1 
 
Phenyl phosphorodichloridate (1.00 g, 4.73 mmol) was added to a solution of 2-hydroxy 
benzyl alcohol (0.50 g, 4.02 mmol) and triethylamine (5 ml, 4.37 mmol) in THF (5 ml). 
The mixture was stirred at 0°C for two hours, and then was refluxed for 20 hours. The 
product was poured into water (40 ml) and extracted with chloroform (3 × 20 ml). The 
combined organic layers were washed with water (3 × 15 ml) and dried (MgSO4). The 
solvent was removed by rotary evaporator under low pressure to afford a crystalline 
compound 1 (0.70 g, 70%).190 δH (400 MHz, CDCl3): 5.33-5.46 (m, 2H, CH2), 7.13-7.27 
(m, 9H, Ar-H); δC (100 MHz, CDCl3): 69.3 (CH2, 
2
JPC 6.7 Hz), 119.9 (
3
JPC 9.5 Hz), 
124.5 (
2
JPC 4.7 Hz) 125.2, 125.5, 129.8, 129.2; δP (CDCl3, 162 MHz): -15.31 ppm. 
4.5.2 The preparation of 2-chloro-4H-1,3,2-benzodioxaphosphorin-2-oxide-2 
 
To a stirred solution of saligenin (1.00 g, 8.05 mmol) and triethylamine (2.50 ml, 2.15 
mmol) in dry DCM (40 ml), was added dropwise phosphorus oxychloride (0.83 ml, 8.83 
mmol) in dry DCM (16 mL) at -78 
o
C. The mixture was stirred for 45 minutes, allowed 
to warm to room temperature and then was concentrated under a vacuum. Dry toluene 
(30 ml) was added and the mixture was allowed to stand in a fridge for one hour then 
filtered, the solvent was removed and the product was dried to obtain the desired 
compound 2 (1.50 g, 91%) in a good purity which can be used in further steps with no 
further purification.191 δH (400 MHz, CDCl3): 5.40–5.50 ppm (m, 2H, CH2), 7.03 (d, 1H, 
J 8.2 Hz), 7.11 (d, 1H, J 7.5 Hz), 7.19 (t, 1H, J 7.5 Hz), 7.32 (t, 1H, J 8.3 Hz); δC (100 
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MHz, CDCl3): 70.1 (CH2, JPC 6.8 Hz), 119.0 (JPC 9.7 Hz), 125.1, 125.5, 130.2, 148.7; 
δP (162 MHz, CDCl3): (s, -5.35 ppm). 
4.5.3 Preparation of N-Boc-6-aminohexan-1-ol-3 
 
The synthesis procedure is according to Forbes et al.192 6-Aminohexan-1-ol (1.00 g, 8.5 
mmol) was dissolved in DCM (5 ml) and di-tert-butyl dicarbonate (2.05 g, 9.3 mmol) in 
DCM (5 ml) was added at 0 
o
C. The mixture was stirred at room temperature for 12 
hours, then the solvent was removed under reduced pressure and the crude compound 
was purified using flash chromatography (silica, 1:1 ethyl acetate/cyclohexane, v/v) 
gaving the title compound 3 (1.85 g, 99%) as a colourless oil, which crystallised to give 
colourless crystals after several days. δH (400 MHz, CDCl3): 1.25-1.31 (m, 4H, Hexyl), 
 
1.38 (s, 9H, Boc), 1.40-1.43 (m, 2H, Hexyl), 1.46-1.52 (m, 2H, Hexyl), 1.98 (s, 1H, 
OH), 3.0-3.7 (m, 2H, Hexyl), 3.48-3.6 (m, 2H, Hexyl), 4.61 (brs, 1H, N-H); δC (100 
MHz, CDCl3): 25.2, 26.3, 28.3, 30.0, 32.5, 40.3, 62.5, 79.0, 156.0. 
4.5.4 Synthesis of a BODIPY 
Preparation of BODIPY-FL was achieved by a five step reaction as described in a 
literature procedure started from commercially available 2,4-dimethylpyrrole as 
follows.116  
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4.5.4.1 (E)-Ethyl 3-(1H-pyrrol-2-yl)acrylate-4 
 
n-BuLi (2.5 M in hexanes, 5.90 ml, 14.70 mmol) was added to ethyl                                       
2-(diethoxymethyl)hydrophosphoryl) acetate (3.00 g, 13.40 mmol) in THF (30 ml, -
78
o
C) and the mixture was stirred for 5 minutes then allowed to warm to 0 
o
C and kept 
stirring for 40 minutes. 1H-Pyrrole-2-carbaldehyde (1.27 g, 13.40 mmol) was added in a 
single portion, and the whole was stirred for a further 2 hours under the same conditions 
then warmed to room temperature and stirred overnight. The solvent was removed, the 
residue was portioned between water (10 ml) and ethyl acetate (15 ml) and the extracted 
by ethyl acetate (3 × 15 ml) and the combined organic phases were dried (MgSO4). The 
solvent was removed by the rotary evaporator which afforded the desired compound 4 
as yellow oil (2.21 g, 94%) which was used directly in the next step. 
4.5.4.2 Ethyl 3-(1H-pyrrol-2-yl) propionate-5 
 
Hydrogen gas was bubbled into a solution of the product 4 (2.21 g, 13.2 mmol) and 
Pd/C (300 mg) in methanol (20 ml) and the mixture was placed under an atmosphere of 
hydrogen (balloon, ~ 1 l) and allowed to stir for 2 days at room temperature. The 
mixture was then filtered and the solvent was removed by rotary evaporator to afford 
the desired compound 5 in acceptable purity for use in the following reaction (2.23 g).115 
δH (CDCl3, 400 MHz): 1.25 (t, 3H, J 7.2 Hz CH3), 2.62 (t, 2H, J 6.9 Hz ), 2.88 (t, 2H, J 
6.8 Hz), 4.16 (q, 2H, J 6.7 Hz ), 5.91 (s, 1H), 6.09 (t, 1H, Ar-H), 6.65 (d, 1H, Ar-H), 
8.52 (brs, 1H, NH); δC (100 MHz, CDCl3): 14.0, 22.4, 34.4, 60.5, 105.2, 107.8, 116.6, 
130.8, 173.9. 
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4.5.4.3 2-Formyl-3,5-dimethylpyrrole-6 
 
To DMF (0.90 g; 12.22 mmol) phosphorus oxychloride (1.88 g; 12.22 mmol) was added 
dropwise during 20 minutes under stirring at 10 °C. The mixture was stirred for 15 
minutes at room temperature, then diluted with dichloromethane (5 ml) and cooled to 0 
°C and a solution of 2,4-dimethylpyrrole (1.00 g, 10.51 mmol) in dichloromethane (5.00 
ml) was added dropwise at 0 °C. The mixture was refluxed for 30 minutes and cooled to 
room temperature, and then sodium acetate (8.30 g, 61.10 mmol) in water (10 ml) was 
added. The mixture was refluxed for 30 minutes and cooled to room temperature and 
the organic layer was separated. The water layer was extracted with diethyl ether (3 × 
50 ml), and the organic layers were combined, washed with a saturated aqueous solution 
of sodium carbonate, and dried (Na2SO4). The solvents were removed, and the residue 
was purified by column chromatography (ethyl acetate, silica) to give product 6 as a 
white solid (0.95 g, 74%).193 δH (CDCl3, 400 MHz): 2.21 (s, 3H, CH3), 2.22 (s, 3H, 
CH3), 5.75 (s, 1H, Ar-H), 9.35 (s, 1H, CHO), 10.74 (s, 1H, NH). 
4.5.4.4 Ethyl 3-[4,4-Difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-
yl]propionate-7  
 
To a stirred solution of ethyl 3-(1H-pyrrol-2-yl) propanoate 5 (1.62 g, 6.96 mmol) and 
3,5-dimethyl-1H-pyrrole-2-carbaldehyde 6 (0.94 g, 7.66 mmol) in DCM (55 ml) 
phosphorus oxychloride (1.17 g, 7.66 mmol, 1.1eq) in DCM (4.00 ml) was added at 0 
o
C . The mixture stirred for 30 minutes at 0 
o
C then at room temperature for further 6 
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hours, the resulting black solution was cooled to 0 
o
C, and boron trifluoride etherate 
(3.55 ml, 28.00 mmol) and DIEA (5.10 ml, 29.25 mmol) were added. After stirring for 
another 12 hours at room temperature, water (100 ml) was added, and the mixture was 
filtered through a bed of celite. The precipitate was washed with DCM (100 ml), the 
aqueous layer was extracted with DCM (2 × 50 ml) and the combined organic layers 
have dried (Na2SO4) and concentrated in vacuo. The crude product was purified by flash 
chromatography (silica, dichloromethane) to give the title compound 7 as red crystals 
(1.41 g, 63%). δH (400 MHz, CDCl3): 1.24 (t, 3H, J 7.2 Hz), 2.16 (s, 3H, CH3-Ar), 2.48 
(s, 3H, CH3-Ar), 2.74 (t, 2H, J 7.7 Hz), 4.14 (q, 2H, J 6.7), 6.09 (s, 1H, Ar-H), 6.25 (d, 
1H, J  4.0 Hz, Ar-H), 6.85 (d, 1H, J 3.9 Hz, Ar-H), 7.99 (s, 1H, Ar-H); δC (100 MHz, 
CDCl3): 11.2, 14.2, 14.9, 23.9, 33.4, 60.5, 116.7, 120.3, 123.8, 128.0, 133.3, 135.1, 
143.7, 157.2, 160.3, 172.5;
 δF (376 MHz, CDCl3): -145.26 (q, JB-F 33.2 Hz). Data were 
consistent with literature.116 
4.5.4.5 7-(2-carboxyethyl)-5,5-difluoro-1,3-dimethyl-5H-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-4-ium-5-uide -8 
 
To a stirred solution of ethyl ester 7 (460 mg, 1.43 mmol) in THF (30 ml) was added 
water (24 ml) and concentrated aqueous hydrochloric acid (37%, 14.5 ml). After stirring 
for 48 hours at room temperature, dichloromethane (100 ml) was added, the organic 
phase was separated, and the aqueous layer was washed with DCM (2 × 75 ml). The 
combined organic layers were washed with brine (100 ml) and concentrated at the 
rotary evaporator under vacuum. The crude product was purified by flash 
chromatography (silica, dichloromethane, step gradient of 0-5% methanol) followed by 
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precipitation from hexane to give the title compound 8 (180 mg, 43%).116 δH (400 MHz, 
CDCl3): 2.22 (s, 3H, CH3-Ar), 2.43 (s, 3H, CH3-Ar), 2.60 (t, 2H, J 8.0 Hz), 3.04 (t, 2H, 
J 7.4 Hz), 6.27 (s, 1H, Ar-H), 6.34 (d, 1H, J  4.0 Hz, Ar-H), 7.05 (d, 1H, J  4.0 Hz, Ar-
H), 7.67 (s, 1H, Ar-H); 10.34 (brs, 1H, OH); δC (100 MHz, CDCl3): 11.0, 14.5, 23.5, 
32.3, 116.6, 120.4, 125.4, 128.8, 132.9, 134.5, 144.3, 156.9, 159.5, 173.4;
 δF (376 MHz, 
CDCl3): -145.26 (q, JB-F 33.23 Hz). Data consistent with literature.
116 
4.5.5  5-(Dimethyl amino)naphthalene-1-sulfonamide-9  
 
To a stirred solution of 5-(dimethylamino)naphthalene-1-sulfonyl chloride (1.1 g, 4.23 
mmol) in dry THF (20 ml) at -78 °C (acetone/dry-ice) bath, ammonia gas was bubbled 
through the condenser until sufficient liquid ammonia had condensed (~50 ml). The 
reaction mixture was then stirred for a further 1 hour before being allowed to warm to 
room temperature overnight. After the ammonia had evaporated, the solvent was 
removed and the solid residue was washed with water (50 ml) then chloroform (50 ml) 
and filtered. The product was dried to give the title compound 9 (900 mg, 87 %) as a 
white solid which used in subsequent reaction with no further purification. δH (DMSO-
d6, 400 MHz): 2.82 (s, 6H, 2 × CH3), 7.26 (d, 1H, J 7.5 Hz), 7-51-7.58 (m, 2H), 7.59 (s, 
2H, NH2), 8.13 (d, 1H, J 8.3 Hz), 8.29 (d, 1H, J 8.6 Hz), 8.43 (d, 1H, J 8.5 Hz). Data 
were consistent with literature. 117 
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4.5.6  5-(Dimethylamino)-N-(2-(2-(2 hydroxyethoxy)ethoxy) ethyl) 
naphthalene-1-sulfonamide-10 
 
 
Following the precedent procedure,194 in a three necked flask, dansylamide 9 (500 mg, 
1.99 mmol), potassium carbonate ( 276 mg, 1.99 mmol), and potassium iodide (18 mg, 
5% mol) were dissolved in dry DMF (95.0 ml) and the mixture was stirred at room 
temperature under a nitrogen atmosphere. Then 2-[2-(2-chloroethoxy)ethoxy]ethanol 
(335 mg, 1.99 mmol) was added to the mixture and the reaction allowed to stir at 100 
o
C 
overnight. The mixture was filtered, the filtrate collected and the solvent was 
evaporated. The resultant crude oil was purified by flash column chromatography 
(silica, ethyl acetate) to give the desired substance 10 (250 mg, 32%) as the first eluting 
compound. δH (CDCl3, 400 MHz):  2.86 (s, 6H, 2 × CH3), 2.98-3.12 (m, 2H, CH2), 3.37-
3.43 (m, 4H), 3.47-3.52 (m, 2H), 3.51-3.57 (m, 2H), 3.71-3.76 (m, 2H), 6.09 (t, 1H, J 
5.8 Hz, SO2NH), 7.16 (d, 1H, J 7.5 Hz, Ar-H), 7.48 (t, 1H, J 7.8 Hz, Ar-H), 7.54 (t, 1H, 
J 8.0 Hz, Ar-H), 8.21 (d, 1H, J 7.3 Hz, Ar-H), 8.32 (d, 1H, J 8.6 Hz, Ar-H), 8.51 (d, 1H, 
J 8.5 Hz, Ar-H); δC (CDCl3, 100 MHz): 42.9, 45.3 (2 × CH3-N), 61.4, 69.4, 70.1 (2C), 
72.6, 115.1, 119.0, 123.1, 128.1, 129.2, 129.5, 129.7, 130.2, 135.0, 151.6. HRMS (NSI) 
(m/z), [M+H] calcd. for C12H14N2O2S   383.1635, found 383.1639. 
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4.5.7 5-(Dimethylamino)-N,N-bis(2-(2-(2-
hydroxyethoxy)ethoxy)ethyl)naphthalene-1-sulfonamide- 10a 
 
 
Further elution afforded 10a (340 mg, 33%) as a thick red oil. δH  (CDCl3, 400 MHz): 
2.82 (s, 6H, 2 × CH3), 3.29 (brs, 2H, 2 × OH), 3.47-3.66 (m, 24 H, 12 × CH2), 7.13 (d, 
1H, J 7.5 Hz, Ar-H), 7.48 (m, 2H, Ar-H), 8.09 (d, 1H, J 7.3 Hz, Ar-H), 8.23 (d, 1H, J 
8.6 Hz, Ar-H), 8.47 (d, 1H, J 8.5 Hz, Ar-H); δC (CDCl3, 100 MHz): 45.3 (2 × CH3-N), 
47.9 (2 × CH2-N-SO2), 61.4 (2 × CH2-OH), 70.0 (4 × CH2), 70.1 (2 × CH2), 72.5 (2 × 
CH2), 115.1, 119.3, 123.0, 127.9, 128.5, 129.9, 130.1, 130.2, 135.2, 151.5; HRMS 
(NSI) (m/z), [M+H]  calcd, for C24H38N2O8S: 515.2422, found 515.2427. 
4.5.8 N-(6-hydroxy-hexyl)-5-dimethylamino-naphthalene-1-sulfonamide 12 
 
As described in the literature procedure,195 a two necked flask was charged with dansyl 
chloride (5.00 g, 18.53 mmol) and DMAP (250 mg, 2.04 mmol) dissolved in dry 
dichloromethane (80 ml); the mixture was stirred under a nitrogen atmosphere at room 
temperature for 20 minutes, followed by the addition of dry triethylamine (10 ml). After 
stirring the reaction mixture at 0 
o
C for 15 minutes, 6-aminohexanol (2.50 g, 21.3 mmol) 
was added and the whole was stirred for a further 15 minutes. The mixture was then 
warmed to 20 
o
C and stirred for 3.5 hours, diluted with DCM (50 ml) and washed with 
water (3 × 40 ml) to produce the sulphonamide 12 (6.22 g, 92%.). δH (CDCl3, 400 MHz): 
133 
 
1.10-1.13 (m, 4H), 1.32-1.35 (m, 4H), 1.85 (brs, 1H, OH), 2.85 (t, 2H J 9.5 Hz), 2.85 (s, 
6H, N(CH3)2), 3.46 (t, 2H, J 6.5 Hz), 5.15 (t, 1H, J 5.9 Hz, SO2NH), 7.14 (d, 1H, J 7.5 
Hz, Ar-H), 7.49-7.52 (m, 2H, Ar-H), 8.21 (d, 1H, J 8.4 Hz, Ar-H), 8.30 (d, 1H, J 8.7 Hz, 
Ar-H), 8.50 (d, 1H, J 8.4 Hz, Ar-H); δC (CDCl3, 100 MHz): 24.9, 25.9, 29.3, 32.2, 42.9 
(C-NH), 45.3 (2C), 62.4 (C-OH), 115.1, 118.7, 123.1, 128.2, 129.4, 129.6, 129.8, 130.2, 
134.8 (C-N(CH3)2), 151.8 (C-SO2N); HRMS (NSI) (m/z), [M+H] calcd, for C19H28N2O3S 
351.1742 found 351.1737. 
4.5.9 Coupling the organophosphate compound with fluorescent tag-13  
  
To a cold (-78 
o
C) stirred solution of the dansylamide 12 (470 mg, 1.34 mmol) in dry 
dichloromethane (20 ml) and triethylamine ( 0.20 ml, 2.01 mmol) under nitrogen, was 
added dropwise the organophosphate chloride 2 (410 mg, 2.00 mmol) in dry  
dichloromethane (10 ml) followed by further stirring at -78 °C for 30 minutes. The 
reaction mixture was allowed to warm to room temperature and kept stirring for a 
further 24 hours. The reaction mixture was then concentrated, dry toluene (30 ml) was 
added, the mixture allowed to stand in a fridge for an hour then filtered and the solvent 
was removed from the filtrate and the residue was dried under a vacuum. Column 
chromatography on the resultant oil, (silica, ethyl acetate), yielded the desired 
compound 13 as an orange oil (150 mg, 22%). δH (400 MHz, CDCl3):1.07-1.17 (m, 2H), 
1.24 (t, 2H, J 7.2 Hz), 1.30 (m, 2H), 1.48-1.51 (m, 2H), 2.82 (t, 2H, J 6.5 Hz), 2.86 (s, 
6H, 2× CH3), 4.02-4.10 (m, 2H), 5.08 (t, 1H, J 6.1 Hz, NH), 5.31 (d, 2H, J 4.0 Hz), 7.00 
(d, 1H J 8.8 Hz), 7.02-7.10 (m, 2H), 7.15 (d, 1H, J 7.5 Hz), 7.26 (t, 1H, J 7.8 Hz), 7.47-
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7.54 (m, 1H), 8.21 (d, 2H, J 8.4 Hz), 8.29 (d, 1H, J 8.6 Hz), 8.51 (d, 1H, J 8.5 Hz); δC 
(100 MHz, CDCl3): 24.5, 25.5, 29.2, 29.72, 42.8, 45.3, 68.4, 115.0, 118.5, 118.5, 118.7, 
123.1, 124.1, 125.2, 128.2, 129.4, 129.5, 129.6, 129.7, 130.2, 134.7, 151.8;P (162 
MHz, CDCl3): -8.87 (q, JABX 14.8, 19.2 and 7.6 Hz); HRMS (NSI) (m/z), [M+H] calc. 
519.1713 found 519.1717. 
4.6 Experimental of Chapter 3 
General Procedure A 
Diazoxide precursors, aminobenzenesulfonamide derivatives, were all introduced as 
starting materials in the following diazoxide analogue preparations; these reactions have 
been performed under conditions of known literature procedure.196  
The 2-aminobenzenesulfonamide analogue was dissolved in acetic acid, then acetic 
anhydride was added. The mixture was stirred at 110 
o
C for 1 hour. After cooling to 
room temperature the mixture was evaporated under reduced pressure to remove the 
acetic acid. The crude compound was reacted with sodium hydroxide solution (3%, 40 
ml) at room temperature for 1 hour then acidified with 2 M hydrochloric acid until 
precipitates were formed. The solid was filtered off, washed with water then dried to 
give the corresponding diazoxide analogue. 
General Procedure B 
A two necked flask was charged with the 2-amino benzenesulfonamide analogue in 
dioxane. The reaction mixture was stirred under nitrogen atmosphere at 30 
o
C for 10 
minutes then glutaric acid monomethyl ester chloride was slowly added. The reaction 
mixture was kept stirring for a further 1 hour, then evaporated under reduced pressure to 
remove the solvent. The obtained product was dissolved in 3% of sodium hydroxide 
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solution (10 mL) and stirred for 1 hour at room temperature, then acidified with 2 M 
hydrochloric acid until precipitates started forming. The mixture was allowed to stand 
overnight to complete the precipitation, and the product was then collected by filtration 
and washed with ether and dried to give the corresponding diazoxide analogue. 
General Procedure C 
To a stirred solution of diazoxide butyric acid analogues, triethylamine and DMAP in 
dry acetonitrile was added tosyl chloride in acetonitrile at 0 
o
C. The mixture was stirred 
for 30 min, then the alcohol in dry acetonitrile was added at 0 
o
C, and then the reaction 
mixture was allowed warm to 25 
o
C then stirred overnight.188 Water was added to the 
mixture which was then extracted with ethyl acetate; the combined organic layers were 
washed with water, brine and dried (Na2SO4). 
4.6.1 4-Bromobenzyl alcohol-O-(tert-butyldimethylsilyl) ether -14 
In a modified literature procedure,171 diazirine 22 was prepared starting from the 
commercially available bromobenzyl alcohol in eight reaction steps as follows.  
 
A two necked round bottomed flask, equipped with a stirring bar, was charged with     
4-bromobenzyl alcohol (25 g, 83.20 mmol) dissolved in dry DCM (125 ml) under a 
nitrogen atmosphere followed by addition of imidazole (21.80 g, 188 mmol) and then 
tert-butyldimethylsilyl chloride (15.00 g, 99.80 mmol) dissolved in dry DCM (25 ml) 
and the mixture stirred for 20 hours. The mixture was washed with water (75 ml), then 
the organic layer was separated, dried (MgSO4) and the solvent was removed in vacuo. 
Column chromatography of the crude compound (silica, DCM) afforded  compound 14 
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(38.00 g, 94%) as a colourless liquid. δH (400 MHz, CDCl3): 0.07 (s, 6H, Si-(CH3)2), 
0.91 (s, 9H, C-(CH3)3), 4.65 (s, 2H, CH2), 7.16 (d, 2H, J 8.2 Hz, o-ArH), 7.41 (d, 2H, J 
8.7 Hz, m-ArH ). Data were consistent with literature.
171
  
4.6.2 4-[(tert-butyldimethylsiloxy)methyl]-2,2,2-trifluoroacetophenone -15 
 
To a stirred solution of 4-bromobenzyl alcohol-O-(tert-butyldimethylsilyl) ether 14 (3.0 
g, 9.95 mmol) in dry THF (60 ml) was added n-butyl lithium (49.70 mmol, 27 ml, 2.50 
M in hexane) at -78 °C (acetone/dry ice) under a nitrogen atmosphere over a period of  
10 min. The reaction mixture was stirred under these conditions for a further 1.5 hours. 
Methyl trifluoroacetate (5.00 ml, 49.70 mmol) was then added dropwise over 10 min 
and stirring continued for a further 1.5 hours. Saturated aqueous ammonium chloride 
(40 ml) was then added and the reaction mixture warmed to room temperature. The 
reaction mixture was diluted with THF (25 ml) and separated, and the organic layer 
washed with saturated aqueous ammonium chloride (2 × 20 ml) and then with water (2 
× 20 ml). The combined aqueous layers were extracted with THF (30 ml) and then the 
combined organics dried over (MgSO4), filtered and concentrated to give compound 15 
as a colourless liquid (2.68 g, 77%). δH (400 MHz, CDCl3) 0.15 (s, 6H, Si-(CH3)2) 0.98 
(s, 9H, C-(CH3)3), 4.85 (s, 2H, CH2), 7.53 (d, 2H, J 8.7 Hz, o-ArH), 8.07 (d, 2H, J 8.2 
Hz, m-ArH); δF (376 MHz, CDCl3): -71.27 ppm. Data were consistent with literature.
171  
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4.6.3 4-[(tert-Butyldimethylsiloxy)methyl]-2,2,2-trifluoroacetophenone-
oxime-16 
 
 
To a stirred solution of 4-[(tert-butyldimethylsiloxy)methyl]-2,2,2-
trifluoroacetophenone 15 (10.51 g, 34.60 mmol) in anhydrous pyridine (100 ml) and 
anhydrous ethanol (47 ml) under nitrogen, hydroxylamine hydrochloride (2.64 g, 38.00 
mmol) was added and then the reaction mixture heated at 80 °C for 16 hours. The 
reaction mixture was then concentrated, suspended in ether (250 ml), washed with water 
(4 × 100 ml), dried (MgSO4), filtered and concentrated. The resulting residue was 
purified by column chromatography (silica, DCM) to yield compound 16 (7.83 g, 72 %) 
as a colourless viscous liquid. δH (400 MHz, CDCl3): 0.04 (s, 6H, Si-(CH3)2), 0.88 (s, 
9H, C-(CH3)3), 4.71 (s, 2H, CH2), 7.35 (d, 2H, J 8.1 Hz, o-ArH), 7.43 (d, 2H, J 7.8 Hz, 
m-ArH), 8.85 and 8.96 (brs, 1H, OH); δF (376 MHz, CDCl3): -66.4 ppm. Data were 
consistent with literature.171  
4.6.4  4-[(tert-Butyldimethylsiloxy)methyl]-2,2,2-trifluoroacetophenone-O-(4 
toluenesulphonyl)oxime-17 
 
A two necked round-bottomed flask equipped with a stirring bar was charged with       
4-[(tert-butyldimethylsiloxy)methyl]-2,2,2-trifluoroacetophenone oxime 16 (220 mg, 
0.71 mmol) and dry DCM (2 ml). To this stirred solution DMAP (5 mg, 0.03 mmol), p-
toluenesulfonyl chloride (150 mg, 0.80 mmol) and triethylamine (180 mg, 0.18 mmol) 
were added, and the mixture was stirred under a nitrogen atmosphere at room 
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temperature for 24 hours. The reaction mixture was then partitioned between water (10 
ml) and DCM (15 ml) and the organic layer washed with additional water (10 ml). 
Solvents were removed in vacuo to yield a brown oil, which was purified by column 
chromatography (silica, DCM/ hexane 3:4) to afford 17 as a pale green oil (290 mg, 
83%). δH (400 MHz, CDCl3): 0.00 (s, 6H, Si-(CH3)2), 0.83 (s, 9H, C-(CH3)3), 2.35 (s, 
3H, ArCH3), 4.66 (s, 2H, CH2), 7.23-7.29 (m, 6H, ArH), 7.72-7.79 (m, 2H, ArH); δF 
(376 MHz, CDCl3): -66.5 ppm. Data were consistent with literature.
171 
4.6.5  3-[α-(tert-Butyldimethylsiloxy)-4-tolyl]-3-trifluoromethyl diaziridine-
18 
 
To a stirred solution of oxime 17 (330 mg, 0.67 mmol) in dry DCM (2.00 ml) at -78 °C 
(acetone/dry-ice bath), ammonia gas was introduced through a condenser until sufficient 
liquid ammonia had condensed (~15 ml). The reaction mixture was then stirred for a 
further 3 hours before being allowed to warm to room temperature over 2 hours. After 
the ammonia had evaporated, the reaction mixture was filtered and concentrated to give 
the title compound 18 as a white translucent paste (150 mg, 67%), which used in 
subsequent reactions without further purification. δH (400 MHz, CDCl3): 0.01 (s, 6H, 
Si-(CH3)2) 0.84 (s, 9H, C-(CH3)3), 2.20 (d, 1H, J 8.7 Hz, NH), 2.76 (d, 1H, J 8.3 Hz, 
NH), 4.65 (s, 2H, CH2), 7.27 (d, 2H, J 8.0 Hz, o-ArH), 7.46 (d, 2H, J 8.0 Hz, m-ArH); 
δF (376 MHz, CDCl3): -75.5 ppm. Data were consistent with literature.
171 
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4.6.6  (4-(3-(trifluoromethyl)diaziridin-3-yl)phenyl)methanol-19 
 
In a two necked flask 3-[α-(tert-butyldimethylsiloxy)-4-tolyl]-3-trifluoromethyl 
diaziridine 18 (250 mg, 0.75 mmol) was treated with as a 1.00 M solution of 
tetrabutylammonium fluoride in THF (1.00 ml, 0.10 mmol) containing water (0.05 ml, 
5%). The solution was stirred at room temperature for 5 hours, then diluted with ether 
(15 ml), washed with water (3 × 4.00 ml), dried (Na2SO4), filtered and concentrated. 
Column chromatography of the resultant oil, (silica, DCM), yielded the title compound 
19 (110 mg, 67%) as a pale yellow oil. δH (400 MHz, CDCl3):1.82 (brs, 1H, OH), 2.14 
(d, 1H, J 8.4 Hz, NH), 2.73 (d, 1H, J 8.4 Hz, NH), 4.66 (s, 2H, CH2), 7.35 (d, 2H, J 8.0 
Hz, o-ArH), 7.35 (d, 2H, J 8.1 Hz, m-ArH); δF (376 MHz, CDCl3): -75.4 ppm. Data 
were consistent with literature.171 
4.6.7 3-[ α - (tert-Butyldimethylsiloxy)-4-tolyl]-3-trifluoromethyl diazirine-20  
 
In a darkened fume hood, to a stirred solution of 3-[α-(tert-butyldimethylsiloxy)-4-
tolyl]-3-trifluoromethyl diaziridine 18 (2.50 g, 7.53 mmol) and anhydrous triethylamine 
(1.75 ml, 1.27 g, 12.55 mmol) in anhydrous methanol (5 ml) was added iodine (1.60 g, 
6.30 mmol) portionwise, until a red/orange colour persisted. The reaction mixture was 
then allowed to stir for a further 20 minutes before being neutralised with 10% aqueous 
citric acid solution till pH ~ 5-6 and then quenched with a few drops of 5 % aqueous 
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sodium meta-bisulphite solution. The reaction mixture was then poured onto ether (150 
ml) dried (Na2SO4) filtered and concentrated. Column chromatography (silica, hexane: 
DCM, 2:1 (NB: column wrapped in newspaper)) afforded the title compound 20 (1.514 
g, 61 %) as a light yellow oil. δH (400 MHz, CDCl3), 0.09 (s, 6H, 2 × CH3) 0.93 (s, 9H, 
3 × CH3), 4.74 (s, 2H, CH2), 7.16 (d, 2H, J 7.7 Hz, ArCH), 7.35 (d, 2H, J 7.7 Hz, 
ArCH); δF (376 MHz, CDCl3): -65.1ppm. Data were consistent with literature.
171 
4.6.8 4-[3-Trifluoromethyl-3H-diazirin-3-yl) benzyl alcohol-21 
 
In a darkened fume hood, 3-[α-(tert-butyldimethylsiloxy)-4-tolyl]-3-trifluoromethyl 
diazirine 20 (1.500 g, 4.54 mmol) was treated with a solution of 4M hydrogen chloride 
in dioxane (5.5 ml, 5.45 mmol). The solution was allowed to stir at room temperature 
for 5 hours, then diluted with ether (40 ml), washed with water (3 × 12 ml), dried 
(Na2SO4), filtered and concentrated. Column chromatography on the resultant oil (silica, 
dichloromethane, (nb: column wrapped in newspaper)) yielded the title compound 21 
(0.791, 81 %) as a pale yellow oil. δH (400 MHz, CDCl3), 2.36 (brs, 1H, OH), 4.66 (s, 
2H, CH2), 7.17 (d, 2H, J 7.7 Hz, Ar-H), 7.35 (d, 2H, 8.5 J Hz, Ar-H); δF (376 MHz, 
CDCl3): -65.0 ppm. Data were consistent with literature.
171 
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4.6.9 3-(4-(Bromomethyl)phenyl)-3-(trifluoromethyl)-3H-diazirine-22 
 
Diazirine 21 (1.60 g, 7.40 mmol) and carbon tetrabromide (2.70 g, 8.38 mmol) was 
dissolved in dry DCM (10 ml)  and triphenylphosphine (2.20 g, 8.38 mmol) was slowly 
added to the mixture at 0 
o
C and the mixture was stirred at room temperature for 5 hours. 
Hexane (50 ml) was added to the reaction mixture and the precipitate was filtered 
through celite, the filtrate was evaporated in vacuo and the residue was purified by 
column chromatography (silica, hexane/ ether 1:1) to give the title compound 22 ( 1.99 
g, 96%) as light yellow oil: δH (400 MHz, CDCl3), 4.46 (s, 2H, CH2), 7.17 (d, 2H, J  8.2 
Hz, ArCH), 7.42 (d, 2H, J 8.2 Hz, ArCH); δF (376 MHz, CDCl3): -65.0 ppm. Data 
consistent with literature.171 
4.6.10 N-Allyl-5-(dimethylamino)naphthalene-1-sulfonamide-23 
 
 
To a stirred solution of commercially available dansyl chloride (0.5 g, 1.85 mmol) in 
dry DCM (8.00 ml) and DMAP (220 mg, 1.8 mmol) at 0 
o
C, allylamine (0.15 ml, 2.03 
mmol) was added, followed by triethylamine (0.50 ml, 3.58 mmol), and the mixture 
stirred for 20 minutes. The mixture was warmed to room temperature and stirred for 3.5 
hours, then diluted with DCM (10 ml), washed with water (2 × 10 ml), dried (MgSO4) 
and evaporated in vacuo. After the addition of chloroform (10 ml), the residue re-
evaporated again and dried to give 23 ( 0.43 g, 80%). δH (CDCl3, 400 MHz): 2.78 (s, 
142 
 
3H, CH3), 2.88 (s, 3H, CH3), 2.53 (d, 2H, J 5.8 Hz), 4.86 (d, 1H, J 10.1 Hz), 5.06 (d, 
1H, J 17.0 Hz), 5.51-5.56 (m, 1H), 6.38 (d, 1H, J 6.5 Hz), 7.07 (d, 1H, J 7.6 Hz,), 7.21 
(d, 1H, J 7.3 Hz), 7.47 (t, 2H, J 7.9 Hz), 8.18 (d, 1H, J 6.5 Hz), 8.22 (d, 1H, J 8.3 Hz), 
8.34 (d, 1H, J 8.5 Hz), 8.50 (d, 1H, J 8.4 Hz). δC (CDCl3, 100 MHz): 39.0, 45.4, 45.8, 
106.5, 115.1, 117.36, 117.42, 118.8, 123.1, 128.2, 128.3, 129, 129.7, 130.4, 149.6. 
4.6.11 A model reaction using benzyl alcohol-24 
 
A two necked flask was charged with sulphonamide 23 (320 mg, 1.10 mmol) in dry 
THF (6.00 ml). The mixture was stirred under a nitrogen atmosphere followed by 
addition of triphenylphosphine (340 mg, 1.30 mmol) and then benzyl alcohol  (0.12 ml, 
1.10 mmol), and then DEAD (1.0 M in THF, 0.16 ml, 0.16 mmol) was added. The 
mixture was stirred at room temperature for a further 4 hours, and then concentrated in 
vacuo. The residue was purified using column chromatography (silica, ethyl acetate/ 
hexane, 1:4), yielded the title compound 24 as a thick light brown oil (180 mg, 43%). δH 
(400 MHz, CDCl3): 2.78 (s, 6H, 2 × CH3 ), 3.72 (d, 2H, J 6.52 Hz), 4.35 (s, 2H, Ph-
CH2), 4.98 (dd, 2H, J 10.0, 17.0 Hz, CH2-vinyl), 5.42 (m, 1H, vinyl), 7.13-7.22 (m, 6H, 
phenyl), 7.43 (dt, 2H, J 7.4 Hz, J 7.6 Hz), 8.16 (d, 1H, J 7.3 Hz), 8.25 (d, 1H, J 8.5 Hz), 
8.44 (d, 1H, J 8.4 Hz); δC (100 MHz, CDCl3): 45.3, 48.4, 49.5 (2 × CH3), 115.1, 119.4 
(2C), 123.0, 127.5, 128.0, 128.3 (3C), 128.4 (3C), 130.1, 130.4, 132.3, 135.0, 135.6, 
151.7. 
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4.6.12 Coupling of diaziridine with fluorescent component-25 
 
In a two necked flask, sulphonamide 23 (130 mg, 0.45 mmol) was dissolved in dry THF 
(5.00 mL) under a nitrogen atmosphere followed by addition of triphenylphosphine 
(210 mg, 0.80 mmol) diaziridine 19 (100 mg, 0.45 mmol), and finally DEAD (1.00 M in 
THF, 0.10 mL, 0.10 mmol). The mixture was stirred at room temperature for 4 hours 
then concentrated in vacuo. The residue was purified using column chromatography 
(silica, ethyl acetate/hexane, 1:4) yielded the title compound 25 as a thick brown oil 
(113 mg, 51%). δH (400 MHz, CDCl3): 2.16 (d, 1H, J 8.3 Hz, NH), 2.75 (d, 1H, J 8.3 
Hz, NH), 2.89 (s, 6H, 2 × CH3), 3.81 (d, J 6.5 Hz, 2H), 4.45 (s, 2H, CH2), 4.96 (dd, 2H, 
J 10.0, 17.0 Hz), 5.39-5,46 (m, 1H, vinyl), 7.09-7.14 (m, 2H), 7.38 (d, 1H, J 8.13 Hz), 
7.45 (dt, 2H, J 8.3 Hz, J 7.6 Hz), 8.18 (d, 1H, J 8.3 Hz), 8.22 (d, 1H, J 8.7 Hz), 8.47 (d, 
1H, J 8.4 Hz); δC (100 MHz, CDCl3): 45.5, 49, 49.3 (2 × CH3), 115.2, 119.3, 119.7, 
123.1, 128.2 (3C), 128.8 (3C), 130, 130.4, 130.7, 131, 132.3, 134.8, 138.2, 151.8; δF 
(376 MHz, CDCl3): -75.4; HRMS (NSI) (m/z), [M+H] calc. 491.1723 found 491.1714. 
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4.6.13 5-(Dimethylamino)-N-(6-hydroxyhexyl)-N-(4-(3-(trifluoromethyl)-3H-
diazirin-3-yl)benzyl)naphthalene-1-sulfonamide-26 
 
 
Sulfonamide compound 12  (570 mg, 1.63 mmol)  was dissolved in dry DMF (15 ml), 
and potassium carbonate (900 mg, 0.65 mmol) was added and stirred under a nitrogen 
atmosphere at room temperature. To the reaction mixture, diazirine 10 (500 mg, 1.79 
mmol) in DMF (15 ml) was slowly added over 10 minutes and the mixture was stirred 
at room temperature for a further 20 hours. The mixture was then filtered and the DMF 
evaporated under a vacuum, the product dissolved in DCM (40 ml) and washed with 
water (3 × 30 ml), saturated sodium bicarbonate solution (20 ml) and dried (MgSO4). 
The product was purified by column chromatography (silica, ethyl acetate: hexane, 1:1 
v/v) to produce the title compound 26 as an orange thick oil (750 mg, 84%). δH (400 
MHz, CDCl3):  0.96-1.02 (m, 4H), 1.18-1.23 (m, 4H), 2.07 (brs, OH), 2.82 (s, 6H, 2 × 
CH3 ), 3.15 (t, 2H, J 7.4 Hz), 3.46 (t, 2H, J 5.5 Hz), 4.47 (s, 2H, Ar-CH2), 7.04 (d, 2H, J 
8.1 Hz), 7.17-7.22 (m, 3H), 7.49 (t, 1H, J 7.4 Hz), 7.55  (t, 1H, J 8.5 Hz), 8.21 (d, 1H, J 
8.4 Hz), 8.26 (d, 1H, J 8.6 Hz), 8.52 (d, 1H, J 8.4 Hz); δC (100 MHz, CDCl3): 24.9, 26.0, 
27.1, 32.3, 45.4 (2C), 46.5, 49.8, 62.5, 115.2, 119.3, 123.1, 126.5 (2C), 128.1, 128.4, 
128.6 (4C), 129.9, 130.0, 130.1, 130.5, 134.7, 138.1, 151.8; δF (376 MHz, CDCl3): -
65.0 ppm; HRMS (NSI) (m/z), [M+H] calc. 549.2142 found 549.2132. 
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4.6.14 Coupling the benzophenone with the dansyl amide-27a 
 
To a stirred solution of the dansyl amide 12 (470 mg, 1.01 mmol) and potassium 
carbonate (520 mg 3.76 mmol) in 25 mL DMF, a solution of                                          
4-(bromomethyl)benzophenone (250 mg, 0.90 mmol) in dry DMF (5.00 ml) was added 
via a dropping funnel over 45 minutes. The mixture was stirred at room temperature for 
24 hours, then filtered and concentrated in vacuo. The residue was dissolved in DCM 
(40 ml), the organic layer was washed with water (3 × 20 ml) then with a saturated 
solution of sodium bicarbonate (20 ml) and dried over anhydrous magnesium sulfate, 
filtered and concentrated. Column chromatography on the resultant oil (silica, ethyl 
acetate: cyclohexane, 1:4 v/v) yielded the title compound 27a as a thick orange oil (492 
mg, 82 %); δH (400 MHz, CDCl3): 0.00 (s, 6H, 2 × Si-CH3), 0.86 (s, 9H, 3 × tBu-CH3), 
1.42 (s, 10 H), 1.09-1.15 (m, 2H), 1.22-1.28 (m, 2H), 1.39-1.45 (m, 4H), 2.05 (t, 2H, J 
7.3 Hz), 2.39 (t, 2H, J 6.9 Hz), 2.59 (t, 2H, J 7.2 Hz), 2.87 (s, 6H, 2 × CH3), 3.26 (t, 2H, 
J 7.3 Hz), 3.96 (t, 2H, J 6.5 Hz), 4.51 (s, 2H, Ar-CH2), 7.18 (d, 1H, J 6.9 Hz), 7.29 (d, 
1H, J 8.3 Hz), 7.44-7.60  (m, 6H), 7.67 (d, 2H, 8.3 J Hz), 7.75 (d, 2H, J 8.3 Hz), 8.25 (d, 
1H, J 7.3 Hz,), 8.32 (d, 1H, J 8.6 Hz), 8.54 (d, 1H, J 8.4 Hz); δC (100 MHz, CDCl3): -
5.2 (2C), 18.4, 25.4, 26.1 (3C), 26.5, 27.0, 27.5, 32.7, 45.5, 46.9, 50.3, 63.0, 115.3, 
119.5, 123.2, 128.1(2 C), 128.2, 128.4 (3C), 130.1 (3C), 130.2, 130.4 (2C), 130.6, 132.6, 
135.0, 137.0, 137.6, 141.2, 152.0, 196.3; HRMS (NSI) (m/z), [M+H] calc.659.3333 
found 659.3326. 
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4.6.15 N-(4-Benzoylbenzyl)-5-(dimethylamino)-N-(6-
hydroxyhexyl)naphthalene-1-sulfonamide-27  
 
 
In a two necked flask (390 mg, 0.59 mmol) of the hybrid molecule 27a was dissolved in 
methanol (5.00 ml), then treated with a solution of hydrochloric acid in dioxane (5 ml, 4 
M). The solution was stirred at room temperature for three hours then concentrated and 
ethyl acetate (30 ml) was added. The organic layer was separated and washed with 
water (3 × 25 ml), dried (Na2SO4), filtered and concentrated. Column chromatography 
of the resultant oil, (silica, ethyl acetate: cyclohexane, 1:6), yielded the desired 
compound 27 as a yellow oil (230 mg, 71%). δH (400 MHz, CDCl3): 0.97-1.03 (m, 4H), 
1.25-1.31 (m, 4H), 1.47 (brs, OH), 2.87 (s, 6H, 2 × CH3 ), 3.21 (t, 2H, J 7.4 Hz), 3.46 (t, 
2H, J 5.5 Hz), 4.56 (s, 2H, Ar-CH2), 7.19 (d, 1H, J 7.5 Hz), 7.29 (d, 2H, J 8.3 Hz), 7.45-
7.58 (m, 5H), 7.67 (d, 2H, J 8.3 Hz), 7.75 (d, 2H, J 8.3 Hz), 8.24 (d, 1H, J 8.5 Hz), 8.31 
(d, 1H, J 8.6 Hz), 8.53 (d, 1H, J 8.4); δC (100 MHz, CDCl3): 24.9, 26.1, 27.2, 32.3, 45.4, 
46.7 (2C), 50.2, 62.5, 115.2, 119.3, 123.1, 128.0 (2C), 128.1, 128.3 (3C), 129.9 (3C), 
130.1, 130.2 (2C), 130.5, 132.5, 134.8, 136.9, 137.3, 141.0, 151.8, 196.3. 
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4.6.16  N-(4-Benzoylbenzyl)-5-(dimethylamino)-N-(2-(2-(2 
hydroxyethoxy)ethoxy) ethyl)naphthalene-1-sulfonamide-28 
 
 
In a two necked round bottomed flask, 5-(dimethylamino)-N-(2-(2-(2 
hydroxyethoxy)ethoxy)ethyl)naphthalene-1-sulfonamide 10 (180 mg, 0.47 mmol) was 
dissolved in dry DMF (10 ml), then potassium carbonate (260 mg, 1.88 mmol) was 
added to the solution under a nitrogen atmosphere. 4-Bromo-methylbenzophenone (145 
mg, 0.52 mmol) in dry DMF (4.00 ml) was slowly added to the mixture and stirred for a 
further 24 h at room temperature. The mixture was then filtered and the DMF was 
removed under a vacuum, and the product dissolved in DCM (40 ml) and washed with 
water (3 × 30 ml), then saturated sodium bicarbonate (30 ml) and dried (MgSO4). The 
product was then purified by column chromatography (silica, ethyl acetate ) gave 
compound 28 as a yellow thick oil ( 92 mg, 34%). δH (400 MHz, CDCl3): 2.39 (brs, 1H, 
OH), 2.86 (s, 6H, 2 × CH3 ), 3.37 (t, 2H, J 4.6 Hz), 3.43-3.50 (m, 6H), 3.51 (t, 2H, J 4.5 
Hz), 3.67 (t, 2H, J 4.2 Hz), 4.66 (s, 2H,  Ar-CH2), 7.17 ( d, 1H, J 7.6 Hz), 7.26 (d, 2H, J 
8.2 Hz), 7.43-7.58 (m, 6H), 7.63 (d, 2H, J 8.3 Hz), 7.73 (d, 2H, J 8.2 Hz), 8.24 ( d, 1H, 
J 8.4 Hz), 8.28 (d, 1H, J 8.6 Hz), 8.52 (d, 1H, J 8.4 Hz); δC (100 MHz, CDCl3): 45.3, 
46.1, 51.7, 61.6, 69.6, 70.1, 72.3, 115.2, 119.3, 123.1, 128.0, 128.1, 128.2, 129.7, 129.9, 
130.2, 130.5, 132.4, 134.9, 136.7, 137.3, 141.1, 151.7,196.2. 
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4.6.17  3-Methyl-4H-benzo[1,2,4]thiadiazine 1,1-dioxide-33 
 
Following General Procedure A; 2-aminobenzenesulfonamide (3.00 g, 17.42 mmol) in 
acetic acid (20 ml) and acetic anhydride (2.50 ml, 26.40 mmol) gave title compound 33 
(2.55 g, 74%).197 δH (DMSO-d6, 400 MHz): 2.26 (s, 3H, CH3), 7.26 (d, 1H, J 8.24 Hz, 
Ar-H), 7.39 (t, 1H, J 7.44 Hz, Ar-H), 7.7.64 (t, 1H, J 6.64 Hz, Ar-H), 7.74 (d, 1H, J 7.90 
Hz, Ar-H) 12.00 (s, NH). δC (DMSO-d6,100 MHz): 22.6, 117.2, 121, 123.4, 126.1, 133, 
135.1, 157.2.  
4.6.18  3-Methyl-7-nitro-4H-1,2,4-benzothiadiazine-1,1-dioxide-34 
 
 
To a stirred solution of diazoxide 33 (100 mg, 0.05 mmol) in sulphuric acid (2.00 ml), 
concentrated nitric acid (0.15 ml) was added at ) 
o
C and the mixture was heated to 80 
o
C 
for one hour. The reaction mixture was cooled to room temperature and neutralized by 
solution of sodium bicarbonate and lift in the fridge overnight to complete crystalizing. 
Crystals were collected and dried gave the title compound 34 as a yellow solid (55 mg, 
44.4%). δH  (DMSO-d6, 400 MHz): 2.33 (s, 3H, CH3), 7.47 (d, 1H, J 8.9 Hz, Ar-H), 
8.40-8.46 (m, 2H, Ar-H); δC (DMSO-d6,100 MHz): 23.3, 119.6, 120.5, 121.1, 128.4, 
140.4, 144.7, 158.9. Data  consistent with literature. 198 
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4.6.19  7-Bromo-3-methyl-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide-35 
 
Following General Procedure A; 5-bromo-2-aminobenzenesulfonamide 37 (1.5 g, 5.9 
mmol) in acetic acid (6.00 ml) and acid anhydride (0.7 ml, 7.4 mmol) gave title 
compound 35 (1.35 g, 82%).199 δH  (DMSO-d6, 400 MHz): 2.29 (s, 3H, CH3), 7.27 (d, 
1H, J 7.72 Hz, Ar-H), 7.82 (d, 1H, J 8.96 Hz, Ar-H), 7.91 (s, 1H, Ar-H), 12.24 (s, NH). 
δC (DMSO-d6,100 MHz): 22.6, 117, 119.8, 122.3, 125.5, 134.4, 135.9, 157.4; vmax: 3256, 
3173, 3105, 1602, 1574, 1515, 1474, 1379, 1277 cm
-1
; HRMS (NSI) (m/z) calcd. for C8 
H8 Br N2 O2 S 274.9484, found 274.9490. 
4.6.20  5,7-Dibromo-3-methyl-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide-36 
 
Following General Procedure A; 3,5-dibromo-2-aminobenzenesulfonamide 38 (200 
mg, 0.56 mmol) in acetic acid (3.00 ml) and acetic anhydride (0.15 ml, 158 mmol) to 
give compound 36 as a pale yellow solid (120 mg, 61%). δH (DMSO-d6, 400 MHz): 
2.31 (s, 3H, CH3), 7.87 (s, 1H, Ar-H), 8.16 (s, 1H, Ar-H), 10.83 (s, 1H, NH); δC 
(DMSO-d6, 100 MHz): 23.32, 111.46, 117.55, 123.54, 125.39, 132.80, 138.81, 159.3; 
vmax: 3295, 3074, 1613, 1569, 1496, 1443, 1372, 1293 cm
-1
; x-ray crystal data for 36: 
C8H6Br2N2O2S, Mr  = 354.03, monoclinic, a = 18.7013(9), b = 5.3063(2), c =  
10.5662(5) Å,  β = 97.264(4), V = 1040.12(8) Å3, Z = 4,  P21/c, Dc = 2.26 g/cm
3, μ = 
7.973 mm
-1
, T = 120(2) K, 2417 unique reflections (Rint=0.0243), 1915 with F
2
 > 2σ, 
R(F, F
2
 > 2σ) =0.027, Rw (F
2
, all data) = 0.064. Crystals grown from 10% MeOH in 
DCM. 
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4.6.21  5-Bromo-2-amino-benzenesulfonamide-37 
 
A two necked round-bottomed flask equipped with a stirring bar was charged with       
2-aminobenzenesulfonamide (4.00 g, 23 mmol), and water (20 ml) was added. 
Concentrated hydrobromic acid (4.20 ml, 23.30 mmol, 45% w/v in acetic acid) was 
added, the mixture was stirred until it became clear, and then the stirred solution 
warmed gently to 45°C. Hydrogen peroxide 30% in water, (5.00 ml, 0.58 mmol) was 
added and rapid stirring initiated. The mixture was then stirred for 15 minutes at 60°C, 
and then the reaction flask cooled in an ice bath. When the temperature had fallen to 
about 25°C, the mixture was filtered at once and the product was washed with water and 
dried to afford 37. (3.80 g, 65%). δH (DMSO-d6, 400 MHz): 5.99 (s, 2H, Ar-NH2), 6.76 
(d, 1H, J 8.8 Hz, Ar-H), 7.34 (d, 1H, J 2.4 Hz, Ar-H), 7.36 (s, 2H, SO2NH2), 7.61 (s, 1H, 
Ar-H). δC (DMSO-d6, 100 MHz): 104.9, 119.0 125.6, 129.7, 135.3, 144.8. Data  
consistent with literature. 200 
4.6.22  3,5-Dibromo-2-aminobenzenesulfonamide-38 
 
A two necked round-bottomed flask equipped with a stirring bar was charged with       
2-aminobenzenesulfonamide (2.00 g, 11.50 mmol) and then water (10 ml) was added. 
Concentrated hydrobromic acid (4.20 ml, 23.30 mmol, 45% w/v in acetic acid) was 
added, and the mixture was stirred until a clear solution was obtained. The stirred 
solution was warmed gently to 45
o
C. Hydrogen peroxide (30% in water, 5.00 ml, 0.58 
mmol) was added and rapid stirring initiated. The mixture was stirred at 60°C for 30 
minutes and then an ice bath was raised about the flask. When the temperature had 
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fallen to about 25°C, the mixture was filtered, and the product was washed with water 
and dried to give 38 (3.30 g, 82%). δH  (DMSO-d6 400 MHz): 6.01 (s, 2H, ArNH2), 7.65 
(s, 2H, SO2NH2), 7.70 (s, 1H, Ar-H), 7.84 (s, 1H, Ar-H); δC (DMSO-d6, 100 MHz): 
105.1, 110.6, 127.0, 129.7, 137.6, 141.5.  Data  consistent with literature.201 
4.6.23  2-Amino-5-vinyl-benzenesulfonamide-40 
 
A two-necked round-bottomed flask was equipped with a magnetic stirring bar, and a 
reflux condenser fitted with a nitrogen inlet. The flask was charged with 5-bromo-2-
aminobenzenesulfonamide 37 (1.50 g, 5.97 mmol), 1,2-dimethoxyethane (20 ml) and 
tetrakis (triphenylphosphine) palladium (0) (0.25 g, 0.21 mmol). Under an atmosphere 
of nitrogen the reaction  mixture was stirred at room temperature for 15 minutes then a 
solution of potassium carbonate (1.60 g, 11.30 mmol) in water (6.00 ml) was added, 
followed by 2,4,6- trivinylcyclotriboroxane-pyridine complex (2.00 g, 8.31 mmol).179 
The reaction mixture was stirred under reflux for 20 hours and then cooled to ambient 
temperature. Distilled water (20 ml) was added, and the resulting mixture was filtered, 
the filtrate extracted with diethyl ether (3 × 20 ml), the combined organic layers were 
dried over (MgSO4), filtered and concentrated by rotary evaporation. The crude product 
was purified by flash chromatography (silica, ethyl acetate/cyclohexane 4:3 parts per 
volume) to give the title compound 40 as a white solid (0.92 g, 77%). δH (CD3OD, 400 
MHz): 4.82 (s, 4H, 2 × NH2), 5.03 (d, 1H, J 11.7 Hz, vinyl), 5.55 (d, 1H, J 17.5 Hz, 
vinyl), 6.57 (dd, 1H, J 10.5, 10.9 Hz, vinyl),  6.78 (d, 1H, J 8.5 Hz, Ar-H), 7.37 (d, 1H, J 
8.4 Hz, Ar-H), 7.68 (s, 1H, Ar-H); δC (CD3OD, 100 MHz): 109.7, 117.2, 124.1, 126.0, 
126.5, 130.5, 135.5, 145.2; HRMS (NSI) (m/z), [M+H] calc.199.0538 found 199.0536. 
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4.6.24  2-Amino-4-vinylbenzenesulfonamide 40a 
 
A two-necked round-bottomed flask was equipped with a magnetic stirring bar, and a 
reflux condenser fitted with a nitrogen inlet. The flask was charged with 4-bromo-2-
aminobenzenesulfonamide 44 (400 mg, 1.59 mmol), 1,2-dimethoxyethane (10 ml) and 
tetrakis (triphenylphosphine)palladium(0) (60 mg, 0.05 mmol). Under an atmosphere of 
nitrogen, the reaction mixture was stirred at room temperature for 20 min then 
potassium carbonate (350 mg, 2.50 mmol) dissolved in distilled water (3.00 ml), was 
added, followed by 2,4,6- trivinylcyclotriboroxane-pyridine complex (310 mg, 1.29 
mmol).179 The reaction mixture was stirred at 82 oC for 20 hours and then cooled to 
ambient temperature, distilled water (10 ml) was added and the resulting mixture was 
filtered. The filtrate was extracted with diethyl ether (3 × 20 ml), and the combined 
organic phases were dried (MgSO4), filtered and concentrated in vacuo. The product 
was then purified by flash chromatography (silica, ethyl acetate/cyclohexane 4:3 v/v) to 
give the title compound 40a (190 mg, 60%). δH (DMSO-d6, 400 MHz):  5.31 (d, 1H, J 
10.7 Hz, vinyl), 5.76 (d, 1H, J 17.6 Hz, vinyl), 5.80 (s, 2H, Ar-NH2), 6.61 (dd, 1H, J 
17.6, 11 Hz, vinyl), 6.74 (d, 1H, J 8.2 Hz, Ar-H), 6.81 (s, 1H, Ar-H), 7.08 (s, 2H, 
SO2NH2), 7.49 (d, 1H, J 8.2 Hz, Ar-H); δC (DMSO-d6, 100 MHz):  112.6, 114.4, 116.1, 
123.5, 128.3, 136.1, 141.2, 145.7; HRMS (NSI) (m/z), [M+H] calc.199.0539 found 
199.0537 
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4.6.25   3-Methyl-7-vinyl-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide-41 
 
A two-necked round-bottomed flask was equipped with a magnetic stirring bar and a 
reflux condenser fitted with a nitrogen inlet. The flask was charged with 7-bromo-3-
methyl-4H-benzo[e][1,2,4]thiadiazine-1,1-dioxide 35 (450 mg, 1.63 mmol), a (2:1) 
mixture of 1,2-dimethoxyethane and acetonitrile (15 ml) and tetrakis 
(triphenylphosphine)palladium(0) (370 mg, 0.30 mmol). The mixture was stirred at 
room temperature for 20 minutes then a solution of potassium carbonate (250 mg, 1.80 
mmol) in water (2.00 ml) was added, followed by 2,4,6-trivinylcyclotriboroxane-
pyridine complex (220 mg, 0.91 mmol). The reaction mixture was stirred at 82 oC for 
20 hours and then cooled to ambient temperature, distilled water (15 ml) was added and 
the resulting mixture was filtered through celite. The filtrate was extracted with 
DCM/acetonitrile, 4:1 (3 × 2 ml), the combined organic phases dried (MgSO4), then 
filtered and the filtrate was concentrated under rotary evaporation. The white solid was 
washed with DCM then dried gave the title compound 41 (160 mg, 44%).
 δH (DMSO-d6, 
400 MHz): 2.28 (s, 3H, CH3), 5.32 (d, 1H, J 10.8 Hz, vinyl), 5.89 (d, 1H, J 17.6 Hz, 
vinyl), 6.81 (dd, 1H, J 17.6, 11.0 Hz, vinyl), 7.25 (d, 1H, J 8.44 Hz, Ar-H), 7.80 (d, 1H, 
J 8.7 Hz, Ar-H), 7.82 (s, 1H, Ar-H), 12.0 (brs, 1H, NH); δC (DMSO-d6,100 MHz): 22.5, 
115.4, 117.6, 121.1, 121.2, 123.0, 134.5, 134.7, 135.2, 157.0; HRMS (NSI) (m/z), 
[M+H] calc. 223.0536 found 223.0538. 
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4.6.26  2-Amino-5-(2-hydroxy-ethyl)-benzenesulfonamide-42 
 
In a two necked flask, 2-amino-5-vinyl-benzenesulfonamide 40 (510 mg, 2.57 mmol) 
was dissolved in 9-BBN solution (0.5 M in THF, 17.00 mL, 8.80 mmol) and stirred at 
25 
o
C for 12 h. At 0 
o
C, hydrogen peroxide (30% in H2O, 0.20 mL, 13.00 mmol) and 
1M sodium hydroxide solution (13.50 mL, 13.50 mmol) were carefully added.180 The 
mixture was stirred at 25 
o
C for 2 hours, diluted with saturated aqueous ammonium 
chloride (100 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic 
phases were dried (Na2SO4), filtered, and evaporated. The product was purified by flash 
chromatography (silica, ethyl acetate) to produce 42 as a white solid (350 mg, 63 %). δH 
(CD3OD, 400 MHz): 2.70 (t, 2H, J 6.9 Hz, ethyl), 3.68 (t, 2H, J 7.0 Hz, ethyl), 4.85 (s, 
4H, 2 × NH2), 6.79 (d, 1H, J  8.3 Hz, Ar-H), 7.16 (d, 1H, J 8.2 Hz, Ar-H), 7.54 (s, 1H, 
Ar-H); δC (CD3OD, 100 MHz):  38.9, 64.0, 118.9, 125.9, 128.8, 129.1, 135.3, 144.6. 
4.6.27  7-(2-Hydroxyethyl)-3-methyl-4H-benzo[e][1,2,4]thiadiazine 1,1-
dioxide-43 
 
Following General Procedure A; 2-amino-5-(2-hydroxy ethyl) benzenesulfonamide 42 
(350 mg, 1.62 mmol), in acetic acid (6.00 ml) and acetic anhydride (0.17 ml, 1.78 
mmol) gave the title compound 43 (170 mg, 40%).
 δH (DMSO-d6, 400 MHz):  1.67 (brs, 
1H, OH), 2.24 (s, 3H, CH3), 2.27 (t, 2H, J 6.5 Hz, CH2), 3.57 (t, 2H, J 6.5 Hz, CH2), 
7.17 (d, 1H, J 8.3 Hz, Ar-H), 7.47 (d, 1H, J 8.4 Hz, Ar-H), 7.58 (s, 1H, Ar-H), 11.92 (s, 
NH); δC (DMSO-d6,100 MHz): 22.4, 38.0, 61.5, 116.9, 120.8, 122.9, 133.1, 133.3, 
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133.8, 138.3, 156.8; vmax: 3412, 2933, 2880, 2533, 2312, 1614, 1527, 1583, 1272 cm
-1
; 
HRMS (NSI) (m/z), calcd. 241.0641, found 241.0645. 
4.6.28  2-Amino-4-bromobenzenesulfonamide-44 
 
In a two necked flask, 4-bromo-1-fluoro-2-nitrobenzene (2.40 g, 10.90 mmol) was 
dissolved in ethanol (30 ml). Subsequently, a suspension of sodium sulphate (3.00 g) in 
a mixture of ethanol (50 ml) and water (62 ml) was added and then the whole was 
stirred at 70°C for 24 hours. Thereafter, at room temperature the reaction mixture was 
adjusted to PH 2 with concentrated HCl. The mixture was filtered and the filtrate was 
concentrated in vacuo. The remaining residue was dissolved under reflux in brine 
(saturated aqueous sodium chloride solution) (50 ml). Subsequently, water (5.00 ml) 
was added and the solution was then cooled in an ice bath. The precipitate was collected 
by filtration and dried to yield 4-bromo-2-nitrobenzenesulfonic acid 44a (2.50 g, 81%) 
as a light yellow crystalline solid, which was used directly in the next step without 
purification. 
4-Bromo-2-nitrobenzenesulfonic 44a (2.50 g, 8.86 mmol) was dissolved in thionyl 
chloride (3.00 ml) and DMF (0.50 ml) and stirred at 90 °C for 2 hours. Subsequently, 
excess thionyl chloride was distilled off under reduced pressure. The residue was co-
evaporated with chloroform (2 × 10 ml). Thereafter, the 4-bromo-2-
nitrobenzenesulfonyl chloride intermediate was dissolved in chloroform (50 ml), then 
the solution was cooled to -40°C and ammonia gas was passed through the reaction 
mixture for 30 minutes. The mixture was stirred at room temperature to allow the 
ammonia to evaporate, and the solution was acidified with concentrated HCl to adjust to 
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pH 2. Subsequently, the mixture was concentrated in vacuo to yield 4-bromo-2-
nitrobenzenesulfonamide 44b (2.00 g, 80%). 
The compound 44b (2.00 g, 7.11 mmol) was dissolved in hydriodic acid (57 vol%, 
18.50 ml). The solution was heated at 90°C for 24 hours. After cooling to room 
temperature, ethyl acetate (30 ml) was added. Thereafter, the solution was cooled in an 
ice bath and solid of (Na2S2O3) was added under stirring until decolourization of the 
solution occurred, and then Na2CO3 was added as a solid for neutralization of the 
mixture. The layers were separated and the aqueous layer was extracted with ethyl 
acetate (10 ml), and the combined organic layers were dried over Na2SO4. After 
filtration and concentration in vacuo the crude product was purified by flash 
chromatography (silica, dichloromethane/ethanol, 10:1 parts per volume) to yield the 
title compound 44 (1.1 g, 61%). δH (CD3OD, 400 MHz): 4.77 (s, 4H, 2 x NH2), 6.71 (d, 
1H, J 8.8 Hz, Ar-H), 6.94 (s, 1H, Ar-H), 7.45 (1H, d, J 8.4 Hz, Ar-H); δC (CD3OD, 100 
MHz): 119.9, 120.3, 124.7 (C-Br), 128.5 (C-SO2), 130.9, 148.3 (C-NH2). 
4.6.29  6-Bromo-3-methyl-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide-45 
 
Following General Procedure A; 2-amino-4-bromobenzenesulfonamide 44 (200 mg, 
0.72 mmol) in acetic acid (3.00 ml) and acetic anhydride (0.09 ml, 0.80 mmol) gave 
compound 45 (140 mg, 64%).199 δH (DMSO-d6, 400 MHz(: 2.22 (s, 3H, CH3), 7.37 (s, 
1H, Ar-H), 7.51 (d, 1H, J 8.0 Hz, Ar-H), 7.65 (d, 1H, J 8.16 Hz, A-rH), 11.96 (s, 1H, 
NH); δC (DMSO-d6, 100 MHz): 23.2, 120.1, 120.5, 126.25, 126.31, 129.6, 137, 158.1; 
vmax: 3285, 3189, 3125, 1607, 1574, 1530, 1464, 1383, 1277 cm
-1
; HRMS (NSI) (m/z), 
calcd. for C8H8BrN2O2S 274.9484, found 274.9491. 
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4.6.30  2-Amino-6-chlorobenzenesulfonamide-46 
Preparation of this compound was achieved by applying a known procedure starting 
from 1,2-chloro-3-nitrobenzene,170 using a three step reaction as described below:  
i) 2-(Benzylsulfanyl)-1-chloro-3-nitrobenzene 46a 
 
A solution of benzyl chloride (5.70 ml, 49.80 mmol) and thiourea (3.80 g, 49.90 mmol) 
in a (1:1)  mixture of ethanol and water (20 ml) supplemented with a few drops of 
ammonia solution was heated at reflux for 3 hours. 1,2-Chloro-3-nitrobenzene (9.60 g, 
50 mmol) in ethanol (20 ml) was added under stirring to this solution and then an 
aqueous solution potassium hydroxide (7.00 g/ 50 ml) was added dropwise and the 
mixture was then heated at reflux for 2 hours. After cooling in an ice bath, the resulting 
precipitate was collected by filtration, washed with water (50 ml), and dried to give 2-
(benzylsulfanyl)-1-chloro-3-nitrobenzene 46a as a yellow crystalline solid (11.20 g, 
80%). The crude compound was used in the next step without further purification.  
ii)  6-Chloro-2-nitrobenzenesulfonamide 46b 
 
Gaseous chlorine, obtained from the reaction of concentrated hydrochloric acid (8.08 g, 
0.08 mmol) on potassium permanganate (1.60 g, 0.01 mmol), was introduced under 
stirring into a solution of 2-(benzylsulfanyl)-1-chloro-3-nitrobenzene 46a (0.50 g, 1.78 
mmol) in acetic acid (12.50 ml) and water (0.25 ml) at room temperature during 30 
minutes. The mixture was poured onto ice (~ 50 g) and extracted twice with diethyl 
ether (25 ml). The organic layer was washed with water (15 ml), dried (MgSO4), 
158 
 
filtered, and concentrated under reduced pressure. The resulting oily residue was 
dissolved in dioxane (5.00 ml) and a 30% aqueous solution of ammonia (10 ml) was 
added dropwise. After 30 minutes of stirring, the mixture was concentrated under 
reduced pressure to a volume of 7.00 ml, giving rise to the formation of a precipitate. 
The aqueous suspension was made alkaline with sodium hydroxide (10% m/v aqueous 
solution) until completed dissolution of the insoluble material. The alkaline solution 
was treated with charcoal, filtered, and adjusted to pH 3 with 6 M hydrochloric acid. 
The resulting precipitate was collected by filtration, washed with water, and dried to 
give 6-chloro-2-nitrobenzenesulfonamide 46b (130 mg, 40 %); mp 129-131, lit. mp 
128-132 
o
C.170
 
iii) 2-Amino-6-chlorobenzenesulfonamide-46 
 
 Product 46b was dissolved in a hot (1:1) mixture of ethanol and water (3.00 ml) and 
then treated with ammonium chloride (80 mg, 1.50 mmol) and iron powder (0.16 g, 
2.87 mmol), and the suspension heated at reflux for 45 minutes. The reaction mixture 
was filtered, and the filtrate was concentrated under reduced pressure to half of the 
volume and then extracted with dichloromethane (3 × 10 ml). The combined organic 
layers were dried (MgSO4), filtered and the filtrate was concentrated under reduced 
pressure. After addition of hexane (2.00 ml), the resulting precipitate was collected by 
filtration, washed with hexane (20 ml), and dried to give the title compound 46 as a 
light brown solid (55 mg, 48%). δH (CD3OD, 400 MHz): 4.86 (s, 4H, 2 × NH2), 6.66-
6.72 (m, 2H, Ar-H), 7.03-7.10 (m, 1H, Ar-H); δC (CD3OD, 100 MHz): 118.1, 119.6, 
129.5, 131.9, 133.4, 134.1. Data was consistent with the literature.170  
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4.6.31   8-Chloro-3-methyl-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide-47 
 
 Following General Procedure A; 2-Amino-6-chlorobenzenesulfonamide 46 (200 mg, 
0.96 mmol) in acetic acid (2.00 mL) and acetic anhydride (0.10 ml, 1.01 mmol) gave 
the title compound 47 as a white solid (120 mg, 54%).
 δH (DMSO-d6, 400 MHz): 2.28 
(s, 3H, CH3), 7.29 (d, 1H, J 8.2 Hz, Ar-H), 7.45 (d, 1H, J 8.0 Hz, Ar-H), 7.62 (t, 1H, J 
8.1 Hz, Ar-H), 12.22 (s, 1H, NH); δC (DMSO-d6, 100 MHz): 22.3, 116.6, 127.5, 129.4, 
133.3, 137.1, 139.6, 155.6; vmax: 3254, 3174, 3100, 1602, 1580, 1522, 1460, 1417 cm
-1
; 
HRMS (NSI) (m/z), calc. 230.9990, found 230.9993. 
4.6.32  4-(1,1-Dioxido-4H-benzo[e][1,2,4]thiadiazin-3-yl)butanoic acid-48 
 
Following General Procedure B; 2-Aminobenzenesulfonamide (1.00 g 5.80 mmol) in 
dioxane (10 mL) and glutaric acid monomethyl ester chloride (1.00 mL, 7.20 mmol) 
gave the title compound 48 as a white solid (820 mg, 53%).182 M.p. 183-185 oC; δH 
(DMSO-d6, 400 MHz): 1.86-1.92 (m, 2H, CH2) 2.32 (t, 2H, J 7.1 Hz, CH2), 2.59 (t, 2H, 
J 7.3 Hz, CH2), 7.30 (d, 1H, J 8.3 Hz, Ar-H), 7.41 (t, 1H, J 7.6 Hz, Ar-H), 7.64 (t, 1H, J 
7.5 Hz Ar-H), 7.77 (d, 1H, J 7.9 Hz, Ar-H), 11.96 (s, 1H, NH), 12.14 (s, 1H, OH); δC 
(DMSO-d6,100 MHz): 21.2, 32.4, 34.2, 117.3, 121.2, 123.4, 126.2, 133.0, 135.1, 159.7, 
173.9; vmax: 3252, 3204, 3168, 3120, 1735, 1609, 1529, 1478, 1279 cm
-1
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4.6.33   4-(7-Bromo-1,1-dioxido-4H-benzo[e][1,2,4]thiadiazin-3-yl)butanoic 
acid-49 
 
Following General Procedure B; 2-Amino-5-bromo benzenesulfonamide 37 (200 mg 
0.79 mmol) in dioxane (10 ml) and glutaric acid monomethylester chloride (1.00 ml, 
7.20 mmol) gave the title compound 49 as a white solid (25 mg, 33%).182 M.p. 246-249 
o
C;
 δH (DMSO-d6, 400 MHz):  1.72-1.78 (m, 2H, CH2) 2.19 (t, 2H, J 7.1 Hz, CH2), 2.47 
(t, 2H, J 7.4 Hz, CH2), 7.15 (d, 1H, , J 8.6 Hz, Ar-H), 7.70 (d, 1H, J 8.7 Hz, Ar-H), 7.80 
(s, 1H, Ar-H), 12.03 (s, 2H, NH, OH); δC (DMSO-d6,100 MHz): 21.0, 32.4, 34.2, 117.1, 
119.9, 122.5, 125.5, 134.4, 135.9, 159.9, 173.9; vmax: 3274, 3184, 3113, 1692, 1605, 
1574, 1526 cm
-1
 
 
4.6.34  4-(5,7-Dibromo-1,1-dioxido-4H-benzo[e][1,2,4]thiadiazin-3-
yl)butanoic acid-50 
 
Following General Procedure B; 2-Amino-3,4-dibromobenzenesulfonamide 38 (200 
mg 0.60 mmol) in dioxane (10 ml) and glutaric acid monomethyl ester chloride (0.10 
mL, 0.75 mmol) gave the title compound 50 as a white solid (170 mg, 66%).182 M.p. 
236-239 
o
C;
 δH (DMSO-d6, 400 MHz): 1.70 (m, 2H, CH2) 2.14 (t, 2H, J 7.18 Hz, CH2), 
2.42 (t, 2H, J 7.40 Hz, CH2), 7.81 (d, 1H, J 8.68 Hz, Ar-H), 8.3 (s, 1H, Ar-H), 10.83 (s, 
1H, NH,), 12.38 (s, 1H, OH); δC (DMSO-d6,100 MHz): 21.1, 32.4, 34.2, 111.5, 117.5, 
123.5, 125.4, 132.8, 138.8, 159.3, 173.7.    
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4.6.35  Hybrid with the non-substituted diazoxide-52 
 
Following General Procedure C using diazoxide butyric acid 48 (100 mg, 0.37 mmol), 
triethylamine (0.15 ml, 0.44 mmol) and DMAP (4.5 mg, 10% mol) in dry acetonitrile (2 
ml), tosyl chloride (85 mg, 0.44 mmol) in acetonitrile (1.50 ml), and alcohol 27 (210 mg, 
0.38 mmol) in acetonitrile (3.00 ml). The product was purified using column 
chromatography (silica, ethyl acetate/cyclohexane, 1:1 v/v) yielded the desired 
compound 52 as an orange thick oil (170 mg, 57 %). δH (400 MHz, CDCl3): 0.93-0.99 
(m, 2H), 1.12-1.19 (m, 2H), 1.23-1.30 (m, 4H), 1.94 (t, 2H, J 8.0 Hz), 2.27 (t, 2H, J 7.2 
Hz), 2.51 (t, 2H, J 7.5 Hz), 2.76 (s, 6H, 2 × CH3), 3.15 (t, 2H, J 7.5 Hz), 3.81 (t, 2H, J 
6.5 Hz), 4.45 (s, 2H, Ar-CH2 ), 7.09 (d, 1H, J 7.0 Hz), 7.11 (d, 1H, J 7.7 Hz), 7.19 (d, 
2H, J 8.2 Hz), 7.23 (t, 1H, J 7.0 Hz), 7.34-7.50 (m, 7H), 7.56 (d, 2H, J 8.2 Hz,), 7.63 (d, 
2H, J 8.5 Hz), 7.76 (d, 1H, J 8.0 Hz), 8.13 (d, 1H, J 8.5 Hz), 8.20 (d, 1H, J 8.7 Hz), 8.44 
(d, 1H, J 8.2 Hz), 10.37 (s, 1H, NH); δC (100 MHz, CDCl3): 21.4, 25.3, 26.0, 27.4, 28.2, 
32.9, 35.1, 45.4 (2C), 47.1, 50.5, 64.5, 115.4, 117.3, 119.2, 121.2, 123.2, 124.0, 126.6, 
128.1 (2C), 128.4 (3C), 130.0 (3C), 130.4 (2C), 130.8, 132.7, 133.1, 134.6, 135.1, 136.8, 
137.3, 141.3, 152.0, 159.8, 173.1, 196.6; vmax: 3267, 2937, 2861, 1727, 1654, 1608, 
1577, 1478 cm
-1
; HRMS (NSI) (m/z), [M+H] calc. 795.2881 found 795.2882. 
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4.6.36  4-(8-Chloro-1,1-dioxido-4H-benzo[e][1,2,4]thiadiazin-3-yl)butanoic 
acid-53 
 
Following General Procedure B; 2-Amino-6-chlorobenzenesulfonamide 46 (260 mg 
1.26 mmol) in dioxane (15 ml) and glutaric acid monomethylester chloride (0.20 ml, 
1.50 mmol) gave the title compound 53 (330 mg, 86%). M.p. 208-210 
o
C;
 δH (DMSO-
d6, 400 MHz): 1.80-1.88 (m, 2H, CH2) 2.30 (t, 2H, J 7.3 Hz, CH2), 258 (t, 2H, J 7.4 Hz, 
CH2), 7.33 (d, 1H, J 8.3 Hz, Ar-H), 7.44 (d, 1H, J 7.8 Hz, Ar-H), 7.60 (t, 1H, J 8.1 Hz,  
A-rH), 12.16 (s, 1H, OH), 12.31 (s, 1H, NH); δC (DMSO-d6,100 MHz): 21.0, 32.4, 33.8, 
116.82, 119.4, 127.6, 129.4, 133.4, 137.0, 158.1, 173.9; vmax: 3293, 3193, 3117, 1696, 
1603, 1580, 1524, 1416, 1287 cm
-1
; HRMS (NSI) (m/z), calc. for C11H11ClN2O4S 
301.0047, found 301.0055. 
4.6.37  Benzophenone-hybrid with 8-chloro- diazoxide-54 
 
Following General Procedure C using 8-chlorodiazoxide butyric acid 53 (58 mg, 0.19 
mmol), triethylamine (0.08 ml, 0.57 mmol), DMAP (2.30 mg, 10% mol) in  acetonitrile 
(2.00 ml), tosyl chloride (44 mg) in acetonitrile (1.50 ml) and alcohol 27 (105 mg, 0.19 
mmol) in acetonitrile (1.50 ml). The product was purified using column 
chromatography (silica, ethyl acetate/cyclohexane, 1:1 v/v) to yield the title compound 
54 as a yellow oil (70 mg, 44%). δH (400 MHz, CDCl3): 1.09-1.15 (m, 2H), 1.22-1.27 
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(m, 2H), 1.38-1.43 (m, 4H), 2.05 (t, 2H, J 7.3 Hz), 2.39 (t, 2H, J 6.9 Hz), 2.59 (t, 2H, J 
7.2 Hz), 2.87 (s, 6H, 2 × CH3), 3.26 (t, 2H, J 7.3 Hz), 3.96 (t, 2H, J 6.5 Hz), 4.51 (s, 2H, 
Ar-CH2 ), 7.08 (d, 1H, J 7.8 Hz), 7.19 (d, 1H, J 7.2 Hz), 7.26 (d, 2H, J 7.2 Hz), 7.28-
7.36 (m, 2H), 7.45-7.59 (m, 6H), 7.65 (d, 2H, J 8.3 Hz), 7.72 (d, 2H, J 8.4 Hz), 8.22 (d, 
1H, J 8.4 Hz) 8.28 (d, 1H, J 8.6 Hz), 8.54 (d, 1H, J 8.4 Hz), 10.26 (s, 1H, NH); δC (100 
MHz, CDCl3): 21.1, 25.1, 25.8, 27.3, 28.1, 32.8, 34.8, 45.4 (2C), 47.1, 50.5, 64.4, 115.3, 
116.1, 119.0, 119.8, 123.1, 128.0 (2C), 128.2, 128.3 (3C), 129.9 (3C), 130.0, 130.3 (2C), 
130.7, 131.3, 132.7, 132.8, 134.4, 136.6, 136.7, 137.2, 141.2, 151.9, 157.8, 173.1, 196.7; 
vmax: 3265, 3182, 2936, 1727, 1655, 1602, 1580, 1524, 1461, 1309, 1156 cm
-1
; HRMS 
(NSI) (m/z), [M+H] calc. 829.2491 found 829.2494.  
4.6.38  Diazirine alkyl linker hybrid with 8-chloro diazoxide-55  
 
 
Following General Procedure C using 8-chlorodiazoxide butyric acid 53 (265 mg, 0.87 
mmol), triethylamine (4.00 ml, 3.50 mmol), DMAP (10 mg, 10% mol) in acetonitrile 
(5.00 ml), tosyl chloride (106 mg, 1.05 mmol) in acetonitrile (5.00 ml) and alcohol 26 
(480 mg, 0.87 mmol) in acetonitrile (3.00 ml). The product was purified using column 
chromatography (silica, ethyl acetate/cyclohexane, 1:1 v/v) gave the title compound 55 
as an orange thick oil (240 mg, 33 %). δH (400 MHz, CDCl3): 1.02-1.11 (m, 2H), 1.20-
1.28 (m, 2H), 1.31-1.39 (m, 4H), 2.06, (d, 2H, J 7.3 Hz), 2.40 (t, 2H, J 7.3 Hz), 2.64 (t, 
2H, J 7.3 Hz), 2.86 (s, 6H, 2 × CH3), 3.19 (t, 2H, J 7.0 Hz), 3.92 (t, 2H, J 6.5 Hz), 4.43 
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(s, 2H, Ar-CH2), 6.99 (d, 2H, J 8.1 Hz), 7.14 (d, 2H, J 8.2 Hz), 7.17 (d, 2H, J 7.6 Hz), 
7.28 (d, 1H, J 7.8 Hz), 7.36 (t, 1H, J 8.0 Hz), 7.48 (t, 1H, J 7.6 Hz), 7.54 (t, 1H, J 7.7 
Hz), 8.18 (d, 1H, J 7.3 Hz), 8.21 (d, 1H, J 8.5 Hz), 8.52 (d, 1H, J 8.2 Hz), 10.24 (s, 1H, 
NH); δC (100 MHz, CDCl3): 21.3, 25.3, 26.0, 27.4, 28.3, 33.0, 34.9, 45.5 (2C), 46.9, 
50.2, 64.6, 115.4, 116.5, 119.1, 119.8, 123.3, 126.6 (2C), 128.4 (2C), 128.6, 128.7 (4C), 
130.0, 130.2, 130.9, 131.3, 133.0, 134.6, 136.8, 138.0, 152.0, 158.2, 173.3; δF (376 
MHz, CDCl3): -65.0; vmax: 3263, 3182, 2936, 1727, 1602, 1580, 1524, 1461, 1307, 155 
cm
-1
; HRMS (NSI) (m/z), [M+H] calc. 833.2164 found 833.2164. 
4.6.39  Benzophenone and PEG linker hybrid with 8-chlorodiazoxide-56 
 
 
Following General Procedure C using 8-chlorodiazoxide butyric acid 53 (78 mg, 0.26 
mmol), triethylamine (0.10 ml, 0.78 mmol), DMAP (3.00 mg, 10% mol) in acetonitrile 
(3.00 ml), tosyl chloride (60 mg) in acetonitrile (2.00 ml) and alcohol 28 (150 mg, 0.26 
mmol) in acetonitrile (2.00 ml). The product was purified using column 
chromatography (silica, ethyl acetate) gave the title compound 56 as a red thick oil (120 
mg, 53 %). δH (400 MHz, CDCl3): 0.81-0.87 (m, 2H), 1.24 (t, 2H, J 7.2 Hz), 1.98-2.05 
(m, 2H), 2.33 ( t, 2H, J 7.0 Hz), 2.46 (t, 2H, J 7.2 Hz), 2.86 (s, 6H, 2 × CH3), 3.41-3.48 
(m, 2H), 3.54 (t, 2H, J 4,3 Hz), 3.66 (t, 2H, J 3.2 Hz), 4.21 (t, 2H, J 4.4 Hz), 4.64 (s, 2H, 
Ar-CH2), 7.08 (d, 1H, J 8.1 Hz), 7.17 (d, 1H, J 7.5 Hz), 7.21-7.29 (m, 4H), 7.32 (d, 2H, 
J 8.1 Hz), 7.44- 7.54 (m, 2H), 7.62 (d, 3H, J 8.3 Hz), 7.72 (d, 2H, J 6.9 Hz), 8.21 (d, 1H, 
J 8.4 Hz), 8.24 (d, 1H, J 8.5 Hz), 8.43 (d, 1H, J 8.5 Hz), 10.26 (brs, 1H, NH); δC (100 
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MHz, CDCl3): 21.4, 32.8, 34.7, 45.5 (2C), 46.4, 51.9, 63.4, 69.1, 69.6, 70.2, 70.4, 115.5, 
116.1, 119.2, 120.1, 123.3, 128.3 (3C), 128.5 (3C), 129.7, 130.0, 130.1 (3C), 130.4 (2C), 
130.9, 131.6, 132.9 (2C), 134.9, 136.7, 136.9, 137.3, 141.4, 152.0, 157.7, 172.9, 196.8; 
vmax: 3266, 3182, 2867, 1731, 1654, 1604, 1580, 1525, 1461, 1310, 1157 cm
-1
; HRMS 
(NSI) (m/z), [M+H] calc. 861.2389 found 861.2384.   
4.6.40  4-(1,1-Dioxido-7-vinyl-4H-benzo[e][1,2,4]thiadiazin-3-yl)butanoic 
acid-57 
 
Following General Procedure B; 2-Amino-5-vinylbenzenesulfonamide 40 (250 mg 
1.26 mmol) in dioxane (10 ml) and glutaric acid monomethylester chloride (0.20 ml, 
1.50 mmol) gave the title compound 57 (260 mg, 70%). M.p. 207-209 
o
C;
 δH (DMSO-
d6, 400 MHz): 1.75-1.86 (m, 2H, CH2) 2.25 (t, 2H, J 7.3 Hz, CH2), 253 (t, 2H, J 7.4 Hz, 
CH2), 5.29 (d, 1H, J 10.9 Hz), 5.88 (d, 1H, J 17.5 Hz), 6.78 (dd, 1H, J 11.1, 10.9 Hz), 
7.27, (d, 1H, J 8.3 Hz), 7.78 (d, 1H, J 10.9 Hz), 7.80 (s, 1H), 12.10 (s, 2H, NH, OH); δC 
(DMSO-d6,100 MHz): 21.2, 32.4, 34.2, 115.5, 117.8, 121.1, 121.4, 130.1, 134.5, 134.8, 
135.3, 159.6, 174.0. 
4.6.41  Benzophenone-hybrid with 7-vinyl diazoxide-58 
 
Following General Procedure C using 7-vinyldiazoxide butyric acid 57 (290 mg, 0.98 
mmol), triethylamine (0.42 ml, 2.95 mmol), DMAP (12 mg, 10% mol) in acetonitrile 
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(5.00 ml), tosyl chloride (230 mg, 1.18 mmol) in acetonitrile (3.00 ml) and alcohol 27 
(530 mg, 0.98 mmol) in acetonitrile (5.00 ml). The product was purified using column 
chromatography (silica, ethyl acetate/cyclohexane, 1:1 v/v) yielded the title compound 
58 as a yellow oil (160 mg, 20 %). δH (400 MHz, CDCl3): 1.07-1.18 (m, 2H), 1.10-1.29 
(m, 2H), 1.36-1.47 (m, 4H), 2.05 (t, 2H, J 7.3 Hz), 2.38 (t, 2H, J 6.8 Hz), 2.57 (t, 2H, J 
7.2 Hz), 2.87 (s, 6H, 2 × CH3), 3.26 (t, 2H, J 7.3 Hz), 3.96 (t, 2H, J 6.5 Hz), 4.51 (s, 2H, 
Ar-CH2 ), 5.30 (d, 1H, J 10.9 Hz), 5.73 (d, 1H, J 17.5 Hz), 6.64 (dd, 1H, J 10.6, 10.9 
Hz), 7.06 (d, 1H, J 8.5 Hz), 7.18 (d, 1H, J 7.4 Hz), 7.26 (d, 2H, J 8.2 Hz), 7.45-7.59 (m, 
6H), 7.65 (d, 2H, J 8.2 Hz), 7.72 (d, 2H, J 8.4 Hz), 7.87 (s, 1H), 8.22 (d, 1H, J 7.3 Hz), 
8.28 (d, 1H, J 8.5 Hz), 8.54 (d, 1H, J 8.3 Hz), 10.21 (s, 1H, NH); δC (100 MHz, CDCl3): 
21.4, 25.3, 25.9, 27.0, 27.5, 28.2, 33.0, 35.2, 45.5 (2C), 47.3, 50.8, 64.6, 115.5, 115.8, 
117.3, 119.2, 121.7, 123.3, 128.2 (2C), 128.5 (3C), 130.1 (3C), 130.5 (2C), 130.9, 132.9, 
134.1, 134.6, 1236.5, 136.9, 137.4, 141.3, 152.1, 159.2, 173.5, 196. 
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4.7 Biological experimental  
4.7.1 UV irradiation test 
A solution of bovine serum albumin protein (BSA) 2.00 mM was prepared by 
dissolving BSA solid (660 mg) in phosphate buffer saline (PBS) solution (5.00 mL), 
then solutions of the fully functional diazoxides were prepared at a final concentration 
of 40 mM in DMSO as shown in Table 2. The diazoxide solutions (25 µL) were added 
to 500 µL of the protein solution and the mixture sample were shaken for 15 min at 
room temperature. ~100 µL of each sample was loaded in a 384 well plate, and then 
exposed to light of 360 nm wave length for variable times of 10, 30 and 60 min. 
Compound No Molecular Wight Mass in 250 ml  
DMSO 
Final concentration 
54 829.42 8.29 mg 40 mM 
55 833.34 8.33 mg 40 mM 
56  861.42 8.61 mg 40 mM 
Table 2 Preparation of solutions of functional molecules for VU irradiation 
4.7.2 SDS Polyacrylamide Gel Electrophoresis  
i)  Preparation of samples 
The irradiated samples were very concentrated therefore, a dilution was carried out to 
prepare samples can be directly loaded to the gel. The overall concentration of the 
sample was (127 µg/ 1 µL), so dilution of 100 times by using the same buffer solution 
PBS was done and a concentration of (1.27 µg/ 1 µL) was obtained.  
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ii) Preparation of polyacrylamide gels 
SDS-PAGE was carried out by the method described by Laemmli (1970) with some 
modifications,202 using the Bio-Rad Mini-PROTEAN III electrophoresis cell, which was 
assembled according to the manufacturer’s instructions. Two glass plates (one with 1.5 
mm spacers) were thoroughly cleaned with 70% (v/v) ethanol and dried before use. The 
plates were then clamped into position in the gel casting stand. Ten ml of resolving gel 
mix were prepared as shown in Table 2.4. TEMED was used as a polymerisation 
inducing agent and was added to the solution immediately before the gel was poured. 
Sufficient space was left above the resolving gel mixture to allow for a stacking gel. 
Distilled water was carefully added by a 1ml pipette above the resolving gel to create a 
smooth overlay. The gel mix was allowed to polymerise at room temperature for 40 
min. After polymerisation of the resolving gel, the distilled water overlay was removed. 
Then TEMED was added to the 4 % (w/v) acrylamide stacking gel mix immediately 
prior to pouring the gel mix on top of the resolving gel to the top of the glass plates. A 
10 tooth comb was placed within the gel to make 10 individual wells. The gel was then 
allowed to polymerise for 20 min at room temperature before the comb was carefully 
removed. The gel assembly was then transferred to an electrophoresis running chamber 
containing SDS-PAGE running buffer as in Table 3. 
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Resolving gels 
Reagent 10 % gel 
Resolving Buffer 
(1.5M Tris–HCl , 0.4 % (w/v) SDS , pH 8.8) 
2.5 ml 
40% (w/v) 29:1 
Acrylamide Bis Acrylamide  solution 
2.5 ml 
Distilled water                                              4.88 ml 
10 % (w/v) ammonium persulphate  (APS) 100 µl 
TEMED 20 µl 
Total volume 10 ml 
Stacking gels 
Reagent  volume 
4% Stacking Buffer 
(0.5 M Tris–HCl , 0.4 % SDS , pH 6.8) 
2.5 ml 
40% (w/v) 29:1 
Acrylamide  Bis Acrylamide  solution 
1 ml 
Distilled water                                                 6.4 ml 
10 %( w/v) ammonium persulphate               100 ml 
TEMED 20 µl 
Total volume                                                    10 ml 
Electrophoresis running buffer 
25 mΜ Tris, 192  mM glycine, 0.1% (w/v) SDS, pH  8.3 
 
Table 3 Preparation and reagents for SDS-PAGE 
iii) One dimensional gel electrophoresis of samples 
Samples were mixed with Laemmli x4 buffer ( 
Table 4) in a 1:3 ratio and boiled for 5 min. Samples were allowed to cool down to 
room temperature prior to loading into the gel. 10 and 20 µg of protein was loaded into 
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each well, to obtain even loading across the gel. After the gel was made up according to 
section above, 2 µl of Blueye prestained protein ladder, (molecular weight range 11-245 
kDa) was added to the well. Gels were then placed vertically in a Mini-PROTEAN III™ 
electrophoresis chamber from Bio-Rad and run in electrode running buffer at 50 volts 
for 10 min using Bio-Radpower pac 300. This initial voltage allows the samples to enter 
the stacking gel. After that, the voltage was increased to 150 volts and run for around 1 
h. As the dye front approached the base of the gel plates, the voltage was switched off. 
Gels were carefully removed and placed in 10% methanol in water solution to stop 
protein moving. Gels were then visualised under UV transillumination imaging system. 
Reagent  Volume (ml) 
Distilled water 0.8  
1 M Tris HCl pH 6.8 2.4 
Glycerol 4.0 
10 % (w/v) SDS  1.6  
β-mercaptoethanol 1.0   
Bromophenol blue 0.05% (w/v) 0.2 
Total volume                                                   10.0     
 
Table 4 Laemmli x4 SDS – PAGE  sample buffer 
 
4.7.3 Incubation of the mitochondrial extract proteins with the diazoxide 
molecules.  
Mitochondrial extract provided by Dr Alan Hargreaves, which was extracted from pig 
brain. The protein concentration was determined using, Bio-Rad DC Protein assay (Bio-
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Rad laboratories, Hertfordshire, UK) with bovine serum albumin as the standard. 
Protein concentration was 6.5 g/l; the samples were prepared as follow: 
Mitochondrial extract 50 l was diluted with TBS buffer solution 64 l, then diazoxides 
molecule (100 M, 3 l) were added and incubated at room temperature for 30 minutes. 
Sample were then divided to two parts 60 l each, one part was suspended in TBS 
buffer solution and centrifuged at 1000 r/m for 5 minutes, the pellets were separated and 
collected. All the samples were loaded in a 384 well plate, and irradiated under 360 nm 
UV light for 10 and 30 minutes for the diazirine and benzophenone respectively. Then 
40 g of each sample was loaded in a polyacrylamide gel for electrophoresis separation, 
as described above.  
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